Novel applications of biomaterials in the management of parastomal hernia and anal fistula by Hammond, Toby Mark
Novel applications of biomaterials in the management of parastomal
hernia and anal fistula
Hammond, Toby Mark
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
https://qmro.qmul.ac.uk/jspui/handle/123456789/530
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
 Novel Applications of 
Biomaterials in the 
Management of Parastomal 
Hernia and Anal Fistula 
 
 
By Toby Mark Hammond 
 
 
A thesis submitted for the higher degree of 
Doctorate in Medical Research (MD Res) 
 
 
  
 
Centre for Academic Surgery, 
Barts and The London School of Medicine and 
Dentistry, 
Queen Mary, University of London 
E1 4NS 
 
 
 
2 
 
Declaration of my contribution 
I, Toby Mark Hammond, confirm that all studies presented within this thesis 
have been my own work. The thesis was registered in January 2004 and 
submitted in April 2009. Assistance was kindly given in the preparation and 
interpretation of histological specimens. Anal physiology investigations and 
anal endosonography were performed and interpreted by colleagues within 
the GI Physiology Unit at The Royal London Hospital. All surgery on patients 
at both The Royal London and Homerton University Hospital was performed 
by Consultant Surgeons working at these institutions. I attended all surgical 
procedures on all patients where possible. I confirm that where information 
has been derived from other sources, this has been indicated in the thesis. 
  
3 
 
Abstract 
The aim of this thesis was to explore novel applications for both traditional and 
contemporary biomaterials in the management of parastomal hernia and anal 
fistula.  
Parastomal hernias can be prevented or repaired using synthetic mesh; 
however, reported complications include infection, fibrosis and potential bowel 
erosion. The prophylactic role of a cross-linked collagen implant was 
assessed in terms of safety, feasibility and potential efficacy. Additionally, the 
human host response to this implant was evaluated. There were no 
complications related to infection or the implant‟s proximity to the bowel. The 
implant had excellent biocompatibility and resistance to degradation in most 
patients, and although fibrovascular in-growth and ECM deposition were 
limited, it seems to have excellent potential for soft tissue reinforcement and, 
more specifically, prevention of parastomal hernias. 
Anal fistulas are in the main successfully treated by surgical fistulotomy, 
however damage to the anal sphincter complex and subsequent incontinence 
have led to the development of other techniques which aim to either lessen or 
avoid such disturbance. One strategy involves the traditional cutting seton, 
and a modification of this technique, the „snug‟ silastic seton was assessed. In 
the short-medium term, this modification was demonstrated to be an effective 
addition to the fistula surgeon‟s armamentarium, although minor incontinence 
remained a concern. Other approaches employing contemporary biomaterials, 
fibrin glue and porcine intestinal submucosa, are aimed at tissue repair, rather 
than minimizing destruction. Their success rates however are highly variable. 
A pilot study aiming to assess the safety and potential efficacy of an 
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alternative biomaterial, cross-linked collagen in two different physical formats, 
was presented. In the short-medium term, both formats were shown to be 
safe, and equally effective. The results justify continued research into the use 
of biologically derived materials to heal anal fistulas. 
In conclusion, although disparate pathologies were addressed, both they and 
the thesis are unified by demonstrating that an understanding of the specific 
disease pathology, wound healing, and the host response to materials 
(synthetic and biological) are central to their successful management. 
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1.1 Background 
1.1.1 History of biomaterials 
Conventionally biomaterials have been defined as substances other than 
drugs or foods contained in therapeutic or diagnostic systems that are in 
contact with tissue or biological fluids1. Throughout history, materials have 
played an important role in the treatment of disease: historians have traced 
sutures back 32,000 years, and metals such as gold were used in dentistry 
over 2000 years ago2;3. However, most early medical implants were doomed 
to failure because important concepts relating to infection, materials and the 
host reaction to materials were not yet established. It is only since the advent 
of synthetic polymers at the end of the nineteenth century, that the use of 
biomaterials in health care has soared. For example, polymethylmethacrylate 
(PMMA) was used in dentistry in the 1930s and cellulose acetate was used in 
dialysis tubing in the 1940s. Dacron was used to make vascular grafts; 
polyether-urethanes were used in artificial hearts; PMMA and stainless steel 
were used in total hip replacements4. Currently, biomaterials as initially 
defined are used in almost every branch of medicine. They are used in many 
pharmaceutical preparations (such as coatings for tablets or capsules, or as 
components of transdermal patches), they play a central role in extracorporeal 
devices (from contact lens to kidney dialysers), and are used extensively 
throughout all the surgical specialities, including cardiovascular surgery 
(prosthetic valves, vascular grafts, pacemakers and stents), plastic and 
reconstructive surgery (breast augmentation or reconstruction), orthopaedics 
(joint prostheses and fracture fixation), neurosurgery (cochlear implants and 
17 
 
hydrocephalus shunts) and general surgery (sutures, staples, tissue 
adhesives and meshes for hernia repair)1. 
An appreciation of the host response to these implanted synthetic materials is 
an important step to understanding the need to develop more biocompatible 
materials that will assist, rather than be the focus of, the normal physiological 
healing response. 
 
1.1.2 The healing response 
 
1.1.2.1 The normal healing response  
 
This is a complex and dynamic process of restoring cellular structures and 
tissue layers. Tissue injury initially results in haemorrhage, and subsequent 
vasoconstriction, after which four distinct phases can be identified: 
haemostasis, inflammation, proliferation, and remodelling5. 
 
1.1.2.1.1 Haemostasis  
 
Following vasoconstriction, platelets adhere to damaged endothelium and 
discharge adenosine diphosphate (ADP), promoting thrombocyte clumping, 
which dams the wound6. The inflammatory phase is initiated by the release of 
numerous cytokines by platelets. Alpha granules liberate platelet-derived 
growth factor (PDGF), platelet factor IV, and transforming growth factor beta 
(TGF-ß), while vasoactive amines such as histamine and serotonin are 
released from dense bodies found in thrombocytes7. PDGF is chemotactic for 
fibroblasts and along with TGF-ß is a potent modulator of fibroblastic mitosis, 
leading to prolific collagen fibril construction in later phases8. Fibrinogen is 
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cleaved into fibrin and the framework for completion of the coagulation 
process is formed. Fibrin provides the structural support for cellular 
constituents of inflammation. This process starts immediately after the insult 
and may continue for a few days8;9. 
 
1.1.2.1.2 Inflammation  
 
Within the first 6-8 hours, the next phase of healing commences, with 
polymorphonuclear leucocytes (PMNs) predominating6. TGF-ß facilitates PMN 
migration from surrounding blood vessels, from which they extrude 
themselves. These cells “cleanse” the wound via phagocytocytosis. The 
PMNs attain maximal numbers in 24-48 hours and commence their departure 
by 72 hours6;9. Other chemotactic agents released include: fibroblastic growth 
factor (FGF), transforming growth factors (TGF-ß and TGF-a), PDGF, and 
plasma-activated complements C3a and C5a (anaphylactic toxins). These are 
sequestered by macrophages or interred within the scab or eschar10. 
As the process continues, monocytes also exude from the vessels, 
differentiating into macrophages. These continue the cleansing process, and 
manufacture crucial growth factors (TGFs, cytokines and interleukin-1 (IL-1), 
tumor necrosis factor (TNF), and PDGF) during days 3-411. The macrophages 
orchestrate the multiplication of endothelial cells and subsequent 
neovascularisation, the duplication of smooth muscle cells (myofibroblasts), 
and in conjunction with recruited fibroblasts create a suitable wound milieu for 
repair12.  
 
19 
 
1.1.2.1.3 Granulation  
 
This phase can be subdivided into fibroplasia, matrix deposition, angiogenesis 
and re-epithelialization, which constitute an overall and ongoing process 
lasting up to 4 weeks in the clean and uncontaminated wound5. On days 5-7, 
fibroblasts migrate into the wound, laying down neo-collagen of the subtypes I 
and III. Early in normal wound healing, type III collagen predominates but is 
later replaced by type I collagen. The wound is also suffused with 
glycosaminoglycans (including include heparan sulfate, hyaluronic acid, 
chondroitin sulfate, keratan sulfate, and proteoglycans – glycosaminoglycans 
covalently bonded to a protein core, contributing to matrix deposition) and 
fibronectin produced by fibroblasts13.  
Angiogenesis is the product of parent vessel offshoots. The formation of new 
vasculature requires extracellular matrix and basement membrane 
degradation followed by migration, mitosis, and maturation of endothelial cells. 
Basic FGF and vascular endothelial growth factor are believed to modulate 
angiogenesis14.  
Re-epithelization occurs with the migration of cells from the periphery of the 
wound and adnexal structures. This process commences with the spreading 
of cells within 24 hours. Division of peripheral cells occurs in hours 48-72, 
resulting in a thin epithelial cell layer, which bridges the wound. Epidermal 
growth factors are believed to play a key role in this aspect of wound 
healing9;11.  
1.1.2.1.4 Remodelling  
 
After the third week, the wound undergoes constant alterations, known as 
remodelling, which can last for years after the initial injury occurred9. Collagen 
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is degraded and deposited in equilibrium, resulting in no change in the 
amount of collagen present in the wound. The collagen deposition in normal 
wound healing reaches a peak by the third week after the wound is created. 
Contraction of the wound is an ongoing process resulting in part from the 
proliferation of the specialized fibroblasts termed myofibroblasts, which 
resemble contractile smooth muscle cells9;12.  
The culmination of these biological processes can result in the complete 
restoration of tissue architecture, however in most cases granulation tissue is 
remodelled into fibroblastic mediated scar tissue. 
 
1.1.2.1.5 Biological response to traditional biomaterials 
 
Synthetic biomaterials tend to result in the formation and organisation of 
granulation tissue with subsequent fibrosis, often succeeded by the 
development of a fibrous capsule at the tissue/ material interface15.  
The initial event upon implantation of the biomaterial is non-specific protein 
adsorption, known as the Vroman effect16. Many proteins adsorb to the 
surface in a range of conformations from native to denatured. However, non-
specific protein adsorption never occurs in the normal physiological process of 
wound healing, and therefore may be an instigator in the response seen. A 
number of key inflammatory cells (monocytes, macrophages, leucocytes and 
platelets) adhere to the biomaterial surface, and as a result may lead to the 
up-regulation of various cytokines and subsequent pro-inflammatory 
processes3. Additionally, biomaterials are not generally phagocytosed, due to 
size disparity between the material and the attached cell, which can lead to 
„frustrated phagocytosis‟. These persistent physical and chemical 
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inflammatory stimuli lead to a chronic inflammatory response, characterised 
by the predominance of macrophages. This response essentially involves two 
processes: the extracellular release of various proteases in an attempt to 
degrade the material, and is specifically dependant on the size of the implant 
(e.g. a material in a phagocytosable form , powder or particulate, may provoke 
a degree of inflammatory response different from that of the same material in 
a non-phagocytosable form, such as a sheet); and the fusion of the frustrated 
macrophages to form multi-nucleated foreign body giant cells that often 
persist for the lifetime of the implant15;17. The end-stage of the foreign body 
reaction involves the walling off of the implant by an avascular, collagenous 
fibrous tissue that is typically 50-200 µm thick3. 
 
Traditional biomaterials therefore initiate an unplanned stochastic biological 
response. Chronic inflammation, contracture of implants, and the formation of 
a surrounding fibrous capsule can lead to implant failure, chronic pain and the 
development of specific site complications. Thus, although traditional synthetic 
biomaterials have played a crucial role in the management of a variety of 
medical disorders, there is a substantial role for improvement, and this should 
be based on the knowledge of the biology of wound healing and inflammation, 
and the crucial role of the extracellular matrix in these mechanisms. 
 
1.1.3 Tissue engineering and the extracellular matrix 
In recent years, the definition of biomaterials has been broadened to include 
materials composed of biologically derived components irrespective of their 
application4. An area where this has recently had an impact is in tissue 
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engineering and regenerative medicine, whereby materials composed of 
naturally occurring extracellular matrix (ECM) components are being studied 
for applications such as direct tissue repair, regeneration and specific de novo 
tissue or organ production. 
The ECM is a vital dynamic and indispensable component of all tissues and 
organs and is the native scaffold for tissue and organ morphogenesis, 
maintenance, and reconstruction following injury18. 
Up until the last two decades it was generally accepted that the ECM was 
simply an inert scaffold stabilizing the physical structure of tissues; a tissue 
component that interconnected (functionally important) tissues, hence the 
term connective tissue, the cement or glue between the elements that really 
mattered. However it is now accepted that the ECM is actually a dynamic 
„virtual information highway‟: dynamic, as it is subject to constant renewal, 
serves a crucial architectural role during foetal development and tissue repair, 
and is interactive. Adjacent parenchymal cells deposit matrix molecules, which 
simultaneously provide cues that modulate the functional activity of these 
cells19;20.   
The ECM is a complex mixture of structural and functional proteins arranged 
in a unique, tissue specific three-dimensional ultrastructure21. At this 
ultrastructural level, it is composed of two domains, the interstitial matrix and 
the basement membrane. The latter is a condensed matrix layer that is 
formed adjacent to epithelial cells, other covering cell sheets (e.g. 
mesothelium), muscle cells, and adipocytes. The main characteristic these 
two domains have in common is that a collagen scaffold defines their basic 
structure, although the collagens that make up the scaffold are quite different, 
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as are their three-dimensional architecture. Adhesive glycoproteins, including 
laminin and tenascin, and proteoglycans (via their side-chain 
glycosaminoglycans) adhere to the scaffold and interact with the cells in or 
adjacent to the matrix20. These proteins collectively serve many functions 
including the provision of structural support and tensile strength, and act as a 
reservoir for growth factors (such as fibroblast growth factor, vascular 
endothelial growth factor and epidermal growth factor) and cytokines that 
modulate such diverse host processes as angiogenesis, cell migration, cell 
proliferation and orientation, inflammation, immune responsiveness and 
wound healing18;22;23. The extracellular matrix is not static: it is remodelled 
constantly, which implies constant breakdown by proteases, notably the family 
of matrix metalloproteases20;24. Furthermore, the composition and structure of 
the ECM are a function of their location within tissues and organs, the age of 
the host, and the physiological requirements of the particular tissue18. The 
ECM interacts with surrounding cells by efficiently presenting various 
signalling factors, via matrix receptors (of which the integrins constitute the 
most important class), to attachment sites for cell surface receptors. The ECM 
also protects these factors from degradation and modulates their synthesis. In 
this manner, the ECM affects local concentrations and biologic activity of 
growth factors and cytokines21;25.  
These intertwined structural and biological properties of the ECM have led to 
attempts to translate this interactive scaffold into a therapeutic use for tissue 
repair and reinforcement.  
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1.1.4 The collagen scaffold 
Collagen is the most abundant, ubiquitous and well-characterised protein 
within the ECM19. It is responsible for maintaining the structural integrity of 
organisms across both the animal and plant kingdoms26. More than 20 distinct 
types of collagen have been identified, although the most prevalent form 
found in mammalian tissues is type I collagen, of which allogenic and 
xenogeneic sources have been long recognised as effective biologic scaffolds 
for tissue repair with low antigenic potential18;25. 
Type I collagen occurs throughout the body, except in cartilage. It is the 
principle collagen in dermis, fascia and tendons and is a major component of 
mature scar tissue. Type II collagen occurs in cartilage, the developing cornea 
and in the vitreous body of the eye20. Type III collagen is predominant within 
immature scar tissue and the wall of blood vessels, intestines and the urinary 
bladder, where non rigid structure is demanded for appropriate function. Type 
IV collagen is present within the basement membrane of all vascular 
structures and is an important ligand for endothelial cells25. Some collagens 
associate with fibril surfaces, such as subtype VII, which is the principal 
component anchoring fibrils of keratinocytes to the underlying basement 
membrane of the epidermis, and others such as subtype VI connect 
glycosaminoglycans to type I collagen, helping to maintain a gel-like 
consistency to the ECM18. 
Collagens are mostly synthesized by proliferating cells within the ECM, such 
as fibroblasts, myofibroblasts, osteoblasts and chondrocytes. Some collagens 
are also synthesized by adjacent parenchymal or covering (epithelial, 
endothelial or mesothelial) cells. The production of specific collagen sub-types 
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is not only influenced by cell type, but also by the impact of both systemic and 
local factors on these cells, including the role of growth factors, inflammatory 
mediators and mechanotransduction on cell signalling and receptor 
mechanisms27. Alpha chains containing up to 1000 amino acids are 
converted, within the endoplasmic reticulum, into rod-shaped molecules of 
procollagen. In an early crucial step, with molecular oxygen as the substrate 
and vitamin C as the essential co-factor, proline and lysine are hydroxylated 
into hydroxyproline and hydroxylysine, which form interchain hydrogen bonds 
that stabilise the triple-stranded helix of procollagen28. Extracellularly, in 
tissues that have to resist shear, tensile or pressure forces (such as fascia, 
tendons, bone cartilage and skin) the procollagen terminal peptides are 
cleaved, by specific procollagen metalloproteases, and following the formation 
of strong covalent bonds between lysine and hydroxylysine residues, the 
collagen is arranged in parallel bundles of fibrils approximately 300nm in 
length and 1.5nm wide with a characteristic 67nm axial cross-striation20.  
Senescent or damaged collagen fibres are degraded and replaced in a 
continuous controlled process of remodelling. Some matrix metalloproteases 
(MMPs) and serine proteases are perceived to specifically degrade collagen, 
and these are characterised as collagenases24;28. MMP activity is controlled at 
least at 3 levels: transcription, proteolytic activation, and inhibition of the active 
enzyme by tissue inhibitors of metalloproteases (TIMPs)24. Of the main 
collagenases, fibroblast collagenase (MMP-1) plays a distinctive role in 
eliminating defective procollagens during the formation of new collagen fibres, 
whereas neutrophil collagenases (MMP-8, MMP-9) are secreted during the 
inflammatory phase of wound healing28. 
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The diversity of collagens and their unique roles within the ECM exemplifies 
the benefits of employing these biomolecular components as tissue repair 
materials. Perhaps more importantly it indicates a potential role for utilising 
materials composed of specific collagen sub-types, which are therefore 
tailored both to the nature of repair required and the anatomical location of the 
defect. 
 
1.1.5 Selected clinical applications of biomaterials 
The field of biomaterials has been essential to the development of surgery, 
allowing for the expansion of existing treatments and the creation of new 
techniques. Surgeons are uniquely positioned to contribute to the ongoing 
development and clinical application of biomaterials, but material selection 
must be based on an understanding of the materials available and their basic 
properties29. Two clinical conditions that have traditionally benefited from the 
therapeutic application of biomaterials are parastomal hernia and anal fistula. 
Current therapies in the management of these conditions have utilised 
synthetic materials and materials that use selected biomolecular components 
of the ECM but to date they have had limited success. The aim of this thesis 
was to identify novel applications of both traditional and contemporary 
biomaterials in the management of these conditions based on an 
understanding of the specific biochemical and mechanical properties required 
to optimise successful tissue repair. 
 
27 
 
1.2 Parastomal Hernia 
1.2.1 Introduction 
„Some degree of herniation around a stoma is so common that this 
complication may be regarded as inevitable‟30 
Goligher, 1984 
A parastomal hernia is an incisional hernia related to an abdominal wall 
stoma31; that is, the protusion of any organ (or part thereof), other than the 
intended stoma, through an abdominal wall trephine created for the sole 
purpose of stoma formation. Parastomal herniation is considered to be an 
inevitable complication of stoma formation32, and their management is a 
common clinical dilemma, as once established they are notoriously difficult to 
treat33-35. 
A stoma is a surgically created opening of the bowel or urinary tract to a body 
surface. Stomas are defined according to their purpose (defunctioning, usually 
temporary, loop stomas; and end or terminal, which are usually permanent) 
and the organ that they involve (e.g. colon, ileum, jejenum, ureter). Loop 
stomas are created to protect anastomoses or to divert luminal content from 
diseased segments of bowel (e.g. tumours or perianal fistulas). End stomas 
are usually created when the diseased segment of bowel cannot be salvaged. 
The thesis herein is concerned only with herniation following ileostomy and 
colostomy formation. 
Parastomal hernias can cause a wide spectrum of complications ranging from 
mild to life threatening. These include poor cosmesis, psychological distress, 
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parastomal discomfort or pain, difficulty with appliance application (resulting in 
leakage of contents and possible skin irritation), and obstructive episodes, 
ranging from intermittent symptoms to incarceration, strangulation, and 
necrosis31;36-38. The contents of the hernia sac may include omentum, small 
bowel, stomach and colon, and these will determine the nature of the 
symptoms37;39;40. 
 
1.2.2 Incidence 
Reported incidence rates vary widely depending on the type of stoma, length 
of follow-up and the mode of detection33;35. Parastomal hernias are usually 
diagnosed clinically, but where uncertainty exists (or as part of a study 
methodology) radiological imaging, in particular computer tomography, has a 
proven role, and those studies that employed imaging as part of their follow-
up protocol consistently reported higher herniation rates than those which 
used clinical examination alone41-43. Reported incidence rates for parastomal 
hernias range from 0 to 78%, increasing with the duration of follow-up33;35;41;42. 
Most will, however, develop within the first 12 months of formation, although 
the risk of herniation extends to the lifetime of the stoma44;45. In a recent 
review article, Carne et al detailed herniation rates for specific intestinal stoma 
types33, and these are summarised in Table 1.1. Interestingly, although loop 
stomas have the lowest rate of incidence, most likely on account of their 
predominantly temporary nature and therefore their comparatively shorter 
follow-up, they are considered more prone to herniation. This is because their 
construction requires a larger abdominal trephine compared with an end 
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stoma, which theoretically places them at greater risk of developing a 
parastomal hernia in the longer term44.  
 
Table 1.1.  Parastomal herniation rates for specific intestinal stoma types33 
 Rate of herniation  
(%) 
Length of follow up 
(months) 
End colostomy 4.0 – 48.1 35 – 120  
Loop colostomy 0 - 30.8 2 - 96 
End ileostomy 1.8 – 28.3 31 – 110 
Loop ileostomy 0 – 6.2 2 – 4 
 
 
1.2.3 Aetiology 
Parastomal hernia development is influenced by both patient and technical 
factors46. 
 
1.2.3.1 Patient factors 
These are considered, acting either alone or in conjunction with each other, to 
weaken the edges of the abdominal wall trephine or increase the pressure 
under which they are subjected, thereby precipitating hernia formation. They 
are similar to those that are thought to influence other types of abdominal wall 
hernias, and traditionally include: obesity, malnutrition, raised intra-abdominal 
pressure (secondary to chronic coughing, straining at micturition or 
defaecation, ascites, or heavy-lifting), corticosteroid use, malignancy, 
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increasing age, post-operative wound sepsis, and previous abdominal 
surgery31;46-49. However, the aetiological basis of these precipitants is based 
on expert opinion rather than scientific fact3. More recently, it has been 
proposed that disturbances in collagen metabolism contribute to recurrent and 
incisional hernias (which by definition include parastomal hernias)50 (Franz 
2008). These include a pathological shift of the collagen ratio within the 
healed wound, from “mature” type I collagen to “immature” type III collagen, 
and the over expression of matrix metalloproteases (MMP), both of which may 
result in a loss of tensile strength and predispose to hernia formation50-53. The 
increased incidence of hernias in those with mutations of the collagen gene, 
Col3A1, associated with familial arterial aneurysm and Ehlers Danlos 
syndromes types III and IV, implies that polyfactorial mutations in the coding 
sequences of collagen genes may be partly responsible50. Tobacco smoking 
has also been implicated, as it is a potent activator of the proteases (including 
elastase and collagenase) and decreases anti-protease activity, and led to 
one group defining abdominal wall hernias as „metastatic emphysema‟54. 
 
1.2.3.2 Technical factors  
Technical factors that are traditionally thought to influence herniation include: 
size of the abdominal wall trephine, trephine location, stoma fixation to the 
abdominal wall fascia, closure of the lateral space and whether constructed 
electively or as an emergency33. 
Various trephine sizes have been suggested, ranging from 1-2 fingerbreadths, 
to two-thirds the width of intestine intended for stoma formation, to a more 
precise 1.5 cm and 2 cm diameter ostomy site for colostomies and ileostomies 
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respectively55-57. It is difficult to determine any meaningful comparisons 
between these strategies as relevant studies are not controlled and numbers 
of participants and follow up are limited. One study, which retrospectively 
compared parastomal herniation to stoma size suggested that an aperture 
greater than 2cm is associated with an increased rate of hernia formation58. It 
has been calculated that the tangential force on the abdominal wall trephine is 
proportional to the radial force on the abdominal wall and the radius of the 
trephine59, meaning that obese patients (large abdominal wall radius) with 
large abdominal wall trephines (loop compared to end stomas, and 
colostomies compared to ileostomies) are at highest risk of herniation. At 
present, however, the best guide appears to be that one should create the 
smallest opening which allows the creation of a viable stoma without 
ischaemia33. 
Current accepted operative technique involves creating a trephine through the 
rectus abdominis muscle, preferably at a pre-marked skin site. However, in 6 
studies that specifically compared herniation rates between those stomas 
formed through the rectus abdominis muscle and those formed lateral to the 
muscle43-45;60-62, only one revealed any significant difference in parastomal 
herniation, in favour of the former technique61. There is no evidence to 
support the notion that fixation of the stoma to the abdominal wall fascia62, or 
that closure of the space lateral to the stoma reduces herniation33. Increased 
incidence of parastomal herniation in stomas created as an emergency has 
been proposed46, but this is not confirmed by the literature33. 
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1.2.4 Assessment  
Diagnosis is mostly by clinical examination35;46. A parastomal hernia should be 
considered present if there is any palpable defect or bulge adjacent to the 
stoma with the patient supine and legs elevated, or erect and coughing or 
straining35. In those patients whose symptoms are suggestive of a hernia, but 
in whom this cannot be clinically demonstrated, consideration should be given 
to radiological investigation43. To date, the preferred method of imaging is by 
computer tomography, which has been shown to significantly increase the 
diagnostic accuracy of parastomal hernia detection, as well as permitting pre-
operative classification43;63-65. 
 
1.2.5 Classification 
Parastomal hernias have been classified into 4 subtypes: subcutaneous, 
where the sac of the hernia lies in the subcutaneous tissues; interstitial, where 
the hernia sac lies within the abdominal wall layers; peristomal, with the bowel 
prolapsing through a circumferential hernia sac enclosing the stoma; and 
intrastomal, where in ileostomies, the hernia sac lies between the intestinal 
wall and everted intestinal layer47. However, there are no data attributing 
difference, in terms of symptoms or outcomes of repair, between the variously 
described subtypes, and as such the classification has not become widely 
used. Recently a new clinico-radiological classification system has been 
proposed which differentiates parastomal hernias according to the contents of 
the hernia sac, as well as the relationship between the hernia sac and the 
bowel forming the stoma42.  
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1.2.6 Management 
 
„A surgeon can do more for the community by operating on hernia cases and 
seeing his recurrence rate is low than he can by operating on cases of 
malignant disease.‟ 
Sir Cecil Wakely, 1948 
President, Royal College of Surgeons 
 
A proportion of parastomal hernias can be managed conservatively, with or 
without the use of a stoma supporting device. However, up to 70% of patients 
will require surgical repair for treatment of their associated symptoms33;35. The 
surgical techniques include local tissue repair, stoma relocation, and mesh 
repair. The former two procedures have largely been superseded by mesh 
repair, which has become widely accepted as the operation of choice given its 
perceived lower hernia recurrence rate, although interestingly, the only study 
which clearly, albeit retrospectively, compares the 3 techniques showed no 
significant difference in recurrence rates between them66. 
 
1.2.6.1 Non-mesh repair 
Local tissue repair involves simple suture closure of the edges of the 
abdominal wall trephine, lateral to the stoma, to close the defect through 
which the hernia passed. Reported recurrence rates range from 46-100%33;35, 
and as such certain authors state that use of this technique cannot be 
justified, unless all other strategies are contraindicated35. Stoma relocation to 
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a new position on the abdominal wall has a lower hernia recurrence rate than 
local tissue repair67, but nonetheless still ranges from 24 – 86%35. Relocation 
can be achieved with or without formal laparotomy68, the advantage of the 
latter being improved recovery time, less post-operative pain and avoidance of 
another site for potential herniation69. Relocation to the other side of the 
abdominal wall is associated with lower recurrence than ipsilateral 
relocation69;70, but regardless of technical considerations, incisional hernia 
formation at the original stoma site is also a concern, with reported rates 
ranging from 8-52%67;69.  
 
1.2.6.2 Mesh repair 
The proven advantages of mesh repair for other forms of abdominal wall 
hernias fuelled the development of a similar strategy for parastomal 
hernias71;72. First described in 197773, there are now over 70 reports in the 
literature on parastomal hernia mesh repair, with differing techniques 
described ranging from the ideal anatomical location to site the mesh (fascial 
onlay, preperitoneal or intraperitoneal)33;35, to mesh fixation and the type of 
mesh used (polytetrafluroethylene, polypropylene, polyvinylidene, composite 
or biological)73-81, to the surgical approach (open or laparoscopic)81-87 
employed. The multitude of techniques and meshes used is testament to the 
fact that hernia recurrence rates are still high (overall recurrence for all types 
of mesh repair is reported as 7.8%33) and additionally highlights the unique 
challenges imposed on surgeons by the complications associated with mesh 
implantation in close proximity to bowel. The majority of studies tend toward 
retrospective case series, often employing small numbers of patients with a 
35 
 
limited duration of follow-up, therefore there are currently little data to support 
the use of one technique or mesh type over another. One retrospective study, 
compared surgical approach (transabdominal versus parastomal), mesh 
placement (onlay versus sublay), and mesh type (polypropylene versus 
polytetrafluoroethylene, PTFE), and despite an overall hernia recurrence of 
63% (10 of 16 repairs), and wound infection rate of 11% (including 1 incidence 
of mesh erosion into bowel resulting in a colocutaneous fistula), none of the 
individual operative variants were deemed to be significantly associated with 
these outcomes88. 
 
1.2.6.2.1 Anatomical site 
The fascial onlay technique involves siting the mesh on the anterior layer of 
the rectus sheath; the pre-peritoneal or sublay position is in between the 
rectus abdominis muscle and the posterior layer of the rectus sheath/ 
peritoneum; and, intraperitoneal mesh placement involves attachment to the 
visceral surface of the peritoneum33;35 (Figure 1.1).  
 
 
1.2.6.2.1.1 Fascial onlay  
This was the first described parastomal hernia mesh repair technique73, and is 
still a commonly used approach80;86;89-93. It involves mobilization of the stoma 
at the mucocutaneous junction and suture repair of the fascial defect, followed 
by mesh placement. This technique requires the mesh to be securely 
anchored to the anterior rectus sheath, to avoid displacement secondary to 
raised intra abdominal pressures, and therefore requires extensive 
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mobilization of the surrounding tissue, increasing the risk of seroma formation 
and consequent mesh contamination35. Skin incision lateral to the stoma, 
aimed at lessening the risk of mesh contamination, has been described80;86;89, 
but has not been widely employed. Overall, the studies reporting on this 
technique are not randomised, and have a limited duration of follow-up (4 - 48 
months). Rates of recurrence and mesh related complications range from 0 – 
37.5% and 0 – 27.5% respectively (see Table 1.2). The 2 studies that 
employed biological mesh, in an attempt to reduce mesh related 
complications74;94, had similar rates of hernia recurrence to those studies 
which used synthetic mesh66;86, and although no specific mesh related 
complications were reported, the numbers involved are too small, and length 
of follow up too limited, to determine any benefit derived from their use. 
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Figure 1.1 Mesh positions for ventral hernia repair. (A) Onlay mesh, placed 
anterior to the anterior rectus aponeurosis. (B) Inlay mesh, of historical 
interest only, placed in the abdominal wall defect and sutured to wound 
edges. (C) Sublay mesh, placed dorsal to the rectus muscle and anterior to 
the posterior rectus sheath. (D) Intraperitoneal onlay mesh (IPOM), placed on 
peritoneum from within the abdominal cavity. This figure is a reprint from 
reference 6 (reproduced with permission by Elsevier). 
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Author Year No. of patients Mesh Follow-up 
(months) 
 
Recurrence (%) Other 
complications 
Rosin & Bonardi
73
 1977 7 Polypropylene 
(Marlex) 
4 – 48 0 0 
 
Abdu
95
 1982 4 Polypropylene 
(Marlex) 
48 0 1 wound infection 
 
Bayer et al
96
 1986 7 Polypropylene 
(Marlex) 
48 0 2 mesh infections 
 
Tekkis et al
80
 1999 5 Polypropylene 
(lateral approach) 
 
21 0 1 haematoma 
1 stomal prolapse 
Kald et al
86
 2001 3 Polypropylene 
(lateral approach) 
 
12 1 (33%) 0 
 
Amin et al
89
 2001 9 Polypropylene 
(lateral approach) 
 
6 0 0 
Venditti et al
97
 2001 8 Polypropylene 36 0 1 wound infection 
 
Reiger et al
66
 2004 18 Synthetic - ?type 44 7 (34%) 7 wound infections 
3 mesh infections 
2 bowel fistulas 
 
Kanellos et al
87
 2004 4 Polypropylene 
(lateral approach) 
36 0 1 skin necrosis 
 
 
Kish et al
94
 2005 3 Acellular dermal 
matrix (Alloderm) 
 
12 1 (33%) 0 
 
Aycock et al
74
 2007 8 Acellular dermal 
matrix (Alloderm) 
 
9 3 (37.5%) 2 wound infections 
Guzman-Valdivia et 
al
85
 
2008 25 Light-weight 
polypropylene 
12 2 (8%) 2 seromas 
2 wound infections 
 
Table 1.2 Published results for fascial onlay mesh repair of parastomal hernias. 
 
3
8
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1.2.6.2.1.2 Pre-peritoneal (sublay) 
This has been proposed as the most advantageous technique for mesh repair of 
parastomal hernias 35;98-100. Intra abdominal pressure will help secure rather than 
displace the mesh, as well as reduce the potential space for seroma accumulation, 
and the peritoneal layer keeps the amount of bowel to mesh contact to a minimum, 
thereby reducing the potential for mesh related complications35. The majority of 
published reports of this technique have described an open approach employing 
polypropylene mesh99;101-104, one of which was complicated by erosion of the mesh 
into an end colostomy101. One case report describes a laparoscopic approach (not 
dissimilar to the transabdominal pre-peritoneal (TAPP) inguinal hernia repair105;106), 
employing an expanded PTFE mesh, whereby a peritoneal flap was used to protect 
the bowel107, with no recurrence at 12 months. The pre-peritoneal technique is 
associated with a recurrence rate of 0 - 2% at up to 5 years follow up99;102;104 (see 
Table 1.3).  
 
 
Table 1.3 Published results for pre-peritoneal (sublay) mesh repair of parastomal 
hernias  
 
Author Year No. of 
patients 
Mesh Follow-up 
(months) 
 
Recurrence 
(%) 
Other 
complications 
Kasperk et 
al
99
 
2000 7 Light weight 
polypropylene 
 
4 - 36 2 0 
Egun et al
102
 2002 10 Polypropylene 54 (22 – 
69) 
0  2 seromas 
 2 wound 
infections 
 1 mesh 
erosion → 
colostomy 
 1 stoma 
infarction 
 
Longman & 
Thompson
104
 
 
2005 10 Polypropylene 30 (2 – 40) 0 0 
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1.2.6.2.1.3 Intra-peritoneal 
Both open75;108-111 and laparoscopic76;77;81;83;112-118 approaches have been described 
for the intra-peritoneal placement of mesh, and their comparative merits and 
complications, in regards to incisional hernias in general, have been discussed in 
meta-analyses119. In specific relation to parastomal hernias, overall recurrence rates 
for open surgery range from 0 – 29% at up to 7 years, and for laparoscopy 0 – 73% 
at up to 6 years. The majority of the reported open and laparoscopic techniques 
have differed in regard to the type of mesh employed, relationship of the mesh to 
stoma, and mesh fixation techniques. Unfortunately, it is impossible to determine 
from the literature any meaningful comparisons between these strategies as yet 
again almost all the reports are retrospective case series of small numbers, with 
mostly limited follow-up (see Table 1.4). Of the mesh application techniques, the two 
most commonly described include: the „Sugarbaker‟ intraperitoneal onlay (IPOM) or 
„non-slit‟ technique, and the „keyhole‟ or „slit‟ method. The former involves fixing the 
colon to the lateral abdominal wall, then covering the abdominal wall aperture 
(through which the stoma still passes) and lateralised colon with mesh, thereby 
creating a flap valve around the stoma110; the latter simply involves passing the 
stoma through an opening in the mesh111. One surgical group has reported the use 
of a combined „sandwich‟ technique, whereby the bowel is brought through a „slit‟ in 
one mesh, followed by an onlay placement of a larger mesh that lateralises the 
stoma loop76. The proposed benefits of the IPOM are that the structural integrity of 
the mesh is not compromised, unlike that observed when the mesh is „slit‟59, and by 
creating an oblique tunnel (akin to the inguinal canal), „direct‟ herniation through a 
mesh aperture can be avoided; a number of authors have reported comparatively 
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low recurrence rates with this method83;114;116. Nonetheless, this technique can lead 
to a novel form of bowel obstruction, in which the stoma loop (as it is lateralised on 
the abdominal wall) is extrinsically stenosed by the edge of the mesh 76;83;114; the risk 
of this occurrence is partly related to the tightness of the mesh fixation technique 
around the lateralised bowel and the acuteness of its resultant angulation. 
Additionally, the technique (and tightness) of mesh fixation must strike a balance 
between extrinsic bowel compression and the potential for a loop of bowel to 
„indirectly‟ herniate between the mesh and abdominal wall. Mesh fixation techniques 
include tacking the mesh to the dorsal layers of the anterior abdominal wall alone, or 
in combination with transfascial sutures or suturing the mesh to bowel serosa112;115; a 
recent review article found no difference in reherniation or other complication rates 
between the methods of fixation120. Another potential concern of the IPOM technique 
is that more mesh is in contact with the bowel than with the „keyhole‟ technique, 
increasing the risk of mesh-related complications, although to date this has not been 
borne out by the literature. The overall mesh-related complication rate ranges from 0 
– 28%, and examples include mesh infection, bowel obstruction secondary to mesh-
related adhesions and enterocutaneous fistula formation83;108;111;112;115. Attempts to 
reduce this have resulted in a number of different synthetic (including polypropylene, 
expanded PTFE and polyvinylidene fluoride, PVDF) and biological materials 
(acellular cross-linked porcine dermal collagen, Permacol®, and acellular porcine 
small intestinal submucosa, Surgisis®) being employed, although no appreciable 
difference in outcome can yet be specifically attributed to any one of them. 
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Table 1.4 Published results for intraperitoneal mesh repair of parastomal hernias 
 
Author Year Surgical 
approach 
No. of 
patients 
Mesh Mesh to 
stoma 
relation 
 
Mesh 
fixation 
Follow-up 
(months) 
 
Recurrence (%) Other 
complications 
Sugarbaker
110
 1985 Open 7 Polypropylene Non-slit ? 48 - 84 0 ? 
 
Morris-Stiff
108
 1998 Open 7 Polypropylene Slit ? 81 2 (29%)  1 bowel 
obstruction 
2
o
     mesh 
related 
adhesions 
 1 mesh 
infection 
 
Voitk
118
 2000 Laparoscopic 4 Polypropylene ? ? 2 - 12 0 0 
 
Kozlowski et 
al
113
 
2001 Laparoscopic 4 ePTFE ? ? 2 – 33 0 0 
 
 
Safadi
117
 2004 Laparoscopic 9 ePTFE Slit Transfascial 
sutures & 
tacks 
 
6 - 33 4 (44%)  1 stoma 
prolapse 
 
 
Stelzner et 
al
109
 
2004 Open 20 ePTFE Non-slit Transfascial 
& peritoneal 
sutures 
 
3 -84 3 (15%)  1 seroma 
 1 wound 
infection 
Van Sprundel 
et al
111
 
2005 Open 16 ePTFE Slit Transfascial 
& peritoneal 
sutures 
 
5 - 52 1 (6%)  1 stoma 
prolapse 
 1 hernia 
between 
mesh & 
abdominal 
wall 
 1 E/C fistula 
 
 
4
2
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Author Year Surgical 
approach 
No. of 
patients 
Mesh Mesh to 
stoma 
relation 
 
Mesh fixation Follow-up 
(months) 
 
Recurrence 
(%) 
Other 
complications 
LeBlanc et 
al
114
 
2005 Laparoscopic 12 ePTFE 5 slit† 
 
7 non-slit 
Transfascial 
sutures & tacks 
 
3 – 39 1 (20%) 
 
0 
 1 seroma 
 
 1 bowel 
obstruction
‡
 
 
Ballas et al
75
 2006 Open 2 ePTFE Slit Peritoneal 
sutures 
24 – 60 0 0 
 
 
Hansson et 
al
112
 
2007 Laparoscopic 
 
Converted to 
open 
47 
 
8 
ePTFE Slit Peritoneal  &  
bowel serosal 
sutures 
2 0 
 
1 (12.5%) 
 1 epigastric 
artery bleed 
 1 bowel 
enterotomy 
 1 mesh 
infection 
 chronic 
seromas 
 
Mancini et al 
115
 
2007 Laparoscopic 25 ePTFE Non-slit  Transfascial 
& bowel 
serosal 
sutures 
 
 Tacks 
 
2 – 38 1 (4%)  1 wound 
infection 
 1 mesh 
infection 
Inan et al
79
 2007 Laparoscopic 2 Porcine 
dermal 
collagen 
(Permacol™) 
 
? ? 3 – 9 0 0 
Muysoms et 
al 
116
 
2008 Laparoscopic 24 ? 11 slit 
 
13 non-slit 
 
? Mean 31 
 
Mean 14 
8 (73%) 
 
2 (15%) 
? 
 
? 
 
4
3
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Author Year Surgical 
approach 
No. of 
patients 
Mesh Mesh to 
stoma 
relation 
 
Mesh 
fixation 
Follow-up 
(months) 
 
Recurrence 
(%) 
Other 
complications 
Craft et al
83
 2008 Laparoscopic 21 ePTFE 5 slit 
 
16 non-slit 
Transfascial 
sutures & 
tacks 
 
3 -36 1 (20%) 
 
0 
 2 mesh 
infections 
 1 wound 
infection 
 2 bowel 
obstructions
‡
 
 
Zacharakis 
et al
81
 
2008 Laparoscopic 4 ePTFE Slit ? Median 9 1 (25%) 0 
 
 
Berger & 
Bientzle
76
 
2008 Laparoscopic 47 PVDF „Sandwich‟ 
technique 
Transfascial 
sutures & 
tacks 
 
Median 20 1 (2%)  2 bowel 
obstructions
‡
 
 2 wound 
infections 
 
Franklin et 
al
77
 
2008 Laparoscopic 2 SIS Non-slit Transfascial 
sutures & 
tacks 
 
Mean 52 0 ? 
 
 
 
E/C  Enterocutaneous fistula 
ePTFE  Expanded polytetrafluoroethylene (Gore-Tex® DualMesh® Biomaterial) 
PVDF  Polyvinylidene fluoride (Dynamesh IPOM®) 
SIS  Porcine Small Intestinal Submucosa (Surgisis®) 
† 2 „slit‟ patches used. After encircling the stoma, the slit in the first mesh is suture closed; a second mesh, with slit on the opposite side, 
is placed over first mesh to provide coverage of the slit in initial mesh.  
‡   Angulation of colon secondary to „non-slit‟ technique, stenosed the bowel causing obstruction. 
* Sandwich technique employs 2 meshes: the first mesh has a slit, which is suture closed around the stoma; a second larger mesh, is 
placed over the first and the stoma loop is lateralised 
  
4
4
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1.2.6.2.1.4 Prevention of parastomal hernias 
Mesh repair of parastomal hernias has now become the gold standard105;106;121 
despite the lack of randomised controlled studies confirming its efficacy over non-
mesh repair techniques. In 2003, Carne et al calculated an overall hernia recurrence 
of 7.8% for mesh repairs, by pooling all published results in series containing more 
than 3 patients33, and this has since been cited in over 20 peer-reviewed publications 
on the subject. By adopting the same approach, the recurrence rate is currently 10% 
(42 recurrences in 415 mesh repairs) at up to 7 years, and recognition of this, in 
conjunction with the associated morbidity and economic concerns of a second 
procedure, has prompted certain surgeons to propose that prevention of parastomal 
hernias may be the best approach33;35;56. To date, 6 surgical groups have reported 
encouraging results regarding the prophylactic placement of mesh in an attempt to 
reduce the rate of parastomal herniation96;122-127 (see Table 1.5). The one 
randomised controlled trial employed a partially absorbable light-weight 
polypropylene mesh (Vypro®), and demonstrated a 5% incidence of parastomal 
hernia formation in the treatment (mesh enforced stoma) arm compared to an 
incidence of 50% in the control (conventional stoma) arm at 12 months. There were 
no reported mesh-related complications, and although the initial results show the 
potential of such a strategy, the trial was stopped before statistically pre-determined 
numbers needed to treat were achieved96;125. Additionally, although the herniation 
rate in the control arm may reflect the experience of some surgeons, it is high 
compared with published results33. The remaining studies are prospective122;123;127 
and retrospective96;98 case series, which employ either polypropylene (of variable 
weight and pore size; with or without vicryl)96;123;125-127 or PVDF122 mesh, sited in the 
fascial onlay96;123, pre-peritoneal98;125-127 or intra-peritoneal positions (the same 
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author combined results for open and laparoscopic approaches)122. The overall 
incidence of parastomal herniation ranges from 0 – 8% (2.2 % incidence, 3 hernias 
in 134 procedures, from pooled results) at up to 4 years, with a similar range for 
mesh-related complications. Despite the lack of uniformity in materials and surgical 
methods, to date the low incidence of parastomal hernias in these studies compared 
to that reported for conventional stomas makes a strong case for the prophylactic 
placement of mesh at the time of stoma formation. However, in view of the mesh-
related complications reported in both treatment and prevention studies, sufficiently 
powered randomised controlled trials, with long-term follow up, are needed to 
determine the best type of material and their most suitable anatomical location for 
this purpose34;127.  
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Table 1.5 Published results for prophylactic placement of mesh to prevent parastomal hernias 
 
†  Composite mesh (Vypro®): Polyglactin 910 (vicryl) and large-pore lightweight polypropylene 
‡  StomaMesh™: Polypropylene mesh with 2cm wide central ring prepared with lasercut technique 
*  PVDF (Dynamesh IPST®): Mesh structure warp-knitted by polyvinylidene fluoride, with polypropylene on parietal surface. Sheet structure 
with a central hole & funnel (2cm diameter)
Author Year Study 
design 
No. of 
patients 
Surgical 
approach 
Mesh Mesh 
position 
Follow-up 
(months) 
 
Incidence of 
parastomal 
hernia (%) 
 
Other 
complications 
Bayer et al
96
 1986 Retrospective 
case-series 
36 Open Polypropylene 
(Marlex) 
Fascial 
Onlay 
Up to 48 0  1 stoma 
stenosis 
→ mesh 
removed  
 4 wound 
infections 
 
Janes et 
al
125;126
 
2004 Prospective, 
randomised 
controlled 
 
21 mesh 
 
26  no mesh 
Open Composite 
(Vypro®)
†
 
 
Pre-
peritoneal 
12 1 (5%) 
 
13 (50%) 
0 
Israelsson
98
 2005 Retrospective 
case-series 
 
13 Open Composite 
(Vypro®)
†
 
 
Pre-
peritoneal 
3 – 25 0  1 wound 
infection 
Gogenur et 
al
123
 
2006 Prospective 
case-series 
24 Open Polypropylene 
(StomaMesh™)
‡
 
Fascial 
Onlay 
2 – 26 2 (8%)  2 meshes 
eroded 
through 
skin 
 
Marimuthu et 
al
127
 
2006 Prospective 
case-series 
18 Open Polypropylene 
(Surgipro™) 
 
Pre-
peritoneal 
6 – 28 0  1 wound 
infection 
Berger
122
 2008 Prospective 
case-series 
25 6 lap 
 
19 open 
 
PVDF 
(Dynamesh 
IPST®)* 
 
Intra-
peritoneal 
„keyhole‟ 
2 – 29 0 
 
0 
 
0 
 
4
7
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1.2.6.2.2 The ideal mesh 
The ideal material for the management of parastomal hernias should have adequate 
strength for the intended surgical application, degrade in parallel with appropriate 
tissue regeneration, and be capable of sterilization. It also should be non-
carcinogenic and relatively inert, causing minimal acute or chronic inflammation 
(biocompatibility)128-131. More specifically, and from a surgeons‟ perspective, it also 
should possess the following qualities128;132: 
 Surgeon friendly handling characteristics; 
 Resistance to bacterial colonisation and chronic infection; 
 Readily available at acceptable cost; 
 Promote parietal tissue in-growth, whilst preventing adhesion to bowel; 
 Avoidance of mesh contraction, fistula formation, chronic pain and seroma 
formation. 
Additionally, in those patients prone to hernias, likely secondary to deranged 
collagen metabolism50;51;53;133-135, then either a more permanent structure (rather 
than one that is completely replaced by host tissue) or one able to correct the 
balance of collagen metabolism will be required for their management128. 
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1.2.6.2.3 Mesh materials  
Currently there are more than 70 meshes available for hernia repair on the 
market132, which are either synthetic or derived from biological sources.  
 
1.2.6.2.3.1  Synthetic mesh 
Synthetic mesh can be permanent or absorbable.  
1.2.6.2.3.1.1 Permanent mesh 
Permanent mesh can be classified according to type of mesh, filament structure 
(monofilament and multifilament), composition and pore size136. They are 
manufactured from one of three basic prosthetic materials: monofilament 
polypropylene (PP), multifilament polyester (PE), and expanded 
polytetrafluoroethylene (ePTFE)132. Monofilament mesh offers the advantages of 
high tensile strength and resistance to bacterial attachment but at the expense of 
decreased pliability and conformity to the abdominal wall137. Multifilament mesh is 
relatively more pliable but is also more susceptible to bacterial infection138. Pore size 
can be described as macroporous (>75µm) or microporous (<75µm). Macroporous 
mesh allows greater tissue in-growth, and therefore improved biocompatibility but 
can also promote adhesiogenesis139;140, whereas microporous mesh tends to 
become encapsulated thereby causing less adhesions132, but is associated with 
higher rates of infection136. This is explained by the bacterial adhesion and 
penetration of the small pores that cannot be accessed by leucocytes, thus offering 
protection from immunological clearance132. 
The original synthetic meshes were made of a heavyweight woven macro-porous, 
monofilamentous polypropylene (Marlex®), or multi-filamentous polyester, 
polyethylene terephthalate (Dacron®)141;142. Manufacturers changed the weaves to a 
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knitted format following complaints of the ends of the mesh unravelling, and these 
now form some of the more commonly known meshes in use today, such as 
Prolene®, Surgipro® and Mersilene®137;143. They work by strengthening the 
abdominal wall by providing innate mechanical tension and by induction of a strong 
chronic inflammatory foreign body response144. This consequently results in mesh 
contraction (by 30–50%, usually within 4-weeks of implantation) and formation of an 
avascular fibrotic conglomerate with the potential for chronic pain and infection, 
bowel adhesions, visceral erosion, and fistula formation143;145;146. Lighter-weight 
macroporous designs (interwoven with absorbable vicryl (Vypro®), or monocryl 
(Ultrapro®), for improved handling) have been shown to reduce the degree of 
inflammatory response, thereby significantly improving (but not completely removing) 
the incidence of these complications, without compromising the strength of 
repair137;147. In view of the inflammatory response incited, despite the advent of more 
biocompatible formats, certain authors advise that surgeons remain wary of 
employing these materials in close proximity to bowel147. Alternatives include ePTFE, 
and composite meshes, which are composed of a polypropylene or polyester parietal 
layer and a relatively inert visceral surface. 
 
Expanded PTFE (Gore-Tex®, MycoMesh® and DualMesh®) is relatively inert and 
microporous, therefore, it tends not to instigate as vigorous an inflammatory 
response as polypropylene or become incorporated into host tissues148. Instead, 
ePTFE becomes encapsulated, which confers the advantage of minimizing intestinal 
adhesions, thus allowing for placement in close proximity to bowel149-151. However 
this benefit is off-set by a potentially weaker hernia repair and a higher prevalence of 
infective complications compared to all other mesh types143. Encapsulation and the 
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microporous character of ePTFE means antimicrobials and the host immune system 
have reduced accessibility to microorganisms152. Therefore, when ePTFE meshes 
become infected they must be removed, and as such their use cannot be 
recommended in contaminated or potentially contaminated fields 132;152;153. Attempts 
to improve tissue integration, by creating full-thickness pores (MycoMesh®) and 
roughening the parietal surface (DualMesh®), as well as the addition of an 
antimicrobial silver chlorhexidene film (DualMesh Plus®), have not yet been proven 
to reduce the incidence of the above stated concerns154. 
  
Composite meshes were developed in response to the increasing popularity of 
intraperitoneal placement of mesh for incisional hernia repair and its associated 
challenges. The manufacturers‟ aims were to produce a mesh with a visceral 
surface, which protects the bowel and avoids adhesion formation, and a parietal 
surface that promotes host tissue integration. Different strategies have been used to 
achieve this goal. Composix® (Bard) and Dynamesh® (FEG Textiltechnik) place 
polypropylene against the abdominal wall for strong in-growth, and PTFE or PVDF 
(polyvinylidene fluoride) respectively, toward the bowel to minimise adhesion 
formation. Proceed® (Ethicon) and SepraMesh® (Genzyme) also use polypropylene 
for strong incorporation to the abdominal wall but coat the material with a resorbable 
cellulose-based material. Similarly, Parietex Composite® (Sofradim) places a 
resorbable collagen-oxidised film onto a polyester mesh base.  The resorbable layer 
provides a temporary barrier between the mesh and viscera, which need to be 
protected for 7 – 14 days. Evidence suggests that adhesion formation to the bowel 
occurs in the first week after surgery, after which a neoperitoneum covers the mesh 
and provides long-term protection143;147;155. Studies have shown that despite the use 
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of these composite materials, adhesions and bowel-related complications still 
occur143;151;156. It is possible these are related to the mesh fixation technique and/ or 
differential in contraction between the inflammatory parietal and relatively inert 
visceral layers, which leads to a rolling of the mesh edges and thus exposure of the 
polypropylene or polyester to the bowel147. 
 
1.2.6.2.3.1.2 Absorbable mesh 
Absorbable meshes, such as those made of polyglactin 910 (Vicryl) and polyglycolic 
acid (Dexon), have the advantage of an improved host tissue response, low risk of 
chronic infection and avoidance of bowel related complications. Theoretically, they 
should provide acute support to the abdominal wall defect, followed by degradation 
in parallel with new fibro-connective tissue, which should take over the functional 
repair. However, long-term follow up data indicates that in terms of hernia 
recurrence, absorbable mesh repair has no benefit over simple suture repair152;157, 
and therefore when used alone, their role cannot be justified in the management of 
abdominal wall hernias.  
 
1.2.6.2.3.2 Biological mesh 
These are harvested from animals (xenogeneic), usually porcine or bovine sources, 
or humans (allogenic). They are rendered acellular via a variety of methods to 
provide a biocompatible scaffold for host cell population, vascularisation and 
eventually complete soft tissue repair. They can potentially therefore avoid acute and 
chronic mesh infection, or exaggerated host immune response and its sequelae, 
seen in response to permanent synthetic meshes. However, premature enzymatic 
degradation of the specific extracellular matrix (ECM) graft components can lead to 
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graft resorption before adequate tissue in-growth has occurred, and consequently 
rates of reherniation not dissimilar to those observed with absorbable synthetic 
grafts158-161. Methods of impeding the rate of resorption, such as chemical cross-
linkage, have been shown to significantly improve the rate of hernia 
recurrence159;161;162, although possibly at the expense of host tissue integration.  
 
Three commercially available biological tissue grafts have been used for ventral 
hernia repair, including parastomal hernias, of which two are biodegradable: porcine 
small intestinal submucosa (Surgisis®), and human cadaveric dermis (AlloDerm®); 
and one is cross-linked: porcine dermal collagen (Permacol®). To date, there have 
been no reports of disease transmission from any of these products to their 
recipients. 
 
1.2.6.2.3.2.1 Surgisis® (SIS) 
 
SIS consists of an acellular non-cross-linked ECM sheet, derived from porcine small 
intestinal mucosa. It is composed of over 90% collagen (in particular subtypes I, III 
and V), and 10% glycoproteins, proteoglycans, glycosaminoglycans and lipids163. 
Available as a 4 or 8-layer product, the latter (Surgisis Gold®) is recommended for 
abdominal wall repair128, on account of its greater mechanical strength than both the 
4-layer product and natural abdominal wall fascia164. Animal models have shown that 
when implanted into the abdominal wall SIS invokes a limited host inflammatory 
response, with evidence of graft neovascularisation (> 50% thickness of the implant 
at 8-weeks) and deposition of well-organised host connective tissue at 90 days128. In 
a rodent model, when compared to polypropylene, there was significantly less 
foreign-body response, consequently less adhesion formation, and collagen 
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deposition was better organised164-168. SIS is biodegradable, and crucial to its value 
as an abdominal wall repair material is its speed of degradation, the comparative 
rate of host remodelling and the quality and strength of the newly formed host tissue. 
Animal studies have shown that SIS is 25% histologically absent at 1 month, 
increasing to 100% absent at 4 months when used to repair abdominal wall defects 
in canine models164. In clinical studies, accelerated degradation has been reported 
when SIS is used to reconstruct abdominal wall defects in contaminated fields, which 
the authors hypothesized was responsible for early hernia recurrence169;170. 
Experimental studies have however shown that the infectivity of inoculated wounds 
implanted with SIS was significantly less compared with a permanent synthetic 
material at 28 days166. 
Although SIS has reportedly only been used in 2 patients with parastomal hernias77 
(no hernia recurrence at 2 years, see Table 1.4), there are a number of studies that 
have evaluated its usefulness for incisional hernia repair in clean, potentially 
contaminated and contaminated wounds 77;169-171. At up to 2½ years follow up, 
recurrence rates for clean and potentially contaminated wounds have been reported 
at up to 10%, and for contaminated wounds range from 30-50%. A relatively high 
rate of seroma formation and post-operative pain has also been reported 172, and this 
is because serous infiltrate accumulates between the laminated layers of SIS, 
thought to be related to the absence of pores and therefore limited capacity for fluid 
to flow through the material77;170. 
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1.2.6.2.3.2.2 AlloDerm® 
 
AlloDerm® is an acellular non-cross-linked allogenic tissue graft, derived from human 
cadaveric skin. As the manufacturers rely on donors, its availability is presumably 
relatively limited, and this is reflected in a cost price at least three times that of those 
biological grafts harvested from xenogeneic sources147. It is composed of a 
structurally intact vascular basement membrane, collagen fibres (subtypes I, III, IV 
and VII), elastin filaments, laminin and glycosaminoglycans128. Clinical and animal 
studies have shown that AlloDerm® does not induce a chronic inflammatory 
response or induce visceral adhesions, that in vivo full-thickness fibrovascular 
integration occurs by at least 8 months173;174, and that complete implant degradation 
can be prolonged (in a porcine model, implant constituents could be detected 9 
months after implantation)174. Experimental studies have shown that Alloderm® has 
no more intrinsic resistance to pathogens than Surgisis® or a number of synthetic 
meshes166;175. Clinically, AlloDerm® has been used to treat both parastomal and 
incisional ventral hernias, and notwithstanding the small number of patients, the 
varying anatomical sites of AlloDerm® implantation and the limited follow-up, the 
rates of hernia recurrence are up to 37% for parastomal hernia repair74;94 (see Table 
1.2) and up to 50% for infected or potentially infected incisional hernias176-178. When 
compared to synthetic mesh (PTFE or woven polyethylene), there was a higher 
incidence of mesh-related complications and hernia recurrence (4.5% vs 13%) in the 
synthetic mesh than AlloDerm® arms128. However, in comparison to Surgisis®, rates 
of recurrence were considerably higher in the AlloDerm® cohort (0% vs 24%) 172. 
Interestingly, unlike synthetic mesh which contracts over time, AlloDerm® thins out 
and stretches173;179, which may at least partly account for the relatively high 
incidence of hernia recurrence associated with its use. Authors have also reported  
56 
 
significant time-consuming effects of using AlloDerm®, as it is only available in small 
sheets and therefore has to be „quilted‟ to cover large defects128. 
 
1.2.6.2.3.2.3 Permacol® 
 
Permacol® is an acellular isocyanate cross-linked collagen sheet derived from 
porcine dermis. It is composed of over 90% type I collagen, with type III collagen and 
elastin fibres comprising the remainder. The implant contains naturally occurring 
pores, in the form of hair follicle remnants, which according to the manufacturer are 
254 - 654µm in diameter. The suitability of Permacol® to act as a bioconstruct for soft 
tissue reinforcement and repair has been investigated both in vitro and in animal 
models. In vitro studies have shown that Permacol® supports cell attachment, growth 
and stratification, does not inhibit cellular proliferation, and that the cross-linking 
confers resistance to collagenase degradation, albeit with a corresponding reduction 
in cellular infiltration180;181. When implanted into rats, Permacol® induced a mild 
chronic inflammatory response with no evidence of significant fibrosis, and cellular 
infiltration and neovascularization limited to its peripheries and native pores182-186. In 
contrast to polypropylene, comparative studies in animal models have demonstrated 
that Permacol® has better tissue compatibility, with less intraperitoneal adhesion 
formation, more orderly collagen deposition and comparable tensile strength at the 
interface between the implant and host tissue, at 90 days after implantation182;183. 
Interestingly, two animal studies have compared Permacol® and Surgisis®, and 
although they showed no difference in the degree of host chronic inflammation or 
adhesion formation185;187, Surgisis® demonstrated a significantly greater degree of 
fibrovascular integration and collagen deposition at 9 weeks187, although there was 
no difference at 20 weeks185. Experimental hernia models comparing Permacol® and 
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Alloderm® demonstrated no significant differences in adhesion formation, or cellular 
in-growth and neovascularisation at 3 months, but at 6 months whereas Permacol® 
continued to provide a robust repair, Alloderm® had lost tensile strength and was 
associated with hernia-like bulging179. 
To date, there is only one published case report on the use of Permacol® to repair 
parastomal hernias79 (see Table 1.4), however a comprehensive Medline search 
(combining the keywords: Permacol®, collagen, ventral, incisional and hernia; and 
limited to English language papers) identified 11 articles reporting the clinical use of 
Permacol® to repair anterior abdominal wall defects in general (See Table 1.6). Two 
of these reported the use of Permacol® to close the abdominal wall in paediatric 
renal transplant recipients, to avoid compartment syndrome, and therefore any 
inferences drawn in regards to adult hernia repair or prevention are limited188;189. 
Hernia recurrence in the remaining studies, all of which were performed (with the 
exception of 2 cases190) in clean-contaminated or contaminated wounds, ranges 
from 0 – 15% at up to 18-months follow up (overall incidence 7.2%; 10 recurrent 
hernias in 137 repairs). The other mesh related complications included 1 mesh 
infection requiring its removal and an overall incidence of 7.2% chronic seroma 
formation.  
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Table 1.6 Published results of Permacol® mesh repair of anterior abdominal wall defects   
Author Year Study Design No. of patients Wound Type Follow-up 
(months) 
 
Recurrence (%) Other 
complications 
Adedeji et al
191
 2002 Case-report 1  Clean-
contaminated 
 
12 0 Nil 
Verey et al
192
 2004 Retrospective 
case- series 
10  2 
contaminated 
 8  clean-
contaminated 
 
2 – 11 0  2 wound 
infections 
 1 removal of 
implant 2
o
 
adhesions 
 
Richards et al
189
 2005 Retrospective 
case- series 
 
3  Clean 18 0 Nil 
Cobb & 
Shaffer
193
 
2005 Retrospective 
case- series 
 
60  5 
contaminated 
 56  clean-
contaminated 
 
Mean 14 4 (6.6%) 
 
 2 wound 
infections 
 2 chronic 
seromas 
Liyanage et al
194
 2006 Case-report 1  Clean-
contaminated 
 
12 0  Seroma 
 Superficial 
wound 
dehiscence 
 
Parker et al
190
 2006 Retrospective 
case- series 
 
9  2 clean 
 2  clean-
contaminated 
 5 
contaminated 
Median 18 0  1 mesh 
sepsis→ 
removal of 
mesh 
 1 superficial 
wound 
dehiscence 
 
Saettele et al
195
 2007 Case-report 1  Contaminated 12 0  Chronic 
seroma 
 
 
5
8
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Author Year Study Design No. of patients Wound Type Follow-up 
(months) 
 
Recurrence (%) Other 
complications 
Catena et al
196
 2007 Prospective 
case-series 
 
7  Contaminated Mean 11 0 Nil 
Shaikh et al
197
 2007 Retrospective 
case- series 
 
20  Clean-
contaminated 
 
Median 18 3 (15%)  2 seromas 
 2 wound 
infections 
 superficial 
wound 
dehiscence 
 
Pentlow et al
188
 2008 Retrospective 
case- series 
 
5  Clean Up to 36 1 (20%)  1 superficial 
wound 
dehiscence 
Hsu et al
198
 2008 Retrospective 
case- series 
 
28  Clean-
contaminated 
 
Mean 16 3 (10.7%)  1 superficial 
wound 
dehiscence 
 1 wound 
infection 
 seromas 
 
  
 
5
9
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1.2.7 Conclusion 
In contrast to published data relating to conventional synthetic implants, there have 
been no reported complications related to the proximity of these biological implants 
to the bowel. These benefits, in conjunction with the perceived merits of cross-
linkage for biologically derived materials, and the aforementioned advantages of 
siting mesh at the time of stoma formation, led to the development of a prospective 
randomised controlled phase 1 study to assess the role of Permacol® in the 
prevention of parastomal hernias (presented in chapter 2). Histological analyses of 
explanted implant specimens further permitted evaluation of the in vivo human 
response to its presence.  
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1.3 Anal fistula 
 
1.3.1 Introduction 
 
„Probably more reputations have been damaged by unsuccessful treatment of cases 
of fistula than by excision of the rectum or gastroenterostomy‟ 
Lockhart-Mummery, 1929 
 
The majority of anal fistula cases can be managed without complication, but a 
significant minority can present a major challenge to both patient and surgeon. The 
difficulty in managing this subset of patients was recorded by Hippocrates in 460 BC, 
and is further emphasized by reports from the middle ages of clinicians whose 
primary function was to treat anal fistula, and the highest surgical fee in history being 
paid for treating the fistula of Louis XIV.  
 
Anal fistulas are chronic pathological connections between the anal canal and the 
skin of the perineum or buttocks, often passing through the anal sphincter complex 
(responsible for maintaining continence to rectal contents, including gas, liquid and 
solid stool). They are subject to either persistent discharge or recurrent episodes of 
pain and swelling (abscess formation), eased by either spontaneous drainage of pus 
or repeated hospital admissions for surgical drainage. Difficulties in their 
management are bestowed by their unique anatomical relationship to the anal 
sphincters. To date the most successful management strategy for the treatment of 
fistulas involves surgically dividing the tissue enclosed by the fistula tract; however 
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division of those sphincter muscle fibres enclosed renders the patient at risk of faecal 
incontinence.  
 
Anal fistulas may be found in association with a variety of specific conditions, but the 
majority (>90%) seen in the U.K. are classified as non-specific, cryptoglandular or 
idiopathic, their exact aetiology having never been fully proven, although the 
diseased anal gland in the intersphincteric space is deemed central199. Anal fistulas 
may be seen in association with Crohn‟s disease200, tuberculosis201, pilonidal 
disease, hydradentitis suppurativa202, malignancy203, trauma and foreign bodies204. 
The work herein is concerned only with the non-specific form of fistula unless 
otherwise stated. 
 
1.3.2 Epidemiology  
Current knowledge of the exact incidence of idiopathic anal fistulas in the general 
population is scarce. However, the most accurate data is from northern Europe, 
which indicates an incidence of 8.6-10/ 100,000 population per year205;206, and more 
recently from a study that analysed the incidence of fistula-in-ano (although not 
specifically of idiopathic aetiology) in four countries of the European Union (England, 
Spain, Italy and Germany), and reported an incidence of 1.2-2.8/ 10,000 inhabitants 
per year207. Nearly all reported series have shown a male predominance, the male to 
female ratio being between 2:1 and 4:1199. This may partly be explained by the 
finding that males have more intramuscular anal glands, the presumed aetiological 
source, than females (1.4:1), and that these are more frequently ramifying and are of 
a more cystic nature, all of which are factors that might make individuals more 
susceptible to infection208. However this is disputed by McColl who found no sex 
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differences in histology or distribution of anal glands in 50 normal human canals209. 
Furthermore, no differences in circulating sex hormones between patients, and age 
and sex-matched controls have been demonstrated210. 
Anal fistulas most commonly afflict people in their third to fifth decade208;211;212. There 
has been no association found between sedentary occupations, poor personal 
hygiene or perianal perspiration and the role of bowel habit is unclear. Diarrhoea and 
constipation have been implicated in the aetiology, in that loose stool may allow the 
easier passage of pathogens to the anal glands213, and hard stool may have a 
similar effect secondary to anal canal abrasions214, but neither theory has been 
substantiated. 
 
1.3.3 Aetiology 
An appreciation of the anatomy of the anal canal is crucial to understanding both the 
cryptoglandular hypothesis215, the most widely accepted (albeit never absolutely 
proven) theory on anal fistula pathogenesis, and its necessarily diverse 
management. 
 
1.3.3.1 Anatomy of the anal canal 
The anal canal in adults is approximately 4cm long and begins as the rectum 
narrows, passing backwards between the levator ani (pelvic floor) muscles, and 
ending at the anal verge216;217. The proximal canal is lined by simple columnar 
(mucosal) epithelium, which changes to stratified squamous epithelium lower in the 
canal via an intermediate transition zone just above the dentate line218. The dentate 
line represents the site of anal valves, embryological remnants of the developing 
foetal hindgut219. Deep to the mucosa lies the subepithelial tissue, composed of 
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connective tissue and smooth muscle217. This forms the basis of the vascular 
haemorrhoidal cushions, which are important in the maintenance of continence220;221. 
Lateral to the subepithelial layer the caudal continuation of the circular smooth 
muscle of the rectum forms the internal anal sphincter218, which terminates at a 
variable distance from the anal verge, with a well-defined border. Continuous with 
the outer layer of the rectum, the conjoint longitudinal muscle of the anal canal lies 
between the internal and external anal sphincters in the intersphincteric space. The 
conjoint longitudinal muscle comprises smooth muscle cells from the rectal wall, 
augmented with striated muscle from a variety of sources, including the levator ani, 
puborectalis and pubococcygeus muscles of the pelvic floor. Fibres from this layer 
traverse the intersphincteric space and both internal and external sphincters, 
inserting distally into the perianal skin, medially to the anal canal mucosa, and fascia 
laterally at the pelvic side walls, to form a complex supporting meshwork of septa, 
which anchors the sphincter complex in place. The striated muscle of the external 
sphincter surrounds the conjoint longitudinal muscle, forming the outer border of the 
intersphincteric space, and terminates subcutaneously below the caudal limit of the 
internal anal sphincter222. Collectively, the internal and external sphincters, and the 
interposed conjoint longitudinal muscle fibres, are termed the anal sphincter 
complex. Lateral to the external sphincter is the ischiorectal fossa, which is 
composed almost entirely of relatively avascular loose areolar tissue, and is 
contained anterosuperiorly by the sloping roof of the levator ani muscle, 
posteroinferiorly by the skin of the buttock, and further laterally by the ischial 
tuberosity of the pelvis (see Figure 1.2). 
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Anal glands sit in both the submucosal and intersphincteric spaces, with those 
situated in the intersphincteric space constituting one to two-thirds of their total209. 
The anal gland ducts traverse the internal sphincter to open into the anal canal 
lumen, via crypts situated above the anal valves (see Figure 1.3). The function of the 
anal glands is uncertain, although they have been shown to secrete mucin223. The 
anal glands in the intersphincteric space are central to the cryptoglandular 
hypothesis of anal fistula formation.  
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Figure 1.2 Anatomy of anal sphincter complex. (A) Anal canal mucosa. 
(B) Submucosal space. (C) Internal anal sphincter (IAS). (D) Conjoint 
longitudinal muscle fibres, seen transversing the internal and external 
anal sphincters. (E) External anal sphincter (EAS), terminating 
subcutaneously below the caudal limit of the IAS. (F) Ischiorectal fossa. 
This figure is a reprint from reference 250 (reproduced with permission 
by Mark Allen Healthcare Ltd). 
A B C D E F 
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Figure 1.3 Anatomy of intersphincteric anal gland. The anal gland duct can be 
seen to traverse the internal sphincter to open into the anal canal lumen, via 
crypts situated at the dentate line. Picture provided courtesy of Peter J Lunniss, 
Senior Lecturer & Honorary Consultant in Coloproctology. 
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1.3.3.2 Cryptoglandular hypothesis 
Parks hypothesised that intersphincteric gland dilatation, congenital or acquired, was 
a precursor to mucin accumulation, which was consequently prone to infection from 
ascending enteric bacteria via the openings of the anal ducts215. The infected 
intersphincteric gland is unable to drain spontaneously back into the anal canal, 
because of inflammatory obstruction of its connecting duct across the internal 
sphincter224, and thus spreads along planes of least resistance, following the fibres 
of the conjoint longitudinal muscle, and usually emerges at the skin as an abscess. 
Parks further proposed that should the initial abscess in relation to the 
intersphincteric anal gland subside, the diseased gland might become the seat of 
chronic infection with subsequent fistula formation215. The fistula is thus a granulation 
tissue-lined track maintained by the infecting source, which is the chronically infected 
anal gland deep to the internal anal sphincter.  
The only studies that have employed microbiology in testing the cryptoglandular 
hypothesis have been unable to demonstrate an abundance of organisms in the 
intersphincteric space of established fistulas225;226. However, it has been shown that 
persistence of anal fistulas, in a similar fashion to those found at other body sites, 
may at least be partly due to the in growth of epithelium from either or both ends of 
the track227. 
The spread of sepsis from an acutely infected anal gland may occur in the vertical, 
horizontal or circumferential planes. Caudal spread in the vertical (intersphincteric) 
plane is the commonest way by which infection disseminates, and presents as a 
perianal abscess, arising at the anal verge. Cephalad spread will result in an 
intermuscular or supralevator pararectal abscess. Horizontal spread across the 
external sphincter will enter the ischiorectal fossa. Caudal spread in this plane will 
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lead to an ischiorectal abscess, terminating at the skin of the buttock; upward spread 
may penetrate the levator ani muscle to reach the supralevator pararectal space 
(see Figure 1.4). Circumferential spread may occur in any of the intersphincteric, 
extrasphincteric or supralevator planes, in a horse-shoe configuration, with one or 
more openings onto the ipsilateral or contralateral skin of the perineum or 
buttocks199. 
 
 
1.3.4 Management  
Traditionally, the initial management of acute anal sepsis is by simple incision and 
drainage of the abscess, and further discussion is not within the remit of this thesis. 
In contrast, the management of chronic anal fistulas is necessarily more diverse, and 
depends upon accurate anatomical knowledge of the fistula‟s course through the 
anal sphincter complex. Failure to appreciate the importance of this relationship may 
result in fistula recurrence, incontinence or catastrophically both. Classification of the 
pathology is therefore of the up most importance, as it will guide surgical 
management. 
 
1.3.4.1 Classification 
The most comprehensive, practical and widely used classification is that devised by 
St. Mark‟s Hospital. It is based on the cryptoglandular hypothesis, and the 
relationship of the primary fistula track to the external sphincter228. Four main groups 
exist: intersphincteric, transsphincteric, suprasphincteric and extrasphincteric (see 
Figure 1.4). These groups can be further subdivided according to the presence and 
course of any extensions or secondary tracks.  
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Intersphincteric fistulas (45%) are usually simple tracks (uncomplicated fistulas 
consisting only of the primary track) passing down through the intersphincteric space 
to the perianal skin; but others may have a high blind track, a secondary high 
opening into the rectum or no perianal opening, or even a high pelvic extension.  
Transsphincteric fistulas (30%) cross the external sphincter to pass through the 
ischiorectal fossa to reach the skin of the buttocks. They may be subdivided into 
„high‟, „mid‟ or „low‟ dependant on where the track crosses the external sphincter into 
the ischiorectal fossa: above, at the level of, or below the dentate line respectively. 
This may not be at the same level the track crosses the internal sphincter.  Fistulas 
may be simple or have a blind high track terminating above or below the levator ani 
muscles.  
Suprasphincteric fistulas (20%) run up the intersphincteric space to a level beyond 
the puborectalis and then curl over it through the levator ani and into the ischiorectal 
fossa to reach the skin. An argument exists as to whether suprasphincteric tracks 
can be part of this classification, as some believe that they are iatrogenic as opposed 
to cryptoglandular in nature.  
Extrasphincteric fistulas (5%) are not of cryptoglandular pathology. They run without 
relation to the sphincters and are classified according to their pathogenesis.  
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Figure 1.4 Classification of anal fistulas. (A) Submucosal fistula. (B) 
Intersphincteric fistula. (C) Transsphincteric fistula. (D) Suprasphincteric 
fistula. (E) Extrasphincteric fistula. This figure is a reprint from reference 250 
(reproduced with permission by Mark Allen Healthcare Ltd). 
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1.3.4.2 Assessment 
1.3.4.2.1 Clinical 
A full history and examination including proctosigmoidoscopy are essential in all 
cases to assist in determining the aetiology of the fistula. Clinical assessment 
involves five essential points229: location of the internal opening, location of the 
external opening, the course of the primary track, the presence of any secondary 
extensions, and the presence of other diseases complicating the fistula. 
Digital assessment of the primary track, by an experienced coloproctologist, in the 
conscious patient has been shown to be 85% accurate230. It is further complimented 
by examination under anaesthesia (EUA), during which a probe can be utilised to 
delineate the primary track. If not initially evident, the instillation of dilute hydrogen 
peroxide via the external opening has been advocated as the best agent to identify 
the internal opening231.  
 
1.3.4.2.2 Imaging 
Although careful examination under anaesthetic is the most important part of any 
assessment, previous surgery can lead to scarring and deformity, and complex 
fistulas with multiple secondary tracks make clinical assessment difficult230. In such 
situations, there is a need for further methods of assessing fistulas and their 
relationship to the sphincters. Two modalities of imaging have to date proven their 
usefulness: anal endosonography and magnetic resonance imaging. 
Anal endosonography (AES) is safe, simple to perform and relatively inexpensive. 
Although initial results indicated a high degree of accuracy in delineating the 
intrasphincteric component of anal fistulas232, later studies showed the technique not 
to be any more accurate than careful digital examination under anaesthesia230. 
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Furthermore, its limited focal range can result in a low positive predicative value in 
the demonstration of extensions beyond the external sphincter, and thus evaluation 
of sepsis within the ischiorectal and supralevator spaces, which limits its usefulness 
when dealing with complex fistulas233. More recent studies however have shown it to 
be superior to clinical evaluation234, and demonstrate good concordance with 
operative findings235;236. Currently, however its main role is in assessing the 
sphincter complex, specifically in determining internal and external anal sphincter 
integrity, prior to planning fistula surgery.  
 
Magnetic resonance imaging (MRI) is considered the gold standard in anal fistula 
imaging237, and a number of studies have now confirmed that the technique 
challenges operative assessment by an experienced coloproctologist234;238. Its 
advantages include the lack of ionising radiation, the ability to image in any plane 
and the high soft tissue resolution239. Short tau inversion recovery (STIR) (a fat 
suppression technique) sequencing, to highlight the presence of pus and granulation 
tissue without the need for any contrast media, has a concordance with operative 
findings of 86% for the presence and course of the primary track, and a positive 
predicative value of 100% in demonstrating secondary extensions and abscesses, 
which if missed at surgery would result in fistula recurrence199;237. Dynamic contrast-
enhanced MR using intravenous gadolinium chelates has been further shown to 
increase track conspicuity, particularly when fat saturation or subtraction is 
employed240;241. MRI has also been shown to predict recurrence following 
treatment242;243. 
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1.3.4.2.3 Physiological 
Continence may be regarded as a balance between rectal pressure and the power of 
the sphincters to overcome this, orchestrated by anorectal sensation199. Anorectal 
physiological studies provide measurements of the sphincteric pressures generated 
along the canal. The internal anal sphincter, made of smooth muscle and not under 
voluntary control, contributes 60-85% of resting anal pressure244-246. Damage to this 
muscle can result in symptoms of passive anal leakage, including soiling of 
underwear, and flatus incontinence247. The external anal sphincter, under conscious 
control, contributes to the maintenance of resting pressure, and in association with 
the puborectalis muscle generates squeeze pressure, the loss of which causes 
symptoms of urgency (reduced ability to retain rectal contents) and frank faecal 
incontinence (inability to retain rectal contents)247. 
Complete division of the puborectalis sling in extrasphincteric and suprasphincteric 
fistulas would result in total incontinence to all rectal contents. Below this level the 
term incontinence becomes relative, dependant more on subjective values of the 
patient (and its impact on individual quality of life) than on objective measurements 
obtained in a physiology laboratory199. However, it is reasonable to assume that the 
higher the level at which the primary track crosses the sphincter complex (ie. the 
more sphincter tissue enclosed by the fistula), the greater the possibility of impaired 
function after surgical division; and the weaker the sphincters before surgical 
intervention, the greater the likelihood of such morbidity248. Preoperative anorectal 
physiology assessment can be used to identify patients at risk of incontinence249, 
and thus guide surgical treatment, but it does not necessarily predict postoperative 
physiological or functional outcomes250.  
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Traditionally, fistula surgeons have apportioned more importance to the preservation 
of the external than the internal sphincter, for the purpose of maintaining continence, 
and it is still believed amongst many surgeons that division of the internal sphincter, 
to eradicate the presumed aetiological source (the diseased anal gland in the 
intersphincteric space), is essential to prevent fistula recurrence. However, it is 
important to realise that division of the internal anal sphincter, as in fistulotomy for 
intersphincteric fistulas, may not only result in diminished resting pressures, but may 
also impact on squeeze pressures in the most distal part of the sphincter complex, 
on account of the subcutaneous external anal sphincter lying below the caudal limit 
of the internal anal sphincter.  
In a prospective study comparing internal sphincter division alone with both internal 
and external sphincter division250, as part of treatment for intersphincteric and 
transsphincteric fistulas respectively, there was no difference, 53% versus 50%, in 
the incidence of functional disturbance between the two groups in the short-term. 
Furthermore, although there were significant differences in pre- and post-operative 
incontinence scores in both groups, there was no difference between the groups. 
Thus, the importance of the internal sphincter in maintenance of continence should 
not be underestimated. However, although this study revealed a relatively high 
incidence of functional disturbance, the majority of patients were satisfied with their 
outcome as a reasonable price to pay to be rid of chronic anal sepsis. Nevertheless, 
the functional consequences of surgically laying open fistulas justifies continued 
attempts at methods that preserve sphincter integrity and function199. 
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1.3.4.2.4 Treatment options 
The management of anal fistulas has traditionally been purely surgical. A wide range 
of surgical techniques have been developed, as none are universally effective at 
achieving the dual aims of permanent fistula eradication and the preservation of 
sphincteric function. At one end of the spectrum is fistula eradication, best achieved 
by fistulotomy, and at the other, preservation of function, with no attempt at complete 
eradication of the fistula, but rather palliation of symptoms, using a loose drainage 
seton. Various strategies have been adopted that lie between these two extremes, 
which can be divided between those that still divide the sphincters, but attempt to 
minimise the functional consequences, including the therapeutic use of setons, and 
those which attempt to preserve sphincteric function, such as the use of 
advancement flaps and more recently, modern biomaterials that can act as a 
scaffold for tissue repair. Unfortunately, it is virtually impossible from the literature to 
determine any meaningful comparisons between strategies as: patient demographics 
(including previous obstetric history, fistula or other anal surgery) are either 
inadequately reported or vary considerably; results are often not reported relative to 
the specific type of fistula aetiology or classification, and interpretation of fistula 
classification may vary (one surgeon‟s „high fistula‟ is another‟s „low fistula‟); reports 
of success tend not to be equalled by reporting of failures or functional disturbance; 
and most reports contain inadequate follow-up. Additionally, in such a field of 
surgery, the use of prospective randomised controlled trials is difficult due to the 
heterogeneity of fistula anatomy, individual surgeon treatment preference, and the 
ethical difficulties of comparing treatment strategies in which functional outcomes 
may be markedly different. 
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Nonetheless, it is well recognised that critical to the success of all techniques in the 
management of anal fistulas are the elimination of acute sepsis and the eradication 
of any secondary fistulous extensions251. More recently, it has further been proposed 
that failure to adequately remove all granulation or epithelial tissue lining the fistulous 
tract, affects fibroblast and endothelial cell migration, and possibly in conjunction with 
inadequate removal of the presumed source (the diseased intersphincteric anal 
gland),  will inhibit healing252;253. 
 
 
1.3.4.2.4.1 Sphincter dividing techniques 
1.3.4.2.4.1.1 Fistulotomy 
This technique, dating back at least to the 14th century254, involves surgically dividing 
the tissue enclosed by the fistula tract and allowing the wound to heal by secondary 
intention. To date it has proven to be the most effective way of eradicating the fistula, 
but through division of the enclosed sphincter muscle fibres, renders the patient at 
risk of continence disturbance, with reported rates ranging from 5-40%255. 
Fistulotomy is thus usually reserved for those patients in whom the consequences of 
sphincter division are anticipated to result in minimal functional disturbance, for 
example, „low‟ fistulas, traditionally interpreted as intersphincteric and 
transsphincteric tracks, the latter involving < 30% of the external sphincter, but not 
anteriorly in women256. Additionally, it is suitable for those patients, preferably with 
good pre-operative function and strong anal sphincters, who are prepared to risk 
continence to be rid of their symptoms.   
Marsupialisation (suturing the divided wound edges to the edges of the fistula track) 
and immediate reconstruction of the divided muscle have been described in attempts 
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to improve wound healing and continence disturbance respectively. They have both 
achieved good results in comparison to conventional fistulotomy257-260. A pooling of 
results from studies which have compared radiofrequency compared to conventional 
fistulotomy have not revealed significant improvements in recurrence or incontinence 
scores, although there were benefits in terms of post-operative pain and healing 
times261-263. 
 
1.3.4.2.4.1.2 Staged fistulotomy 
An alternative treatment for „higher‟ fistulas is a two-stage fistulotomy, in which 
initially part of the sphincter beneath the primary track is divided, and a loose seton 
placed across the remaining sphincter. This aims to reduce the consequences of 
sphincter division at a single stage by allowing fibrosis in the area of division and 
therefore theoretically reducing retraction of that muscle divided at the second stage. 
At least three series have reported good fistula eradication rates using this 
technique, but the functional consequences (when reported) are variable, and it is 
difficult to draw meaningful comparisons between the studies due to the 
heterogeneity of the fistulas, the amount and level (proximal or distal) of sphincter 
divided at the first stage, the seton material employed and the varying length of 
follow-up264-266. 
More recently, at St. Mark‟s Hospital the loose seton has been used with the aim of 
entire external sphincter preservation in transsphincteric fistulas267. The internal 
sphincter is divided up to the level of the internal opening (thereby removing the 
infecting source, the chronically inflamed anal gland in the intersphincteric space) 
and the external sphincter is enclosed within a loose seton. This is removed once all 
the wounds have healed satisfactorily (this occurs in about 60% of patients), to allow 
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spontaneous healing of the remaining tract. However, this technique has two 
drawbacks: the functional consequences of internal sphincter division; and that in a 
retrospective analysis covering two time periods, although there was an 
approximately 50% healing rate in the short term, in the longer-term, as 
demonstrated by a report of the same patients 8 years later, only 3 of 14 contactable 
patients remained healed268. 
 
1.3.4.2.4.1.3 The tight seton 
The tight or cutting seton is a classic example of a traditionally termed biomaterial, 
and one that has been used in the surgical management of anal fistulas since the 
time of Hippocrates, who recorded the use of a horse hair thread, tightened 
intermittently „until the enclosed flesh was eaten through‟ 269. The rationale of the 
technique is similar to that of the staged fistulotomy, in that the sphincter complex is 
gradually severed, by repeated tightening or replacement of the seton, followed by 
fibrosis which supposedly prevents the divided muscle springing apart.  
Table 1.7 summarises the published results of the cutting seton technique in the 
management of anal fistulas. Direct comparisons of the published data are difficult 
due to heterogeneity of fistula aetiology and anatomy, whether the first stage 
incorporated internal sphincterotomy, the seton material employed (Penrose drain270, 
stainless steel271,  rubber band or elastic equivalent272-278, braided synthetic 
suture279;280, silk281-283, prolene284 and nylon285 sutures, and plastic cable ties286;287), 
interval and frequency of tightenings, the time taken for the seton to cut through the 
encircled tissue, and the varying lengths of follow-up. Nonetheless, nearly all the 
studies reported successful eradication of anal fistulas using this method, although 
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the majority had unacceptable rates of both frequency and severity of anal 
incontinence270;273-275;277-279;281-285;288-290. 
The rates of incontinence associated with the conventional cutting seton are likely to 
be proportional to the speed of sphincter division. In 1986, Christensen reported a 
series of 24 patients with high transsphincteric fistulas in whom the seton was 
tightened every second day, resulting in a 62% incontinence rate, with 29% of 
patients requiring regular use of pads288. Ten years later, Goldberg reported a series 
of 13 patients, in whom the seton was tightened every second week, rather than 
every second day, and in that series only one patient suffered major incontinence, 
although 54% suffered minor incontinence274. Additionally, the technique is 
associated with considerable patient discomfort and there is the need for repeated 
replacement/ tightening of the cutting material.  
There are clearly areas of modification to the cutting seton technique, which can be 
employed to take advantage of its excellent fistula eradication rates whilst reducing 
continence disturbance, the requirement for repeat tightenings and patient 
discomfort. These modifications to a traditionally defined biomaterial and the results 
of its application are described in a retrospective study in chapter 3. 
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Table 1.7 Results in published studies of cutting setons for the treatment of anal fistula.  
Author Year Study type n Aetiology Anatomical 
Classification 
Surgical 
IAS 
division 
Seton 
Material 
Time to 
cut 
through, 
weeks 
(range) 
Recurrence 
(%) 
Incontinence 
(%) 
 
Duration 
of follow-
up, 
months 
(range) 
 
Culp
270
 1984 Retrospective 16 Cryptoglandular SS No Elastic 
(Penrose  
drain) 
 
Mean 2 0 Minor 15 
Major 0 
> 24 
Christensen et 
al
288
 
1986 Retrospective 21 Cryptoglandular High TS No NS  Median 1  
(<1-14) 
0 Minor 29 
Major 33 
Median 96 
(24-168) 
 
Misra et 
Kapur
271
 
1988 Retrospective 56 Cryptoglandular Low fistulas: 
IS/ low TS/ 
submucosal 
(48) 
High TS (8) 
 
NS Braided 
stainless 
steel 
NS 3.5 0 NS 
Ustynoski et 
al
277
 
1990 Retrospective 11 Cryptoglandular TS Yes Rubber 
band 
Mean 7  
(2-17) 
18 NS Mean 48  
(8-144) 
 
Williams et 
al
278
 
1991 Retrospective 13 Non-Crohn‟s NS Yes Elastic 
band 
Median 16 
(8-36) 
 
0 Minor 54 
Major 7 
Median 24 
(4-60) 
 
Graf et al
279
 1995 Retrospective 29 Cryptoglandular 
(25) 
IBD (4) 
High TS Yes Mersilene 
0/0 
(braided 
polyester) 
 
> 4 8 
 
25 
Minor 44 
 
Minor 100 
 
Mean 46  
(3-94) 
McCourtney et 
Finlay
283
 
1996 Retrospective 27 Cryptoglandular 
(22) 
Crohn‟s (4) 
Hydradentis 
suppurativa, HS 
(1) 
IS (1) 
TS (16) 
SS (5) 
RVF (5) 
No Silk 1/0 Median 20  
(4-76) 
 
4 (HS patient) Minor 7 
Major 4 
 
>12 
Goldberg et 
Garcia-
Aguilar
274
 
 
1996 Retrospective 13 Cryptoglandular TS Yes Rubber 
band 
Mean 16  
(8-36) 
0 Minor 54 
Major 7  
 
Median 24  
(4-60) 
 
8
1
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Author Year Study type n Aetiology Anatomical 
Classification 
Surgical 
IAS 
division 
Seton 
Material 
Time to 
cut 
through, 
weeks 
(range) 
Recurrence 
(%) 
Incontinence 
(%) 
 
Duration 
of follow-
up, 
months 
(range) 
 
Hamalainen 
et Sainio
280
 
1997 Retrospective 35 NS High TS (25) 
Low TS (5) 
SS (2) 
ES (3) 
NS 0/0 Non-
absorbable 
braided 
suture 
Mean 12.5  
(3-26) 
6 Minor: 
64 High TS 
40 Low TS 
100 SS 
67 ES 
 
Major NS 
 
Mean 70 
(28-184) 
Dziki et  
Bartos
273
 
1998 Retrospective 32 NS High TS (21) 
SS (4) 
ES (7) 
Yes Rubber 
band 
Mean 3  
(< 
5.5months) 
0 Minor: 
52 High TS 
100 SS & ES 
 
Major: 
9.5 High TS 
50 SS 
28.5 ES 
 
Mean 16  
(4-22) 
Hasegawa et 
al
289
(abstract) 
2000 Retrospective 28 Cryptoglandular TS (>80%) NS NS NS 29 Minor 25 
Major 11 
 
NS 
Isbister et al 
Sanea
282
 
2001 Retrospective 47 Cryptoglandular High TS (16) 
Low TS (31) 
No Silk 1/0 Mean 24 2 Minor 36 
Major 2 
 
Mean 13 
Joy  et 
Williams
275
  
2002 Retrospective 17 NS TS Yes Snug 
silastic 
Mean 20 6 Minor 50 
(5/10)* 
 
Major 20 
(5/10)* 
 
Mean 19  
(9-54) 
Durgan et 
al
281
  
2002 Prospective 
case series 
10 NS ES Yes (EAS 
also 
divided up 
to dentate 
line) 
 
Silk 1/0 NS 0 Minor 20 
Major 0 
3-108 
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Author Year Study type n Aetiology Anatomical 
Classification 
Surgical 
IAS 
division 
Seton 
Material 
Time to 
cut 
through, 
weeks 
(range) 
Recurrence 
(%) 
Incontinence 
(%) 
 
Duration 
of follow-
up, 
months 
(range) 
 
Theerapol 
et al
284
 
2002 Prospective 
case series 
41 NS NS No Prolene 
0/0 
Median 9  
(4-64) 
2.5 0 Median 4  
(<1-17) 
 
Zbar et al 
285
 
2003 Prospective, 
randomised: 
Seton via IAS 
only versus 
Seton via IAS 
& EAS 
 
34 Cryptoglandular High TS No  
 
Nylon 0/0 Mean: 
14 IAS 
only 
 
12 IAS & 
EAS 
 
11 IAS only 
 
7 IAS & 
EAS 
Minor: 
5.5 IAS only 
 
12.5 IAS & 
EAS 
 
Major 0 
 
Median: 
13 (6-30) 
IAS only 
 
12 (5-28) 
IAS & EAS 
Pescatori 
et al
290
 
2004 Retrospective 17 NS TS (n=?) 
ES (n=?) 
`Yes NS NS NS Minor 6 
Major 18 
Median 22  
(5-89) 
 
Mentes et 
al
276
 
2004 Retrospective 20 Cryptoglandular High TS (14) 
Anterior TS in 
females (6) 
No Elastic 
seton 
(created by 
cutting 2-
3mm strip 
from 
surgical 
glove) 
 
Mean 2.5  
(1.5-4) 
5 ↓ baseline 
continence in 
20%  
patients; no 
SD in pre & 
post op 
Wexner 
scores  
6- 24 
Vatansev 
et al
287
 
2007 Retrospective 32 No Crohn‟s High TS (17) 
SS (8) 
ES (7) 
No Nylon 
cable  tie 
(ratcheted 
for 
tightening) 
 
Mean 7.5 
 (6-10) 
0 Minor 15.5 
Major 0 
~ 26 
Gurer et 
al
286
 
2007 Retrospective  17 Cryptoglandular High TS (8) 
Low TS (4) 
SS (1) 
IS (4) 
No Nylon 
cable  tie 
(ratcheted 
for 
tightening) 
Mean 2.5 
(1-6.5) 
0 ?; no SD 
between 
fistula types 
in post-op 
Wexner 
scores† 
 
Mean 8  
(2-15) 
 
8
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Author Year Study type n Aetiology Anatomical 
Classification 
Surgical 
IAS 
division 
Seton 
Material 
Time to 
cut 
through, 
weeks 
(range) 
Recurrence 
(%) 
Incontinence 
(%) 
 
Duration 
of follow-
up, 
months 
(range) 
 
Chuang-
Wei et al
272 
2008 Retrospective 112 No Crohn‟s High TS or SS 
(84) 
ES (28) 
 
No Elastic 
band (from 
wrist of 
surgical 
glove) 
 
Mean 4 
(2.5-6) 
1(ES fistula) Minor 24 
Major 0 
Median 
38.6  
24-60) 
 
Abbreviations: IAS, internal anal sphincter; EAS, external anal sphincter; RVF, rectovaginal fistula; TS, transsphincteric; IS, intersphincteric; SS, 
suprasphincteric; ES, extrasphincteric; SD, significant difference; NS, not stated. 
*  Overall incontinence stated as 6% (1/17), however, continence disturbance as assessed by questionnaire (n=10) reveals 
tabulated result. 
†   No comparison between pre and postoperative continence scores performed. 
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1.3.4.2.4.1.4 The chemical seton 
An alternative to the traditional cutting seton, and one which has been used for many 
centuries in eastern parts of the world, is the so called chemical seton, or Kshara 
sutra. This seton is a thread dipped in multiple layers of agents derived from plants 
which, apart from endowing antibacterial and anti-inflammatory properties, impart an 
alkaline (approximate pH 9.5) caustic nature that essentially burns through the 
enclosed tissues at a rate of approximately 1cm every 6 days291;292. 
Two prospective randomised trials have compared the chemical seton with 
fistulotomy, and shown no differences in rates of incontinence or recurrence rates, 
but did reveal longer healing times (8 weeks versus 4 weeks) and worse patient 
discomfort293;294. Furthermore, the trial designs excluded all those with anything but 
low transsphincteric fistulas, so it is uncertain whether such a technique has a role 
for the more problematic higher fistula. 
 
1.3.4.2.4.2 Sphincter preserving techniques 
1.3.4.2.4.2.1 Fistulectomy 
Fistulectomy excises rather than incises the fistula track. However, when compared 
to fistulotomy, recurrences rates were similar and the time to healing was prolonged, 
secondary to excess tissue loss295. 
The core-out technique has been advocated on the following basis296: the precise 
course of the track can be more accurately determined than by imaging or probing, 
thereby avoiding the potential creation of false tracks; core out reduces the risk of 
missing secondary tracks, which are seen as transected granulation tissue and thus 
can also be excised; the relationship of the track to the sphincter complex can be 
more accurately ascertained; and, a complete specimen is available for histology297.  
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Core out and laying open the resultant tunnel was employed in 67 patients with low 
fistulas, resulting in one recurrence. In 32 patients, with high transsphincteric or 
suprasphincteric fistulas, treated by core-out and simple stitch closure, a temporary 
colostomy was raised in 4 patients, and 3 had recurrences297. Unfortunately, the 
functional consequences were not reported in either series, and in the case of 
recurrent or more complex fistulas the author recommended the adoption of 
alternate sphincter-conserving methods.  
More recently, the use of a new mechanical device, a “fistulectome”, has been 
described which cores-out an approximately 2mm circumferential thickness of the 
fistula tract298. Of 13 patients treated with this device, at a mean follow-up of 13 
months, there was one recurrence and two patients developed symptoms of 
continence disturbance, but unfortunately the fistulas were heterogeneous in terms 
of aetiology and classification and it is therefore unclear in which fistulas this device 
may have a potential role. 
 
1.3.4.2.4.2.2 The loose drainage seton 
The loose drainage seton can be used for different reasons in the management of 
anal fistulas248;278. A loosely tied thread can be used to drain sepsis, to allow 
subsidence of acute inflammation and either safer subsequent definitive surgery or 
as a long term palliative measure aimed at symptom control (by preventing the fistula 
track from occluding, and allowing sepsis to drain, thereby avoiding recurrent 
abscess formation). It can also be used as a marker to help determine the amount of 
muscle enclosed by the fistulous track, perhaps because scarring from previous 
surgery or relaxation under anaesthesia makes assessment difficult. In such 
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circumstances, the proportion of enclosed sphincter may be more accurately 
determined when the patient is awake and the track marked by the thread.  
 
1.3.4.2.4.2.3 Advancement flaps 
The use of advancement flaps to treat anal fistulas was first documented in 1912 by 
Elting299. He described two key principles: separation of the track from the 
communication with the bowel; and adequate closure of that communication with 
eradication of all diseased tissue in the anorectal wall. At later dates others have 
added adequate flap vascularity, formation of a tension free flap, anastomosis of the 
flap to a site well distal to previous internal opening, and resolution of any acute 
sepsis prior to definitive surgery300. Most surgeons agree that the flap should include 
part if not all of the underlying internal sphincter in order to maintain vascularity, but 
even when the internal anal sphincter is preserved, despite overall resting pressures 
being unchanged as a group, in certain individuals there is a profound drop in resting 
pressure300. Additionally, advancement flaps are contraindicated in the presence of 
large internal openings (>2.5cm), due to the risk of anastomotic breakdown, and a 
heavily scarred, indurated, woody perineum precludes adequate exposure and flap 
mobilisation199;301. 
Two literature reviews of the technique were published in 1998302 and 2008263. The 
earlier review included all relevant publications, whereas the latter only prospective 
randomised controlled studies of idiopathic fistulas. However it is again difficult to 
compare series, as there are so many variables such as: flap thickness (mucosal, 
mucosal and partial internal anal sphincter, or full thickness internal anal sphincter); 
flap shape and orientation (caudally or cranially based); whether the internal anal 
sphincter is divided concomitantly; and, how the extrasphincteric component is 
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treated. Nevertheless, overall the reported continence and recurrence rates are 
extremely impressive, although interestingly when specifically compared to 
fistulotomy alone303 or fistulotomy with sphincter reconstruction304 no significant 
differences were reported for either outcome. Furthermore, a report by 
Athanasiadis305, raises an important paradigm: in a series of 224 patients, in whom 
internal sphincterotomy was performed (to eradicate the presumed aetiological 
source), the eradication rate was 79%, although this was tempered by a 19% rate of 
significant anal incontinence; whereas in 55 patients in whom the internal sphincter 
was preserved there was only a 4% rate of soiling reported, although eradication 
rates were not stated. Therefore, it seems that, as with all traditional surgical 
management strategies, the successful eradication of fistulas and the maintenance 
of continence remain directly competing variables. 
 
1.3.4.2.4.2.4 Use of modern biomaterials 
Over the last 30 years, coloproctologists have increasingly looked towards the 
rapidly developing world of biologically derived materials and tissue engineering to 
provide a panacea for the treatment of anal fistulas: permanent fistula healing 
without sphincter compromise. Intuitively, the ideal biomaterial for this purpose 
should allow full host tissue incorporation and neovascularisation, whilst withstanding 
premature degradation and bacterial colonisation. To date, two novel materials have 
been used as part of sphincter preserving strategies for the treatment of anal fistulas: 
fibrin glue and lyophilised porcine-derived small intestinal submucosa (Surgisis® 
AFP™, anal fistula plug). 
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1.3.4.2.4.2.4.1 Fibrin glue 
Fibrin glue, the first modern biomaterial to be used in the management of anal 
fistulas, was initially received with great enthusiasm on account of its perceived 
benefits, in that the technique seemed simple to apply, repeatable (in that treatment 
failure did not compromise subsequent surgical options), it spared the anal sphincter 
mechanism, and avoided the prolonged discomfort associated with wound healing 
and repeated dressing changes. However, although early reports demonstrated 
excellent initial results, a wide-ranging variability in subsequent reports, has led to no 
less than six published review articles attempting to unravel the question of its 
uncertain efficacy263;306-310. The author of this thesis published the first of these 
reviews in 2004. 
 
1.3.4.2.4.2.4.1.1  Historical background 
Fibrin glue (also referred to as fibrin sealant or fibrin tissue adhesive) was first used 
as a haemostatic agent at the beginning of the last century. During the First World 
War, fibrin tampons and patches were used to control bleeding from 
parenchymatous organs311;312. In 1944 the addition of bovine thrombin to fibrinogen 
allowed Cronkite et al to demonstrate that it could be used as a sealant to facilitate 
skin grafting procedures313. However, a relatively high failure rate due to poor 
adhesive strength and durability of the sealants meant the technique was not further 
pursued. In 1972, the concept of fibrin glue application in surgical procedures 
resurfaced314, as a method was developed which used highly concentrated 
fibrinogen in combination with factor XIII (fibrin stabilizing factor) and delayed 
fibrinolysis with aprotonin (fibrinolysis inhibitor). Further progress was made when 
commercial plasma fractionation methods generated concentrated fibrinogen 
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preparations, which were made available in Europe in the late 1970s. However, 
pooled fibrinogen concentrates were associated with viral transmission, leading to 
license revocation for fibrinogen concentrates in the United States by the Food and 
Drug Administration (FDA) in 1978. Since that time implementation of viral 
elimination procedures has abolished contamination from known viruses. Thus, in 
1998, the FDA re-licensed fibrin sealant for limited operative procedures. In the 
interim, hospitals in the USA, on account of interest generated by the clinical 
success of fibrin sealants in Europe and Asia, had used as a source of human 
fibrinogen, autologous, single donor, or small pool cryoprecipitate fibrinogen 
preparations. These were mixed with bovine thrombin, providing home-made 
sealants, thus avoiding the risk of disease transmission307. 
Fibrin glue has been used to treat a variety of fistulas, including cerebrospinal, 
tracheoesophageal, bronchopleural, chylous, upper gastrointestinal, pancreatic, 
proximal colorectal, and urological fistulas, with variable success rates307. Its use in 
the management of complicated perineal fistulas, albeit not specifically anal fistulas, 
was first reported in the early 1980s, with closure rates of 44% (9–24 months follow-
up) and 80% (0–5 months follow-up) 315;316. 
 
1.3.4.2.4.2.4.1.2  Mode of action307 
Fibrin glue is a tissue sealant that simulates physiological clot formation. Activation is 
initiated by mixing a fibrinogen solution (containing fibrinogen, factor XIII, fibronectin, 
and aprotonin) with thrombin and calcium ions. The fibrinogen is cleaved into fibrin 
monomers, which loosely aggregate to form a soluble clot. Concomitantly, the 
thrombin and calcium ions activate factor XIII (F XIIIa), which cross links the soluble 
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clot into an insoluble, stable form. Fibrinolysis is retarded by the addition of a specific 
inhibitor, aprotonin. The F XIIIa also cross links fibronectin present in the sealant 
mixture, and further cross-links the fibrin and fibronectin with the collagen of the 
surrounding tissue. When applied to a fistula the fibrin clot: seals the fistula tract; 
stimulates the migration, proliferation and activation of fibroblasts; and via the 
bridging action of fibronectin, serves as a matrix for the in growing fibroblasts and 
pluripotent endothelial cells. These cells take on the function of normal tissue after 
fibrin degradation. Plasmin, activated from plasminogen, in the surrounding tissue 
causes eventual lysis of the fibrin clot and this is estimated to take 7–14 days 
following application. Collagen synthesis, initiated by the fibroblasts, would mark the 
next stage in the healing of the fistula. 
 
1.3.4.2.4.2.4.1.3  Method of instillation307 
After EUA, identification of both the internal and external openings, and tract 
cleansing (by debridement and lavage) the glue is instilled. The individual 
components are mixed and warmed, then drawn up into two syringes (syringe 1: 
fibrinogen, factor XIII, aprotinin, and fibronectin; syringe 2: thrombin and calcium 
chloride solution), which are subsequently placed in a two-syringe clip, which shares 
a common plunger. A plastic double-lumen- Y-connector joins the two syringes. The 
trunk of the Y-shaped connector is then connected to a single lumen catheter, which 
is inserted into the tract, and if the internal opening has been left open, until the tip 
can be seen at the internal opening. On injection, the components mix at the tip of 
the catheter to form fibrin glue. Slow withdrawal of the catheter at instillation is 
performed and visualization of the glue should occur, if the internal opening is patent 
at this opening, and in all cases at the external opening. Once the glue is set the 
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procedure is complete; it takes 3–5 minutes for the fibrin glue to adhere firmly to the 
surrounding tissue and 10 min to reach 70% of its maximum strength (full strength 
occurs after 2 hours). 
 
1.3.4.2.4.2.4.1.4  Results of treatment 
Fistula eradication 
Fistula eradication rates have been reported to range from 0-100%, with an overall 
average of 50-60%307-310. This wide range of results most likely stems from 
differences in patient and fistula selection (in terms of aetiology and classification), 
treatment protocols, and follow-up duration; and as with other techniques, leads to 
difficulties in comparing published data. 
There is little concordance in the literature as to whether healing of complex fistulas 
is better or worse than simple fistulas after treatment with fibrin glue. Although the 
one randomised controlled trial comparing fibrin glue treatment with conventional 
therapy (fistulotomy or loose seton insertion with or without subsequent 
advancement flap, depending on the assessment of complexity) concluded that 
although an advantage for fibrin glue was not shown for simple fistulas (fistulotomy 
being more successful), a statistically significant advantage for fibrin glue over 
conventional treatment of complex anal fistula (recurrence rates of 31% for fibrin 
glue versus 87% for conventional treatment) was demonstrated317.  
Cited reasons for failure can be divided into those associated with recurrence after 
conventional therapy and those specific to fibrin glue307;318. As stated earlier, critical 
to the success of all techniques in the management of anal fistulas is the elimination 
of acute sepsis, the eradication of secondary fistulous extensions, and the adequate 
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removal of all granulation or epithelial tissue lining the fistulous tract318. A variety of 
strategies have been utilised to achieve these aims including: employing a two-stage 
procedure, whereby at the first procedure the fistula is simplified by extrasphincteric 
lay open and placement of a drainage seton, and once adequate healing has 
occurred, a second stage of fibrin glue instillation; electrocautery destruction of the 
intersphincteric anal gland; and a variety of methods to degranulate or de-
epithelialise the fistula lining, mostly involving blunt curettage or abrasion with a 
gauze strip, although laser ablation has been described307. Certain authors have 
stated that that the inability of fibrin glue to permanently heal anal fistulas is 
secondary to: a liquid consistency, allowing it to run out of the fistula tract, and that 
shorter tracts are therefore more prone to failure; the inability of the fibrin glue to 
securely close the internal opening; the potential of certain bacterial species to cause 
early clot degradation; and extrusion of the glue shortly after surgery because of 
raised intra-anal pressures. However there is insufficient evidence to determine 
whether shorter fistula tracts are more prone to recurrence than longer tracts, and 
whether measures to reduce intra-anal pressures (such as pre-operative bowel 
preparation, and post-operative dietary restrictions and laxatives) produce better 
outcomes. One randomised controlled trial has compared intra-adhesive antibiotics 
(100 mg of cefoxitin added to fibrin sealant), surgical closure of the internal opening 
(using absorbable suture), and the two strategies combined319. At one year, the final 
healing rates were 25%, 44% and 35% respectively but this did not reach statistical 
significance (P = 0.37), and the authors concluded that these methodological 
adjuncts were no more successful than their historical control, treatment with fibrin 
sealant alone. Interestingly, a randomised study comparing internal opening 
advancement flap closure alone with fibrin glue instillation and flap closure resulted 
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in better outcomes in the former group (20% versus 46.4% recurrence, P < 0.05), the 
difference attributed to the glue preventing adequate drainage deep to the flap320; 
these findings are further supported by two subsequent case-series321;322. 
There are also biological factors, specific to fibrin glue, that are likely to account for 
its failure to permanently heal anal fistulas, and these are two-fold. Buchanan et al 
demonstrated that epithelialisation over the external opening of the fistula tract is 
often misinterpreted as evidence of fistula healing, and in such circumstances 
recurrence is inevitable252. Indeed, studies have shown that although fibrin glue 
encourages fibroblast migration and epithelialization across its surface, it does not 
permit fibroblastic infiltration or the synthesis of crucial extracellular matrix 
proteins323;324. Additionally, the rate of fibrin glue degradation may limit its ability to 
act as a scaffold for tissue repair, and studies have shown that the majority is 
resorbed within five to ten days, which is insufficient time for establishment of a 
permanent extracellular matrix253;325. 
 
Continence disturbance 
All the reports in the literature comment on the maintenance of continence after the 
instillation of fibrin glue. However, only 3 studies have specifically assessed 
continence317;326;327. El-Shobaky et al compared 30 anal fistulas treated with fibrin 
glue to 30 matched anal fistulas treated by fistulotomy326. Those treated with fibrin 
glue were noted to have no impairment of postoperative anal sphincter function 
opposed to those treated by fistulotomy, in whom one patient remained incontinent 
for flatus and two patients had minimal soiling which persisted for more than 3 
months. Zmora et al retrospectively noted any recorded symptoms of incontinence in 
95 
 
the pre- and postoperative medical records of 37 patients treated with fibrin glue and 
rectal advancement flap, and contacted patients by telephone to assess long-term 
outcome and anal sphincter function. They were no symptoms of incontinence noted 
in the patients‟ medical records and none of the patients reported any change in anal 
continence327. Lastly, in the only randomised comparative trial of fibrin glue versus 
conventional treatment for anal fistula, no change in either continence scores or 
sphincter pressures were reported in those patients treated with fibrin glue compared 
to 15% of patients managed with traditional surgical techniques317. 
 
Other complications 
Septic complications, including abscess formation and the development of further 
secondary extensions, have been reported in up to 10% of cases317;326;328;329, and 
rare cases of allergic reaction to fibrin glue have been reported307 
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1.3.4.2.4.2.4.2 Anal fistula plug (Surgisis® AFP™) 
The anal fistula plug (AFP) is composed of lyophilised porcine-derived small 
intestinal submucosa. To date, Surgisis® has been used to treat enterocutaneous 
fistulas; incisional, inguinal and para-oesophageal hernias; and, as a urethral sling in 
urogynaecological procedures77;169;170;330-332. The biological properties of this 
material, and its potential to act as bioscaffold for soft tissue repair and 
reinforcement, have been discussed in the introductory section on the role of SIS in 
parastomal hernias. In 2006, the first report of the use of Surgisis® to treat anal 
fistulas, as a biological plug, was published333.  The authors cited the reasons for 
employing the plug were that it overcame the technical failures of fibrin glue as 
previously described, and due to the relative success of Surgisis® in treating hernias 
in potentially contaminated and contaminated wounds. Interestingly, as discussed in 
the previous section on fibrin glue, those studies which employed measures to 
counteract the former concerns (for example, occlusion of the internal opening to 
prevent intra-operative leakage of fibrin glue, and bowel preparation to avoid early 
bowel movements, and consequent early clot extrusion), do not report better 
success rates than those that did not use either protocol318. Additionally, those 
studies that employed Surgisis® to reconstruct abdominal wall defects in 
contaminated fields, reported accelerated degradation of the implant, which the 
authors hypothesized was responsible for early hernia recurrence77;170. 
 
1.3.4.2.4.2.4.2.1  AFP procedure 
In 2007, on account of concerns of lower success rates with this procedure than 
those initially published (83% at 12 months follow up333;334), surgeons experienced 
with the AFP convened to develop a consensus paper on the proper technique, 
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patient selection criteria, and pre- and postoperative management in order to 
maximise its success335;336. The procedure is indicated in all Park‟s classification of 
fistulas, including those of cryptoglandular and Crohn‟s aetiology, which are 
unsuitable for fistulotomy (due to the amount of sphincter involved or poor pre-
operative function). It is contraindicated in those with pouch or rectal vaginal fistulas, 
acute sepsis (which if identified, placement of a drainage seton is suggested) but not 
secondary extensions, patients with an allergy to porcine products, and an inability of 
the surgeon to identify both the internal and external openings. No recommendations 
are made regarding bowel preparation, although a single dose of preoperative 
systemic antibiotics is advised. After EUA and identification of both the internal and 
external openings, the tract should be irrigated with either saline or H2O2. 
Debridement, curettage or brushing is not advised, since this may lead to a larger 
tract and risk expulsion of the plug. A suture or ligature is placed at the narrow end of 
the plug and then pulled from the internal to the external opening until the plug is 
snug. Excess plug should be trimmed from the internal opening, and an absorbable 
suture placed, incorporating the internal sphincter, to close the os and anchor the 
plug. The excess external plug is then excised flush with the skin, and the external 
opening left open to allow drainage of any exudate. Post-operatively, no restriction in 
diet is recommended, but constipation and diarrhoea should be prevented or treated. 
Patients are advised to refrain from strenuous or sexual activity, and heavy lifting for 
2 weeks, in order to avoid dislodgment of the plug. During follow-up visits the tract 
should not be probed. 
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1.3.4.2.4.2.4.2.2  Results of treatment 
Since the first report of this technique there have been at least 11 studies, published 
in full text, on the AFP; these are summarised in Table 1.8. The majority (8 of 11) are 
prospective case-series, and the remainder comprise retrospective studies.  
 
Fistula eradication in idiopathic fistulas 
Fistula eradication rates range from 24 - 93%, with an overall average of 50 -
60%322;334;337-345. As with fibrin glue and other fistula treatment strategies, differences 
in patient demographics (such as previous fistula surgery), fistula aetiology and 
classification, treatment protocols, duration of follow-up, small participant numbers, 
and the absence of randomised controlled trials, mean comparisons between 
published data are almost impossible. However, two non-randomised studies have 
compared the AFP technique with other sphincter preserving procedures: Johnson et 
al compared the short-term results of two prospective groups of patients with high 
transsphincteric fistulas, and using fibrin glue in the alternate study arm 
demonstrated a significantly higher rate of fistula eradication for those treated with 
the AFP (87% vs 40%, P<0.05)333; Ellis compared retrospectively collected data on 
patients treated with mucosal advancement flap repair or the AFP, and despite a 
trend in favour of the AFP showed no significant difference in overall fistula 
eradication between the two groups (67% vs 88% respectively, P value not 
published)339. The results of a randomised controlled multi-centre trial, comparing 
mucosal advancement flaps with the AFP for the treatment of cryptoglandular high 
transsphincteric fistulas, are awaited346. 
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The reported fistula eradication rates incorporate single tract fistulas, and those with 
secondary extensions and horse-shoe configurations. Despite the widely accepted 
view that untreated secondary and horseshoe extensions are significantly associated 
with fistula persistence251, this stance is not upheld in those studies that addressed 
this issue in the setting of the AFP technique334;340;341;344. It could be argued however 
that the numbers involved in this subset of patients are too small to draw any 
meaningful conclusions. From the data available, those variables which have been 
shown to significantly affect closure rates include height of the fistula (the higher the 
fistula, the lower the chance of fistula eradication, P<0.05)337, and whether the fistula 
was undergoing plug placement for the first-time or a repeat procedure (first vs 
repeat attempt: 64% vs 12.5%, P=0.011)341. The authors of the former observation 
further demonstrated that the higher failure rate in higher fistulas (and therefore 
presumably those with longer tracts), was at least partly secondary to higher plug 
extrusion rates (< 1/3 vs 1/3 - 2/3 vs >2/3 EAS involvement: 7% vs 19% vs 38% plug 
extrusion respectively, P=0.04). These findings are in conflict with the anecdotal 
reports from other surgeons, recognised as experienced in the plug technique, who 
suggest that plug extrusion is more likely in short tracts, thus the contraindication for 
AFP use in rectovaginal fistulas335;336. Nonetheless plug extrusion is a recognised 
cause of plug failure, and has been reported to occur in 10-41% of patients336;337;343-
345. This is despite the majority of studies performing pre-operative bowel preparation 
and/ or prescribing post-operative dietary restrictions and laxatives, in order to avoid 
raised intra-anal pressures (the presumed cause of early fibrin glue expulsion). Other 
reasons cited for early plug extrusion include the tract being too wide, the plug being 
pulled too tightly, and inadequate plug fixation336.  
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Two studies deviated from the recommended operative technique by using the AFP 
in conjunction with a dermal or mucosal advancement flap, and both reported 
eradication rates of 67%341;342. However, as there were no control groups, no benefit 
over the standard AFP protocol can be demonstrated. 
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Table 1.8 Results of published studies (in full text) of the anal fistula plug (AFP) 
  
Author Year Study type N Aetiology Anatomical 
Classification 
Management 
Protocol* 
Fistula 
eradication 
(%) 
Incontinence 
(%) 
 
Other 
Complications 
Duration of 
follow-up, 
months 
(range) 
 
Champagne 
et al
334
** 
2006 Prospective 
case-series 
46 Cryptoglandular High TS  Bowel 
preparation 
 Abx 
prophylaxis 
 Post-op: 
Liquid diet 
for 48hrs/ 
topical 
flagyl/ 
activity 
restriction 
 
38/46 (83%)
‡
 
 
NR NR Median 12  
(6-24) 
O‟Connor et 
al
347
 
2006 Prospective 
case-series 
 
20 Crohn‟s - As above 16/20 (80%) NR NR Median 10  
(3-24) 
Ellis
339
 2007 Retrospective  18  13 Cryptoglandular  
 
 
5 Crohn‟s 
TS 
 
 
RVF 
 Nil pre-op 
protocol 
 Post-op: 
Laxatives/ 
activity 
restriction 
 
12/ 13 
(92.5%) 
 
4/5 (80%) 
NR 
 
NR Median 6  
(3-11) 
van Koperen 
et al
345
 
2007 Prospective 
case-series 
17 14  Cryptoglandular 
 
1 Crohn‟s 
 
2 HIV 
 
High TS 
 
- 
 
- 
 Bowel 
preparation 
 Abx 
prophylaxis 
 Post-op: 
Activity 
restriction 
 
4/14 (28.5%) 
 
1/1 (100%) 
 
2/2 (100%) 
NR NR Median 7  
(3-9) 
 
1
0
1
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Author Year Study type N 
 
Aetiology Anatomical 
Classification 
Management 
Protocol 
Fistula 
eradication 
(%) 
Incontinence 
(%) 
 
Other 
complications 
Duration of 
follow-up, 
months 
(range) 
 
Christoforidis 
et al
337
 
2008 Retrospective 46 39  
Cryptoglandular 
 
3 Crohn‟s 
 
3 Post-IPAA/ IAA 
 
39 TS 
 
4 SS 
 
2 IS 
 
2 Anovaginal 
 
 Bowel 
preparation 
 Post-op: Nil 
protocol 
20/47 
(42.5%) 
†
 
(31% 
Crypto-
glandular) 
NR 2 acute post-op 
sepsis 
 
9 c/o ↑ fistula 
discharge 
Median 5  
(1-11) 
Schwandner 
et al
343
  
2008 Prospective 
case-series 
18 11  
Cryptoglandular 
 
7 Crohn‟s 
19 TS  Bowel 
preparation 
 Abx 
prophylaxis 
 Post-op: 
Activity 
restriction 
5/11 (45.5%) 
 
 
6/7 (85.7%) 
No change in 
Cleveland or 
QoL scores 
(0%) 
 
 
 
 
NR Mean 10  
(SD 2.5 ) 
Lawes et al
342
 2008 Retrospective 17 AFP 
alone 
 
3 AFP & 
transanal 
flap 
 
20 
Cryptoglandular 
17 TS 
 
3 Ano-perineal 
 Abx 
prophylaxis 
 
4/17 (24%) 
 
 
2/3 (67%) 
NR 5/17 (29%) 
acute post-op 
sepsis 
Mean 7.4 
Thekkinkattil 
et al
344
 
2008 Prospective  
case-series 
43 32  
Cryptoglandular 
 
7 IBD 
3 IPAA 
1 Other 
 
29/32  TS 
3/32 SS 
 Bowel 
preparation 
 Post-op: 
Oral abx/ 
laxatives/ 
activity 
restriction 
 
17/32 (53%)
‡
 
(55%, TS; 
0% SS) 
 
3/11 (27%) 
  
NR NR Median 10.5  
(3-17) 
 
  
 
1
0
2
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Author Year Study type N 
 
Aetiology Anatomical 
Classification 
Management 
Protocol 
Fistula 
eradication 
(%) 
Incontinence 
(%) 
 
Other 
complications 
Duration of 
follow-up, 
months 
(range) 
 
Ky et al
341
 2008 Prospective 
case-series 
44 AFP & 
mucosal 
flap 
30 
Cryptoglandular 
(4 RVF; 1 
horseshoe) 
 
14 Crohn‟s 
 
 -  Bowel 
preparation 
 Abx 
prophylaxis 
 Post-op: 
Topical 
flagyl/ oral 
antibiotics/ 
laxatives/ 
activity 
restriction. 
20/30 
(67%)
‡
 
 
 
 
4/14 
(28.5%)
¥
 
 
0% 5/44 (11%) 
acute post-op 
sepsis 
Median 6.5  
(3-13) 
Echenique 
et al
338
 
2008 Prospective 
case-series 
23 Cryptoglandular - - 14/23 
(61%) 
NR 3/20 (15%) 
acute post-op 
sepsis 
 
- 
Garg
340
 2008 Prospective 
case-series 
21 Cryptoglandular High TS  Bowel 
preparation 
 Abx 
prophylaxis 
 Post-op: 
Liquid diet 
for 48 hrs/ 
Topical 
flagyl/ oral 
antibiotics/ 
laxatives/ 
activity 
restriction 
 
15/21 
(71.5%)
‡
 
0% 1/21 (5%)  
acute post-op 
sepsis 
Mean 9.5 
(6.5-18) 
 
  
 
1
0
3
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Abbreviations: RVF, rectovaginal fistula; TS, transsphincteric; IS, intersphincteric; SS, suprasphincteric; Abx, antibiotics; NR, not reported; IBD, 
inflammatory bowel disease; IPAA, ileal pouch anal anastomoses; IAA, ileo-anal anastomisis. 
* All studies report uniformity in tract management (no curettage, only saline or H2O2 lavage), plug placement, suture closure of 
internal os, and leaving the external os open for drainage. 
** This study presents the longer term results of a previously published study by Johnson et al333, hence only the later paper is 
included. 
†  The only significant variable was the height of the fistula; the higher the fistula the lower the chance of fistula eradication. 
‡  No significant difference in closure rates between those fistulas with single vs multiple tracts or horse-shoe configurations. 
¥  Significant difference (p< 0.05) in closure rates between Crohn‟s and Non-Crohn‟s fistulas 
 
 
1
0
4
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Continence and other complications  
Only 3 publications report on continence as an outcome measure. Schwander et al 
focussed on functional outcome and quality of life, using the Cleveland Clinic Florida 
Incontinence Score (CCFIS) and the Faecal Incontinence Quality of Life Scale 
(FIQL). They documented no difference in the pre-and post-operative CCFIS, and 
significant improvements in the FIQL depression/ self-perception and 
embarrassment scales (P<0.01)343. Ky et al simply stated that no incidence of 
incontinence to stool or flatus was found at post-operative interviews341, and Garg 
reported that post procedure none of the patients complained of any change in 
continence340. 
Septic complications, including abscess formation and worsening of fistula 
discharge, have been reported in a range of 5 – 29% of cases, with an overall mean 
incidence of 17%337;338;340-342. 
 
1.3.5 Conclusion 
 
Although the successful management of anal fistulas has traditionally been surgical, 
the functional risks to the anal sphincter complex mean fistula surgeons will continue 
to explore new methods that avoid such compromise, and the variable success of 
biological agents, such as fibrin glue and the anal fistula plug, show that they have 
potential to achieve these hitherto conflicting outcomes. Permacol® is a porcine-
derived dermal collagen implant which is cross-linked to impede enzymatic 
degradation. As with Surgisis®, its biological properties have been discussed in the 
section on parastomal hernias. The potential role of this cross-linked collagen 
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implant in the management of idiopathic anal fistulas is investigated in a prospective 
phase 1 study presented in chapter 4.  
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Chapter 2  
Parastomal Hernia Prevention Using A Novel Collagen 
Implant: A randomised controlled clinical (phase 1) and 
histological study 
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2.1 Introduction 
 
Parastomal hernias have a reported incidence of up to 70%, increasing with the 
length of follow-up33;35;41;42. They can lead to complications ranging from poor 
cosmesis, mild discomfort and difficulty with appliance application (causing skin 
irritation and leakage of bowel contents) to life-threatening complications such as 
strangulation, obstruction and perforation31;36-38. Up to 70% of patients require 
surgical repair33;35, and, of the documented techniques, prosthetic mesh repair (to 
reinforce the edges of the stoma trephine) is the most efficacious, although it still has 
reported recurrence rates of up to 8%, as well as the associated morbidity and cost 
of a second procedure33. As such, certain surgeons have recognised that prevention 
of parastomal hernias may be the best approach33;56. To date, a number of studies 
have reported encouraging results regarding the prophylactic placement of 
polypropylene mesh in an attempt to reduce the rate of parastomal 
herniation98;123;125-127. 
Although only polypropylene (and modifications thereof), have been described to 
prevent parastomal hernias, several different synthetic and biologically derived 
materials have been used to repair parastomal hernias (see Chapter 1). This is 
predominantly as none completely succeed in fulfilling the hernia surgeons‟ 
requirements of the ideal abdominal wall repair material, which include adequate 
strength for the intended surgical application, surgeon friendly handling 
characteristics, and promotion of host tissue in-growth. Such a material must also fail 
to elicit an acute hypersensitivity reaction or rejection, or to induce a chronic 
inflammatory or foreign body reaction (biocompatibility), and be capable of 
sterilization130;131. 
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Traditionally, non-absorbable synthetic materials, such as polypropylene, have been 
employed as they are associated with the lowest rates of hernia recurrence164;348. 
However, polypropylene mesh strengthens the abdominal wall both by mechanical 
tension and by induction of a strong chronic inflammatory foreign body response144. 
This consequently results in mesh contraction and formation of an avascular fibrotic 
conglomerate146, with the potential for bowel fistulation, erosion into abdominal 
viscera, intraperitoneal adhesions, and increased susceptibility to infection169;349-351. 
Furthermore, if complications occur, mesh extraction can be challenging due to 
dense tissue incorporation. 
Absorbable repair materials have also been used, and have the advantage of an 
improved host tissue response. These include synthetic materials, such as 
polyglactin, and xenografts, such as ovine and porcine dermal collagen and bovine 
pericardium158;159;161. However they are not indicated when prolonged tensile 
strength is required160;352, as their use is associated with frequent reherniation rates 
as a consequence of premature implant degradation before adequate tissue in-
growth has occurred161. Use of chemically cross-linked xenogeneic implants, with the 
aim of impeding the rate of resorption, has significantly decreased the reherniation 
rate159;161;162;182;183;191. 
An acellular cross-linked collagen sheet derived from porcine dermis (Permacol®, 
Tissue Science Laboratories, Aldershot, UK) has been used successfully for 
laparoscopic inguinal and parastomal hernia repair79;353, repair of large abdominal 
wall defects191;194, and general surgical soft tissue augmentation in both animals and 
humans182;184-186. Comparative studies with polypropylene in rat models have 
demonstrated that it has better tissue compatibility, with less adhesion formation, 
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more orderly collagen deposition and comparable tensile strength at 90 days after 
implantation183.  
The aim of this phase 1 study was to assess the safety, feasibility, and potential 
efficacy of preventing parastomal hernias using this cross-linked collagen implant. 
Additionally, biopsies of the collagen implant were obtained from patients who have 
since undergone stoma reversal, providing a unique opportunity to evaluate its 
biocompatibility, degradation, and cell integration. Host neo-extracellular matrix 
(ECM) protein deposition and neovascularisation were also evaluated.  
 
2.2 Materials and methods 
The study was approved by the local ethics committee (REC reference: P/02/263). 
2.2.1 Patients 
All patients requiring a defunctioning loop ileostomy, performed as part of an elective 
procedure, were prospectively invited to participate in the study on an intention-to-
treat basis. After obtaining informed consent, patients were randomised, by means of 
opening consecutively numbered sealed envelopes, to receiving either a 
conventional loop stoma or the same procedure with addition of the collagen implant. 
Patients were blinded as to which arm of the trial they had been entered. Patient 
age, sex, and body mass index (BMI) were recorded. Details on previous abdominal 
surgery and the primary procedure requiring a loop stoma were also recorded. 
 
2.2.2 Materials 
Permacol® is a porcine-derived acellular dermal sheet, predominately composed of 
type I collagen (93–95 per cent), with type III collagen and a small amount of elastin 
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comprising the remainder. Its manufacture involves trypsinization (to remove all 
living cells and non-collagenous debris), solvent extraction (to remove all lipid and fat 
deposits), γ irradiation and cross-linkage with hexamethylene-diisocyanate186. The 
implant contains naturally occurring pores, in the form of hair follicle remnants, which 
number 5–13 pores/cm2 and are 254–654 μm in diameter. Sterile sheets 10 × 10 cm 
in size and 1·0 mm thick were used, which were kept moist in sterile saline. The 
sheets were double vacuum packed and heat sealed in sachets of aluminium foil 
(inner) and polyester/polythene (outer), and stored at room temperature. 
 
 
2.2.3 Surgical technique 
 
2.2.3.1 Stoma formation 
All patients had a circular incision (approximately 2cm in diameter) at a pre-marked 
skin site, followed by a 2 x 2 cm cruciate incision in the anterior rectus sheath, and 
where present (ie. above the arcuate line) in the posterior rectus sheath. A trephine 
was subsequently created through all the layers of the anterior abdominal wall. In 
those receiving the implant, initially the potential space between the subcutaneous 
fat and the anterior layer of the rectus sheath (the fascial onlay position) was 
dissected in all directions around the trephine to allow the subsequent placement of 
the Permacol® implant (five patients), although this was later changed (for reasons 
discussed later) to between the posterior layer of the rectus sheath and the 
peritoneal membrane (preperitoneal position; ten patients).  
A cylindrical defect, approximately 2 cm in diameter, was fashioned in the centre of 
the collagen sheet, and the implant was inserted into the previously created plane 
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(Figure 2.1(A)). The central defect was sutured to the appropriate layer of the rectus 
sheath (at the 12, 3, 6 and 9 o‟clock positions), using interrupted 3/0 prolene sutures, 
so as to encircle the abdominal trephine (Figure 2.1 (B)). The outer four corners of 
the implant were also sutured to the rectus sheath in the same fashion (Figure 2.1 
(C)). The cut edge of the peritoneum was sutured to the corresponding edge of the 
posterior layer of the rectus sheath to enclose the implant. 
In all patients, the appropriate loop of bowel was brought through the peritoneum, 
the implant (if present), and the remaining layers of the anterior abdominal wall, 
without any tension. The stoma was fashioned in the standard manner using 3/0 
vicryl rapide®. 
 
2.2.3.2 Stoma reversal 
In those undergoing stoma reversal, the bowel was dissected down to the peritoneal 
cavity. If present, the collagen implant was biopsied, and the opening in the bowel 
either primarily closed with 3/0 vicryl or the adjacent bowel resected and 
anastomosed using a linear stapler. The peritoneum, rectus sheath and, if present, 
the implant trephine, were closed using either 1/0 loop PDS or interrupted 1/0 nylon 
sutures. The skin was closed in the standard manner using staples.  
Biopsy specimens were taken from the edge of the implant trephine, and 
immediately fixed in 4% formal saline. 
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Figure 2.1. (A) Implant with a central trephine measuring 2 cm in diameter, just before insertion within the 
preperitoneal space. (B) Central trephine of implant sutured to the posterior layer of the rectus sheath (at 12, 3, 6 
and 9 o‟clock positions), using interrupted polypropylene sutures, so as to encircle the abdominal trephine. (C) 
Outer four corners of the implant sutured to the rectus sheath in the same fashion as the edges of the central 
trephine.  
A. Implant before insertion B. Sutured central trephine C. Sutured outer four corners 
 
1
1
3
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2.2.4 Follow up 
Patients were followed-up until the time of stoma reversal or, in the event of the 
stoma not being reversed, until 12 months after stoma formation. Patients completed 
a questionnaire assessing for symptoms associated with parastomal herniation on a 
monthly basis, and underwent a clinical examination for signs of a parastomal 
hernia, and other complications, at 6 weeks postoperatively and then every 3 months 
until stoma reversal or 12-months post-stoma formation. In those patients whose 
stomas were reversed, at the time of the second procedure any evidence of stomal 
herniation was recorded. Serum white cell count, C-reactive protein levels and 
erythrocyte sedimentation rates were performed on a monthly basis, for 6 months, to 
establish whether there was any serological evidence of a systemic inflammatory 
response related to the presence of the implant. Ultrasound examination of the 
stoma site was performed at least 3 months after stoma formation, usually on the 
day prior to reversal, to detect for evidence of localised chronic seroma formation 
related to the presence of the implant. 
 
2.2.5 Histological and immunohistochemical examination 
After fixation, appropriate samples were embedded in paraffin and 5-μm thick 
sections were cut. Samples for histology were stained with haematoxylin and eosin 
and Masson‟s trichrome. The latter stains the nuclei of the cells blue–black, 
cytoplasm, muscle and erythrocytes stain red, and collagen stains blue354. Samples 
for immunohistochemistry were incubated with the antibodies of interest. The avidin 
biotin complex method was used. The antibodies used to determine the nature of the 
host inflammatory response, and those to identify specific ECM protein deposition 
and neovascularization, are summarised in Table 2.1. The presence of the various 
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inflammatory cells was quantified microscopically. Five fields per slide were counted 
at a magnification of x40 (Leica DMR; Leica, Solms, Germany) by two independent 
observers; three slides per patient were analysed. These fields were selected 
randomly within the collagen implant itself, at the native pores within the implant, and 
at the interface between the implant and surrounding host tissue. For descriptive 
purposes, a histological scoring criterion analogous to that described previously was 
used183;355: cellular presence was ranked as absent (no cells/field), mild (1–5 
cells/field), moderate (6–10 cells/field) or severe (more than 10 cells/field). Evidence 
of neo-ECM protein deposition, neovascularization and their patterns of distribution 
were described qualitatively. Neovascularization was defined by the presence of 
structures exhibiting typical vascular walls and staining positively for laminin. The 
organization and composition of host neocollagen was determined by examination of 
Masson‟s trichrome-stained sections. The implant could be distinguished clearly from 
human tissue by its distinct morphological appearance. 
 
 
2.2.6 Statistical analysis 
Comparisons were made between the two groups, stoma reinforcement with mesh 
and conventional stoma (Fishers exact test). Analysis was performed using a 
commercially available software package (Prism 4, Graftpad software, San Diego, 
CA, USA). Statistical significance was assigned at the 5% level.  
Formal statistical analysis was not performed on the histological data, as this was 
primarily assessed in a descriptive manner. However, summary data have been 
provided as median (range) values (Table 2.4). 
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Table 2.1 Antibodies used for immunochemistry 
 
MMP, matrix metalloproteases; ECM, extracellular matrix. Labvision, Thermofisher 
Scientific Runcorn, UK; Dako, Ely, UK; Novocastra, Vision BioSystems, Newcastle 
upon Tyne, UK. 
  
Antigen Cell type/ process 
identified 
Dilution Supplier 
CD3 T cells 1:250 Labvision 
CD4 T-helper cells 1:100 Dako 
CD8 T-suppressor cells 1:50 Dako 
CD20 B cells 1:400 Dako 
CD57 Natural killer cells 1:30 Novocastra 
CD68 Macrophages 1:4000 Dako 
CD138 Plasma cells 1:100 Dako 
Myeloperoxidase Granulocytes 1:2000 Dako 
Vimentin Fibroblasts 1:8000 Dako 
Fibronectin ECM protein deposition  1:1000 Novocastra 
MMP-1 ECM protein deposition 1:100 Novocastra 
Laminin Neovascularisation 1:500 Novocastra 
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2.3  Results 
Twenty-five patients were included in the study. Fifteen were randomised to 
receiving the mesh, and ten to a conventional stoma. Patient demographic and 
relevant surgical data are summarised in Table 2.2. 
 
Table 2.2 Patient and operative characteristics 
Demographics Conventional stoma 
(N=10) 
Stoma + implant  
(N=15) 
Median age in years (range) 50 (22-70) 43 (21-69) 
Sex ratio (M:F) 4 : 6 6 : 9 
Median BMI (range) 26.3 (20.1 – 44) 27 (22.6 – 31) 
Median no. of previous abdominal 
operations (range) 
1 (0 - 2) 1 (0 – 3) 
Indication/1° procedure 
Megarectum/rectal reduction 
Slow transit constipation/loop 
ileostomy 
Faecal incontinence/gracilis 
neosphincter 
Rectal cancer/anterior resection 
Ulcerative colitis/proctocolectomy 
and pouch 
 
1 
1 
 
3 
 
3 
2 
 
1 
1 
 
5 
 
4 
4 
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2.3.1 Clinical and operative 
The clinical and operative findings are summarised in a flow chart (Figure 2.2). Of 
the ten patients randomised to receiving a conventional stoma, 5 had their stomas 
reversed at a median of 5 (range 3–8) months, and 3 patients had evidence of 
parastomal herniation. Of the 15 patients recruited to receiving the implant, 12 
underwent stoma reversal at a median of 7 (range 1–10) months. The first 5 patients 
recruited to this arm of the trial had the implant sited in the fascial onlay position, of 
which one developed a hernia between the implant and the anterior layer of the 
rectus sheath, prompting subsequent preperitoneal placement of the implant in the 
following 10 patients. None of these ten patients had any evidence of parastomal 
herniation. There was no significant difference between the two arms (P=0.31). 
At the time of stoma reversal, the collagen implant was found to be present and 
intact in 11 of the 12 patients. The peritoneal and muscular surfaces of the implant 
had become bordered with non-fibrous, well-vascularised connective tissue with 
mild-to-moderate adherence. Fibrous scar tissue was only evident at the suture 
sites. Adherence to bowel serosa was absent or minimal. The presence of the 
implant did not complicate reversal of the stoma. The remaining patient developed a 
multi-resistant Staphylococcus aureus wound infection after stoma formation, which 
presumably resulted in the implant being fully degraded, as there was no evidence of 
the implant at the time of re-operation.  
There were no other infective complications, and no patient experienced fistula 
formation or bowel erosion. Reasons for patients not undergoing stoma reversal by 
12 months included patient preference (n = 3), patient co-morbidities preventing 
further complex surgery (n = 2), recurrent anal carcinoma requiring proctectomy (n = 
1), severe pouchitis (n = 1), and prolonged chemotherapy for advanced rectal cancer 
(n = 1). 
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Figure 2.2 Flow chart of clinical and operative findings.  
 This patient had the implant sited in the fascial onlay position, and the hernia 
developed between the implant and the anterior layer of the rectus sheath, 
prompting pre-peritoneal mesh placement in subsequent patients.   
Consented to 
randomisation 
N=25
Stoma & Implant 
N=15 
Reversal of 
stoma at median 
7 (1 -10) months
N=12
Parastomal 
hernia
N=1
Stoma not 
reversed at 12-
months
N=3
Parastomal 
hernia 
N=0
Conventional 
stoma
N=10
Reversal of 
stoma at median 
5 (3-8) months
N=5
Parastomal 
hernia
N=1
Stoma not 
reversed at 12-
months
N=5
Parastomal 
hernia 
N=2
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2.3.2 Patient questionnaire 
The results of the patient questionnaire are summarised in Table 2.3. Of the ten 
patients randomised to receiving a conventional stoma, three documented the 
presence of a parastomal bulge, which corresponded to the same three patients in 
whom a clinically detected parastomal hernia was evident. These three patients 
documented symptoms related to the presence of a parastomal hernia, including 
difficulty with bag application, leakage of stoma bag contents, nausea, vomiting, 
bloating, and parastomal discomfort. Of the fifteen patients recruited to receiving the 
implant, two documented a parastomal bulge, one of whom was the patient who had 
developed a hernia between the anterior rectus sheath and the implant. This 
patient‟s predominant symptom was difficulty with bag application and discomfort. 
The other patient had no hernia evident on clinical examination, ultrasound 
examination or at the time of stoma reversal. One patient complained of symptoms 
of intermittent small bowel obstruction (nausea, vomiting, bloating and cessation of 
wind and stool per stoma) shortly after stoma formation, prompting early stoma 
reversal (1 month post initial stoma formation); no hernia was detected clinically, on 
ultrasound or at the time of stoma reversal, but a loop of small bowel proximal to the 
stoma was found to be wrapped around an intra-peritoneal adhesive band at a 
distance from the abdominal wall trephine and implant. Another patient (1 of 15) 
complained of regular nausea, vomiting and bloating but these symptoms were 
unaltered in frequency or severity compared to those experienced pre-stoma 
formation. 
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Table 2.3 Results of patient questionnaire 
 
(A), patient in whom hernia developed between anterior layer of rectus sheath and 
fascial onlay implant; (B), No hernia evident on clinical examination, ultrasound or at 
time of stoma reversal; (C) Symptoms secondary to small bowel obstruction 
secondary to intra-peritoneal adhesions; (D), Symptoms present  pre-operatively and  
no hernia evident on clinical examination, ultrasound or at time of stoma reversal.  
Symptoms Conventional stoma 
N=10 
Stoma + implant 
N=15 
Stomal bulge 3 2A, B 
Bulge → difficult bag application 2 1B 
Stoma bag leakage 2 0 
Bulge → pain 1 1A 
Stoma ceases to produce flatus 0 1C 
Stoma ceases to produce stool 0 1C 
Nausea & vomiting 2 2C, D 
Abdominal bloating 2 2C, D 
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2.3.3 Stoma site ultrasonography 
Of the 10 patients randomised to receiving a conventional stoma, nine of ten 
underwent stoma site ultrasonography at a median of 5 (range 3–12) months post-
operation, and none (0 of 9) had ultrasonographic evidence of a chronic seroma or 
fluid collection. Of the 15 patients randomised to receiving the implant, twelve 
underwent stoma site ultrasonography at a median of 6 (range 1–10) months post 
operation, and none (0 of 12) had ultrasonographic evidence of a chronic seroma or 
fluid collection. 
 
2.3.4 Serology 
Serology results are illustrated in Figure 2.3. The white cell count was neither 
decreased nor elevated beyond the limits of the normal range in either group, with 
the exception of day 1 post-operation in the no-implant arm (Figure 2.3A). The 
erythrocyte sedimentation rate (Figure 2.3B) and C-reactive protein level (Figure 
2.3C) were elevated beyond the upper limit of the normal range in both groups post-
operatively, but there was no apparent difference between the groups. 
 
123 
 
   
Figure 2.3 (A-C). Serology results at varying time-points post stoma formation. 
(A), mean white cell count; (B), Mean erythrocyte sedimentation rate (ESR); (C), 
Mean C-reactive protein (CRP) level. 
A 
B 
C 
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2.3.5 Microscopic findings 
Eleven sets of biopsies were available for microscopic analysis. 
 
2.3.5.1 Histology 
Ten of the 11 sets of biopsies revealed a clear line of demarcation between the 
collagen implant and host connective tissue, with a mild mononuclear cell response 
and new vessel formation limited to the interface between the collagen implant and 
host connective tissue, and via native pores within the collagen implant (Figure 2.4). 
No polymorphonuclear cell response was evident, and the only foreign body giant 
cells were associated with stitch granulomas. There was focal evidence of organized 
and controlled host neo-collagen formation, albeit limited to regions of cellular 
infiltration and neovascularization (Figure 2.5). The collagen fibres paralleled the 
implant, with full-thickness penetration occurring via native pores. Host neo-collagen 
was clearly distinguishable from the distinctive collagen bundles associated with the 
implant.  
The remaining biopsy, taken from a patient who had been treated with 
chemoirradiation for a locally advanced rectal adenocarcinoma, showed a florid 
foreign body giant cell reaction resulting in localized destruction of the collagen 
implant. 
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B. 6 months after implantation A. 1 month after implantation 
Figure 2.4 Haematoxylin and eosin stain of the implant and surrounding host tissue (A) at 1 month and (B) at 6 months. 
At 1 month a clear line of demarcation could be seen between the collagen implant and the host connective tissue, with 
a mild mononuclear cell response and new vessel formation limited to the interface between the implant and host 
connective tissue. At 6 months partial cellular infiltration was observed along the length of the implant (original 
magnification x40) 
 
1
2
5
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A. 1 month after implantation B.  6 months after implantation 
Figure 2.5 Masson‟s trichromate stain of the implant and surrounding host tissue (A) at 1 month and (B) at 6 months. 
At 1 month organized host neo-collagen, distinct from the amorphous collagen bundles associated with the implant, 
could be seen running in parallel with the implant, with little integration. At 6 months there was focal evidence of host 
neo-collagen integrated with the implant (original magnification x40) 
 
1
2
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2.3.5.2 Immunohistochemistry 
Results for markers of the inflammatory response are shown in Table 2.4. No B cells, 
natural killer cells, plasma cells or granulocytes were identified. There was a mild T 
cell response, with a similar proportion of T-helper cells to T-suppressor cells and a 
moderate macrophage response. All responses were limited to the interface between 
the implant and the host connective tissue, and native pores within the implant, with 
minimal apparent interindividual variability.  
Over a median of 7 months in vivo, the expression of vimentin, a fibroblast marker, 
strongly increased within both the implant and the surrounding granulation tissue 
(Figure 2.6).  Fibronectin and laminin expression (Figures 2.7 and 2.8 respectively), 
both adjacent to and within the implant, seemed proportional to the increasing 
expression of vimentin and CD68 (macrophage marker). Similarly, over time MMP-1 
appeared to be expressed strongly around the mesenchymal cells within the 
Permacol® and surrounding tissue (Figure 2.9), although there was no evidence of 
implant degradation. All controls stained negatively. 
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Table 2.4 Inflammatory response to collagen implant 
 
Values are median (range). The presence of various inflammatory cells was evaluated microscopically. Five fields per slide were 
counted at a magnification of x40 by two independent observers. Three slides per patient were analysed. These fields were selected 
randomly within the collagen implant itself, at the native pores within the implant, and at the interface between the implant and 
surrounding host tissue. 
  
  CD3 CD4 CD8 CD20 CD57 CD68 CD138 Myeloperoxidase 
Within collagen 
implant 
 0 (0 - 4) 0 (0 - 2) 0 (0 - 2) 0 0 0 (0 - 8) 0 0 
Native pores  3 (0 - 12) 2 (0 - 8) 3 (0 - 15) 0 (0 - 12) 0 9 (0 - 22) 0 (0 - 4) 0 (0 - 1) 
 
Interface (between 
implant and host 
tissue) 
 4 (0 - 32) 2 (0 - 9) 2 (0 - 17) 0 (0 - 3) 0 5.5 (0 - 36) 0 (0 - 4) 0 (0 - 7) 
 
1
2
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A. 1 month after implantation B. 6 months after implantation 
Figure 2.6 Vimentin stain of the implant and surrounding host tissue (A) at 1 month and (B) at 6 months. The strength 
and frequency of vimentin expression, a fibroblast marker, increased substantially from 1 to 6 months, both at the 
edges and infiltrating the implant (original magnification x40) 
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A. 1 month after implantation B. 6 months after implantation 
Figure 2.7 Fibronectin stain of the implant and surrounding host tissue (A) at 1 month and (B) at 6 months. The 
strength and frequency of fibronectin expression increased substantially from 1 to 6 months, both at the edges and 
throughout the implant (original magnification x40) 
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Figure 2.8 Laminin stain of the implant and 
surrounding host tissue at 6 months. Laminin both 
bordering and within the implant, and in conjunction 
with structures exhibiting typical vascular walls, was 
indicative of ongoing neovascularisation. 
Figure 2.9 Matrix metalloproteinase (MMP) 1 stain of 
the implant and surrounding host tissue at 6 months. 
MMP-1 expression at the edges and at focal points 
within the implant was proportional to the 
fibrovascular infiltration seen in previous figures. 
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2.4  Discussion 
 
The view that prevention is the best approach to the management of parastomal 
hernias has been expressed in two review articles33;98, and there is good clinical 
evidence to date for placing a mesh at the time of stoma formation in order to 
achieve this aim122;123;125-127. However, the ideal material for this purpose and the 
most appropriate anatomical layer of the anterior abdominal wall within which to site 
the mesh has yet to be determined.  Intuitively, the specific success determining 
characteristics of such a material would include: avoidance of a foreign body 
inflammatory response (biocompatibility), and therefore fibrosis, contraction and 
potential bowel erosion; adequate mechanical strength; and prolonged 
biodegradation, thereby avoiding herniation following early implant resorption. 
Furthermore, it has been proposed that both recurrent and incisional hernias (which 
by definition include parastomal hernias31) can be regarded as a consequence of a 
disturbed process in the wound healing pathway52;356. In the proliferation phase, type 
III collagen acts as a temporary scaffold for fibroblast attachment. Through a 
complex process of remodelling under the influence of the MMPs, this is replaced 
with type I collagen, which imparts long term strength. A shift of the ECM collagen 
ratio in favour of the „immature‟ type III collagen may result in a loss of tensile 
strength, and predispose to hernia formation50. It is therefore reasonable to 
hypothesise that any biological material used to reinforce or repair the abdominal 
wall should either be predominantly composed of type I collagen or correct the 
balance of collagen metabolism.  
Permacol® is composed of up to 95% type I collagen, and has been shown in both in 
vitro and animal studies to possess the aforementioned qualities. In vitro studies 
have shown that the cross-linking confers resistance to collagenase degradation180, 
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and when implanted into the abdominal wall of rat models, Permacol® induced a mild 
chronic inflammatory response with no evidence of significant fibrosis182;183. 
However, up until this study no evaluation of the human host response to this 
biomaterial had been performed. 
The clinical results of this pilot trial suggest that this cross-linked collagen is safe to 
use: there were no complications related to infection or the proximity of the implant to 
the bowel, and there was no ultrasonographic evidence of localised chronic seroma 
formation or serological evidence of a systemic inflammatory response related 
specifically to the implant. Technically, the procedure is easy to perform and did not 
complicate stoma reversal. Most importantly, although there was no significant 
difference between the groups, there was a trend in favour of stoma reinforcement to 
prevent parastomal hernias, in that only one of fifteen patients who received the 
implant developed a parastomal hernia compared with three of ten patients who 
underwent a conventional stoma. The hernia that occurred in the implant arm of the 
trial, formed between the anterior layer of the rectus sheath and the implant itself, 
which highlights one of the main concerns of the fascial onlay technique, and led to 
the subsequent placement of the implant in the pre-peritoneal space. No hernias 
developed in this sub group of patients. It could be argued that all patients should 
have undergone post-operative CT imaging, the gold standard for parastomal hernia 
imaging. However, CT is only indicated in those patients whose symptoms are 
suggestive of a hernia, but in whom this cannot be clinically demonstrated43. In this 
regard, the two patients in the implant arm of the trial with symptoms suggestive of a 
hernia (one of whom complained of a parastomal bulge and the other nausea, 
vomiting and abdominal bloating) did not undergo CT imaging as a decision was 
made to determine whether a hernia was present at the time of stoma reversal. 
Additionally, it is acknowledged that Permacol® costs significantly more than Vypro® 
134 
 
(£770 per 10x10cm, 1.0mm thick, sheet compared to ~ £60 per 10x15cm sheet), the 
mesh employed by Janes et al in the only published randomised controlled trial for 
parastomal hernia prevention to date126. Further appropriately powered studies will 
have to be undertaken to assess not only the efficacy of Permacol® reinforcement of 
stomas compared to conventional stomas, but also the efficacy, safety and economic 
cost-benefit of Permacol® over large pore light-weight polypropylene meshes in the 
prevention of parastomal hernias. 
The decision to pilot the technique on defunctioning loop stomas was based on a 
number of factors. Previous studies have demonstrated a 6% herniation rate in loop 
stomas at 3 months33, and it is reasonable to assume that the rate increases with the 
duration of follow-up, as has been shown with end stomas98. Moreover, the 
construction of loop stomas requires a comparatively larger abdominal trephine than 
end stomas, which theoretically places them at greater risk of developing a 
parastomal hernia in the longer term. These are important points when considering 
that the median time to stoma reversal in those patients who underwent stoma 
reversal was 6.5 (range 1–10) months, and that the remainder, either being 
unsuitable or unwilling to undergo reversal, are therefore at increased risk of 
herniation in the longer term. Other factors included the greater technical ease of 
reversing loop stomas, compared to end stomas, in the event of complications, and 
the unique opportunity this study model provided for histological assessment of the 
human host response to the implant.  
The histological data demonstrate that, in this setting of parastomal hernia 
prevention, Permacol® has excellent biocompatibility and resistance to degradation. 
At a median of 7 months in vivo Permacol® induced a mild-to-moderate non-foreign 
body inflammatory response with no evidence of fibrosis or implant contraction, and 
underwent minimal implant degradation. There was evidence of increasing fibroblast 
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integration, proliferation, synthesis of neo-ECM proteins (fibronectin, laminin and 
MMP-1) and neovascularization at the periphery of the implant and via native pores. 
Neo-collagen deposition occurred in an organized pattern, the collagen fibres 
paralleling the implant both at the visceral and parietal surfaces, presumably 
resulting in greater mechanical tissue strength than when originally implanted. 
Although no tensiometer studies were performed, a previous study of this material 
confirmed that it provides adequate and durable prosthetic–native tissue tensile 
strength for use as an hernia prosthesis183. The present observations also concur 
with findings in vitro and in animal model studies180-182;184-186, and further support the 
application of the implant for soft tissue reinforcement, especially when retention of 
mechanical strength is desirable and bowel proximity is a concern. In this context, 
the results suggest that the implant not only has the potential for safe and effective 
use in the extraperitoneal management of parastomal hernias, but also supports the 
role of laparoscopic intraperitoneal placement of this mesh for parastomal and other 
incisional hernias. 
Although the data indicate that the implant exhibits a number of the crucial 
requirements of an abdominal wall repair material, only limited (rather than full 
thickness) fibrovascular ingrowth was observed. For implants to fulfil a repair 
function a balance must be struck between implant degradation, cellular infiltration 
and neovascularization, and subsequent formation of a neo-ECM. The implant‟s 
biocompatibility and prolonged biodegradation is largely dependent on isocyanate-
induced cross-links between the polypeptide chains. These have the dual function of 
suppressing biodegradation, by inhibiting polymorphonuclear cell phagocytosis and 
resisting MMP activity, and consequently improving biocompatibility by reducing the 
availability of cleaved antigenic molecular components. It is this resistance to the 
action of MMPs that mostly probably limits fibrovascular ingrowth357, although the 
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increasing deposition of MMP-1 observed over the study period suggests that further 
fibrovascular integration may occur with longer follow-up. Two rodent model studies 
comparing Permacol® with a non-cross-linked porcine derived alternative (Surgisis®), 
showed that although Surgisis® demonstrated a significantly greater degree of 
fibrovascular integration and collagen deposition at 9-weeks187, there was no 
difference at 20-weeks185.  
Increasing the porosity of a biomaterial has been shown to increase subsequent 
cellular ingrowth and neovascularisation, the pore size of the biomaterial being 
critical to its performance358. A further consideration is the distance of cells more 
than 200µm from a blood vessel being prone to hypoxia and limitation of other 
nutrients358. However, attempts to increase the rate and degree of vascularisation of 
Permacol®, by increasing porosity with a diamond CO2 laser and topical application 
of vascular endothelial growth factor (VEGF), demonstrated that vascular ingrowth 
was still limited to the laser pores alone and pre-soaking the implant in VEGF did not 
influence the vascularity of the surrounding material40. Studies employing alternate 
cross-linked biomaterials have shown that the time taken for full-thickness 
fibrovascular integration increases proportionally with the percentage cross-linkage 
of the implant359, and therefore although Permacol® has excellent potential for soft 
tissue reinforcement, modifications (such as reducing the degree of cross-linkage) 
may be required if more rapid full-thickness cellular integration is deemed necessary 
for its intended purpose.  
In conclusion, using a cross-linked xenogeneic collagen implant to prevent 
parastomal hernias seems safe (especially in regards to bowel related 
complications), technically feasible and is potentially efficacious. Further study, 
employing appropriately powered sample sizes, longer-term follow-up and cost-
benefit analysis, is now required to establish whether this implant is at least as 
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effective as synthetic mesh at preventing parastomal herniation, and which is 
associated with the fewest complications and provides the best economic cost-
benefit. In this respect, and as a progression of the pilot study, a multi-centre 
randomized controlled trial (Permacol® Reinforcement of Permanent Stomas Versus 
Standard Technique in Reduction of Parastomal Hernia, PROPHECI) aiming to 
prospectively recruit 300 patients is currently in progress. An additional challenge will 
be to identify whether all patients undergoing stoma formation should undergo 
prophylactic primary mesh placement or if the procedure should be targeted at those 
most at risk of such a complication. 
 
2.5 Permission to reprint 
 
The majority of clinical data presented, including Tables 2.3 & 2.4 and Figures 2.2 & 
2.3, are reproduced from the article: Hammond TM, Huang A, Prosser K, Frye JN, 
Williams NS. Parastomal hernia prevention using a novel collagen implant: a 
randomised controlled phase 1 study. Hernia 2008; 12(5):475-481.  Permission was 
granted by Springer on behalf of Hernia 
The majority of histological data presented, including Tables 2.1 & 2.2 and Figures 
2.1 & 2.4 – 2.9, are reproduced from reference 377. Permission was granted by J 
Wiley & Sons on behalf of the British Journal of Surgery. 
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Chapter 3  
The Snug Seton: short and medium term results of slow 
fistulotomy for idiopathic anal fistulas 
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3.1 Introduction 
The treatment of anal fistulas is necessarily diverse, not least because no single 
technique is universally effective. To date, fistulotomy remains the most effective 
way of eradicating the pathology, but division of those sphincter muscle fibres 
enclosed by the tract, renders the patient at risk of faecal incontinence, with reported 
rates ranging from 5 to 40%255. A prospective study of the effects of fistulotomy has 
revealed that even division of the internal anal sphincter alone is associated with a 
significant incidence of functional impairment250. Fistulotomy is thus usually reserved 
for those patients in whom the consequences of sphincter division are anticipated to 
result in minimal functional disturbance, i.e. „low‟ fistulas, as interpreted by the 
individual surgeon, and those patients with good pre-operative function and strong 
anal sphincters. For those in whom fistulotomy is not recommended (including those 
in whom even minor degrees of incontinence would be unacceptable), alternative 
strategies exist including „sphincter conserving‟ methods or the placement of a long-
term loose draining seton. The former have outcomes that are relatively poor in 
terms of fistula persistence275;297;302;307 and the latter, whilst not placing the sphincter 
at risk, is simply palliative248. A study of the loose seton technique for healing 
transsphincteric fistulae (in which the external anal sphincter is preserved) has 
revealed significant recurrence rates over the long-term268. 
An alternative to one-stage fistulotomy is the tight or cutting seton, by which the 
muscle enclosed by the seton is more slowly divided. Although several studies have 
reported successful eradication of „high‟ fistulas using this method, the majority have 
unacceptable rates of both frequency and severity of anal incontinence270;272-275;277-
290, especially when the interval between tightening is short288. Thus, the cutting 
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seton is not recommended in „high‟ fistulas or patients predisposed to continence 
disturbance274. 
A modification of the cutting seton technique was therefore conceived, based upon 
the following principles: 
• Reduced continence disturbance, effected by a slower gradual severance of tissue 
(it seeming intuitive that the incidence and severity of incontinence might relate to 
the speed with which sphincter division is effected: the slower the division, the lower 
the risk to continence222;274). 
• The lack of requirement for replacement or re-tightening, and minimal patient 
discomfort, thereby allowing early return to normal activity, due to the elastic nature 
of the seton which ensures it slowly migrates caudally.  
The aim of this study was to assess the short and intermediate outcomes of this 
technique. 
 
3.2  Patients and methods 
 
3.2.1 Patients 
Patients were selected from those undergoing surgery for anal fistula by a single 
Consultant Surgeon at 2 hospitals over a 5-year period, during which a total of 191 
anal fistula operations were performed. These included one-stage fistulotomy, 
palliation by long-term loose seton and the snug seton technique. 
The snug seton technique was offered to patients based on the following criteria: 
• The fistula aetiology was deemed cryptoglandular. 
• The patient was keen for fistula eradication, rather than palliation. 
• No symptoms of incontinence, but a substantial threat to continence posed by 
conventional fistulotomy. 
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• Acute sepsis and secondary tracts, if present, had been dealt with adequately 
previously, leaving a single primary tract (as with all „advanced‟ techniques). 
3.2.2 Snug seton surgical technique 
Informed consent was obtained from all patients. They were given appropriate 
thromboembolic prophylaxis and a pre-operative phosphate enema. Detailed 
examination was performed under anaesthesia (EUA) in the lithotomy position and 
the fistula characterized according to both Parks‟ classification215;228, and for 
transsphincteric fistulas, the level defined according to where the tract crossed the 
external anal sphincter (EAS) in relation to the dentate line (high, mid (at the level of 
the dentate line) or low). The extrasphincteric component of the primary tract was 
either excised by core fistulectomy, or laid open, using diathermy. The primary tract 
traversing the sphincter was thoroughly curetted if granulation tissue was present, 
and cored out if epithelialized. Excised tracts were sent for routine histopathological 
analysis. Sharp division of the skin and anoderm was performed to denude the 
sphincter below the tract, but with no internal sphincter division. A 1 mm silastic 
seton (silicone nerve vessel retractor, Medasil®) was drawn into position using a 0 ⁄ 0 
nylon suture, passed along a grooved fistula probe. This was then „snugly‟ tied 
around the sphincter muscle, so that it abutted the enclosed tissue, but with only 
minimal tension. A Spongostan® (Johnson & Johnson Medical Ltd, Skipton, UK) 
intra-anal dressing was inserted, and Kaltostat® lightly tucked into any external 
wound. Gauze, dressing pad and mesh pants were used to support the dressing. 
Post-operatively, patients received regular Milpar, Fybogel, Paracetamol and 
Diclofenac (if not contraindicated). Patients were discharged home when 
comfortable, usually the evening of surgery or the following morning, depending on 
the size of the external wound. When necessary, patients had a daily change of 
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wound dressing performed by a district nurse. In those in whom it was evident that 
the seton would not completely cut through spontaneously, patients were 
subsequently admitted as a day case, for EUA and division of the remnant of tissue 
enclosed by the seton (on occasions involving a few subcutaneous EAS fibres). 
Follow-up was performed on a regular basis until the seton had come out 
(spontaneously or surgically released), the fistula was deemed to have been 
eradicated and all wounds had satisfactorily healed.  
 
3.2.3 Data collection 
The study was approved by the local ethics committee. Short-term assessment was 
performed by case note review to ascertain: 
• The proportion of patients in which the seton cut out completely, without 
intervention, and the time to achieve this; 
• The proportion of patients requiring division of residual enclosed tissue; 
• The proportion of patients with fistula healing, determined by documented symptom 
resolution and no clinical evidence of fistula persistence; 
• The proportion of patients with initial continence disturbance (and severity thereof). 
Medium-term assessment was performed by mailing to each patient an invitation to 
participate with an attached questionnaire, as described by Garcia-Aguilar et al (see 
appendix)360. Patients were contacted two weeks later by telephone, in order to 
record the results. This was performed at a median duration of 42 months (range 
10–64 months) after the seton had either cut through or the residual enclosed tissue 
laid open. The questionnaire specifically assessed: the initial success of the 
procedure, time taken to return to work and for the perianal wound to heal, 
symptoms associated with recurrence (perianal pain, swelling or discharge), 
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continence disturbance (type, grade and duration), the necessity of wearing a pad, 
patient satisfaction and lifestyle alteration caused by the incontinence. Anal 
incontinence was defined as any reported difficulty holding gas, soiling of underwear, 
or accidental bowel movements since surgery360. 
 
3.2.4 Statistical analysis 
Comparisons were made between the time taken for the seton to cut through 
intersphincteric vs transsphincteric fistulas (Mann–Whitney U-test), and the levels 
(high, mid and low) of transsphincteric fistulas (Kruskal–Wallis one-way ANOVA). 
Analysis was performed using a commercially available software package (Prism 4, 
Graftpad software, San Diego, CA, USA). Statistical significance was assigned at the 
5% level. 
 
3.3  Results 
During the study period, 35 patients underwent the snug seton technique. 
3.3.1 Short-term assessment 
Six patients were not included in the analysis. One patient died from an unrelated 
cause before the seton had cut out; one patient‟s seton fell out prematurely through 
knot slippage, and declined re-insertion; and the remaining four patients‟ case notes 
could not be retrieved. Therefore, 29 patients‟ notes (median age: 42 years, range 
26–70 years; 3 female) were available for short term analysis. Seven patients had 
undergone previous fistula surgery (5 fistulotomies, 2 core-out and loose seton 
placements), one had previously undergone manual anal dilatation, and two women 
had experienced obstetric trauma requiring suture repair. However none had any 
symptoms of anal incontinence prior to treatment. Fistulas were classified intra-
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operatively as 9 intersphincteric and 20 transsphincteric (5 high, 6 mid, 9 low). 
Histological analysis revealed no features suggestive of a specific aetiology in any 
patient. 
The results are summarised in Table 3.1. All fistulas (100%) were reported as 
healed. There were no episodes of major incontinence (frank faecal incontinence). 
Ten (34%) patients (1 female; 5 previous surgery; 8 transsphincteric; 3 low, 3 mid, 2 
high; 2 intersphincteric) experienced minor continence disturbance (occasional 
soiling of underwear and ⁄ or flatus incontinence). Other complications included one 
patient complaining of occasional pain on defaecation secondary to development of 
a superficial fissure in the anal scar, one complaining of pruritus in the region of the 
scar tissue, and one patient who developed an abscess lateral to the external 
opening of the fistula 12 weeks post snug seton insertion. This was treated by 
incision and drainage with reinsertion of snug seton, after which no further 
complications developed. 
The time taken for the seton to cut through intersphincteric fistulas (median 7, range 
2–24, weeks) was significantly shorter than for transsphincteric fistulas (median 26, 
range 1–164, weeks, P = 0.004) (Fig. 3.1A). Similarly, the time taken for the seton to 
cut through transsphincteric fistulas was significantly related to the level of the fistula: 
low, median 10 (range 1–38) weeks; mid, median 31 (range 25–80) weeks; high, 
median 84 (range 20–164) weeks (P = 0.045) (Fig. 3.1B). 
 
3.3.2 Medium-term assessment 
Of 29 patients in whom short-term data were available, one patient declined to 
participate, and 12 could not be contacted. Therefore 16 patients (3 female) were 
reassessed: 4 intersphincteric, 12 transsphincteric fistulae (2 high, 4 mid, 6 low). The 
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results are shown in Table 3.2. No patient suffered recurrence, but minor 
incontinence persisted in 4 ⁄ 16 (25%) patients (0 females; 2 previous surgery; 3 
transsphincteric - 2 low, 1 mid; 1 intersphincteric). Two patients (12.5%) felt that their 
lifestyle had been adversely affected (both of whom had permanent minor 
continence disturbance), however, all patients were either „satisfied‟ or „very 
satisfied‟ with the procedure and its outcome (Table 3.3). 
 
Table 3.1 Short-term assessment (n = 29) 
 No. of patients (%)  
or median value (range) 
No. of patients in whom seton cut-out 
without further intervention 
15 (52%) 
Time to cut-out without further 
intervention in weeks 
Median 24 (1 – 164) 
No. of patients requiring division of 
residual tissue 
14 (48%) 
Time to further intervention in weeks  Median 35 (6–118) 
No. of patients whose fistula healed  29 (100%) 
Initial continence disturbance 
In transsphincteric fistulas 
In intersphincteric fistulas 
10 (34%) 
8 ⁄ 20 (40%) 
2 ⁄ 9 (22%) 
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Table 3.2 Medium-term assessment (n = 16) 
 
 
 
  
 No. of patients (%) 
or median value (range) 
Time to perianal wound healing in 
weeks 
Median 3 (1 – 24) 
Time to return to work in weeks Median 2 (0 – 8) 
No. of patients satisfied 
Very satisfied 
Satisfied 
 
11/ 16 (69%) 
5/ 16 (31%) 
No. of patients with fistula recurrence 0 (0%) 
No. of patients with initial continence 
disturbance: 
In transsphincteric fistulas 
In intersphincteric fistulas 
 
7/ 16 (44%) 
5/ 12 (42%) 
2/ 4 (50%) 
No. of patients with persistent 
continence disturbance: 
In transsphincteric fistulas 
In intersphincteric fistulas 
 
4/ 16 (25%) 
3/ 12 (25%) 
1/ 4 (25%) 
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Figure 3.1 (A) Time taken for seton to cut through the enclosed tissue within an 
intersphincteric (IS) vs transsphincteric (TS) fistula. P = 0.004 (Mann–Whitney 
U-test). The horizontal lines represent the median values for each fistula type. 
(B) Time taken for seton to cut through the enclosed tissue vs level of 
transsphincteric (TS) fistula. P = 0.0445 (Kruskal–Wallis one-way ANOVA). The 
horizontal lines represent the median values for each fistula level. 
(A) 
(B) 
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Table 3.3 Effect on lifestyle at medium-term assessment (n = 16) 
 
 
 
 
3.4 Discussion 
Anal fistula management can be problematic; both the individual fistula anatomy and 
the amount of sphincter across which it passes are highly variable, as is the 
individual sufferer‟s expectations of treatment (often dependent upon the duration 
and severity of symptoms, and the number and types of previous attempts at 
eradication). The number of different approaches attests to the failure of any one 
technique to achieve the dual aims of permanent fistula eradication and the 
preservation of sphincteric function. For most people, eradication of symptoms is the 
primary goal, and fistulotomy is the gold standard in this respect. Nevertheless, there 
is a functional price to pay, even for „simple, low‟ fistulas such as distal 
intersphincteric250, just as there is for lateral internal sphincterotomy, the 
questionable gold standard surgical treatment for chronic anal fissure361.  
The traditional use of the loose seton in eradicating transsphincteric fistulas has two 
drawbacks. Firstly, the internal sphincter is divided so as to eradicate the presumed 
infecting source (the diseased anal gland in the intersphincteric space); and 
secondly, initial cure rates of around 50% are compromised by a cumulative 
 Physical activities Social activities Sexual activities 
Not at all 16 (100%) 15 (94%) 15 (94%) 
To some extent 0 0 1 (6%) 
Greatly 0 1 (6%) 0 
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recurrence rate over time268. Cutting or tight setons in contrast, replicate the role of 
fistulotomy in terms of fistula eradication, but also carry the functional risks of 
sphincter division270;272-275;277-286;288-290. The rates of incontinence associated with the 
conventional cutting seton are likely to be proportional to the speed of sphincter 
division. Additionally there is the need for repeated replacement/ tightening of the 
cutting material, unless ingenious appendages are added such that thigh flexion and 
extension effect the cutting362. 
The chemical seton, in which the enclosed tissue is divided by the caustic nature of 
the thread (at a rate of approximately 1 cm every 6 days), when compared to 
fistulotomy has been shown to have no difference in rates of incontinence or 
recurrence, but because the trial designs excluded all those with anything but low 
transsphincteric fistulas, we do not know whether such a technique has a role for the 
more problematic higher fistula293;294. 
The anal sphincter mechanism consists not simply of the internal and external 
sphincters, but also of a complex supporting meshwork derived from the conjoint 
longitudinal muscle layer, which holds these muscles in place, and also gives 
attachment to skin, anal canal mucosa and fascia laterally at the pelvic side walls222. 
Division of the anal sphincter complex thus involves division of this supporting 
framework. The main theory behind the development of the „snug‟ seton was that 
disruption to this framework, and therefore of separation of those muscles it 
supported would be minimized. Furthermore, the use of an elastic material such as 
silastic would avoid the need for repeated replacement or tightening, and be 
relatively comfortable, especially if the underlying sensitive skin and anoderm had 
been divided. 
The results of this procedure, for the treatment of 35 patients with idiopathic anal 
fistula, have been presented. Clearly, the design of the study (retrospective review) 
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has limitations, and mailed and telephone questionnaires are subject to criticism. It 
has been shown that fewer mild symptoms are reported by telephone than by mail 
questionnaire363, and missing data are more frequent for mailed questionnaires than 
for telephone interviews364. The response rate of 55%, at medium-term review, is 
disappointing, and it is therefore possible that data from the remainder of patients 
may have significantly impacted on the medium-term results. However, the response 
rate does reflect the relatively young and highly migrant population within Tower 
Hamlets and Hackney365. Additionally, the preponderance of male patients (26 of 29) 
is a function of the natural preponderance of anal fistulas in males210, and the 
exclusion of those female patients who may have suffered a disturbance to 
continence secondary to obstetric trauma. 
Nevertheless, based on the data presented, the technique has a recurrence rate of 
0%, and short and medium term rates of minor continence disturbance of 34% and 
25%, respectively, with all patients being at least satisfied with their outcome at 
medium-term review. These results merit comparison with those available from other 
procedures. However, difficulties clearly exist with such comparisons in relation to 
fistula aetiology, level or complexity, age, gender, previous anal trauma, as well as 
the methods of assessment. Thus the question of whether, for example, a one-stage 
fistulotomy or traditional cutting seton are superior to the snug seton remains. An 
appropriately constructed prospective randomised controlled trial, employing 
endoanal ultrasound, or preferably MRI using an endoanal coil, to quantify and 
compare the degrees of internal and external sphincter disruption and separation 
incurred, might give the answer366;367. However, the risks to continence of these 
techniques, in the majority of this cohort, would make such a trial debatably 
unethical, and the results of these approaches from the relevant literature support 
this stance255;275. Similarly, the results of this study in terms of fistula eradication 
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would also make it difficult to justify, by strict scientific methodology, comparison with 
sphincter conserving techniques such as mucosal advancement flaps or fibrin glue, 
in which efforts to retain function are compromised by poorer cure rates302;307. The 
use of a silastic cutting seton in the management of transsphincteric fistulas has 
been reported previously, but in that study of 17 patients, initial internal 
sphincterotomy was performed, subsequent tightening was achieved by the 
application of Barron‟s haemorrhoidal bands, and the authors admitted that external 
sphincter involvement (< 40%) was less than that in patients treated by loose setons 
or advancement flaps275. A technique involving an alternative „elastic‟ seton, 
fashioned from the wrist of a surgical glove, has been described which similarly 
relies on the natural recoil of the seton to avoid any need for further tightenings276. 
However the mean time taken for the seton to cut through was 2.5 (range 1.5-4) 
weeks, which implies a tight rather than snug application, and a 20% reduction in 
baseline continence scores in treated patients further emphasises the need for a 
slow severance of enclosed sphincteric muscle. 
There was clearly a wide spectrum of time to sphincter division in this study. It could 
be argued that there is no quantitative assessment of the degree of tension imposed 
by the silastic seton. The aim was that muscle division takes place as slowly as 
possible by snugly applying the seton, so that it abuts the enclosed sphincteric 
tissue, with only minimal tension. The relations between fistula classification and 
level, and time to cut through, indicate that similar tension was in fact applied 
amongst the patients. Numbers were too small to determine relations of sex, 
previous anal surgery⁄ trauma, fistula classification or level, time for the seton to cut 
through or lay open of residual enclosed tissue, and postoperative continence. Knot 
failure in one patient has led to subsequent knot securement with a reinforcing 0 ⁄ 0 
Ethibond™ (Ethicon™, Johnson & Johnson International) thread. 
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It might be argued that patients should have undergone both pre-operative magnetic 
resonance imaging (MRI), the gold standard for anal fistula imaging233;368-370, and 
anorectal physiological testing. However, MRI is not clinically indicated in the 
majority of cases of anal fistula, in whom fistula topography may be accurately 
obtained clinically, or at surgery, by an experienced fistula surgeon (in this case, the 
senior trial investigator and supervisor of this thesis). The fact that the snug seton 
method was successful in fistula eradication, in all cases when assessed at medium-
term review, attests to this. Nevertheless, the importance of converting a fistula, 
complicated by secondary extensions or collections, to a single primary tract (with 
the external opening adjacent to the denuded sphincteric component), cannot be 
overstated, and if there is uncertainty then MRI, whose clinical usefulness lies mainly 
in the detection of secondary extensions, should be employed. The results of pre-
operative physiological assessment may identify patients at risk249, but have been 
shown in a prospective study, not in fact, to predict postoperative physiological or 
functional outcomes250. In that study, disturbances in postoperative continence 
appeared to relate mainly to anodermal sensitivity and reduced postoperative resting 
pressure profiles (rather than squeeze pressures). The latter relates predominantly 
to internal anal sphincter division (presumably in terms of both length and width of 
the resultant defect), and the former to scarring, relating more to the proportion of the 
anal luminal circumference affected, especially after lay open of transsphincteric 
fistulas. In such situations, the degree of separation of the divided mucosa ⁄ anoderm 
would presumably be greater, incurred by division of both main sphincteric muscle 
components.  
Although in the short term, the majority of patients have previously been shown to be 
happy to put up with „minor‟ degrees of incontinence as a reasonable price to pay to 
be rid of sepsis250, and that with time continence improves in some patients, a 
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proportion will remain in status quo or may in fact in the longer term deteriorate371.  
The technique of the snug seton goes some way to improving the functional outcome 
for such patients, without compromising on the rates of fistula eradication achieved 
by more established „lay open‟ techniques, and merits addition to the fistula 
surgeon‟s list of possible surgical approaches. However these purely surgical 
strategies, irrespective of novel adaptations to technique or material, by their very 
nature will always require fistula eradication and maintenance of continence to be 
directly competing priorities. The recent use of strategies employing modern 
biomaterials aimed at tissue repair, rather than minimizing destruction, although not 
yet as efficacious as their traditional counterparts, represent a great leap forward and 
offer the most likely path to achieving the fistula surgeons‟ panacea. 
 
3.5 Permission to reprint 
All data, figures and tables are reproduced from reference 373. Permission was 
granted by J Wiley & Sons on behalf of Colorectal Disease. 
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Chapter 4  
Management of Idiopathic Anal Fistula Using Cross-
linked Collagen: A prospective phase 1 study 
  
155 
 
4.1 Introduction 
The balance between fistula eradication and preservation of continence has already 
been addressed. Biomaterials in the form of fibrin glue and an anal fistula plug, 
composed of lyophilised porcine small intestine submucosa (Surgisis®, Cook 
Surgical, Bloomington, USA), have been recently used as part of novel strategies to 
promote fistula healing whilst avoiding sphincter disruption307;333.  Both have similar 
widely variable initial success rates, which decrease with the duration of follow-
up263;306-310;334;337-345.  Proposed reasons for their failure include those associated 
with recurrence after conventional therapy, early extrusion of the biomaterial, and 
those specific to their biology318;336. Deemed critical to the success of all traditional 
sphincter sparing techniques are the elimination of acute sepsis, the eradication of 
secondary extensions, and the adequate removal of all granulation or epithelial 
tissue lining the tract227;251;253. Interestingly, only the former is recommended by a 
published consensus statement on the optimal management protocol for the AFP335. 
Biologically, fibrin glue‟s limitations are two-fold: it seems to encourage 
epithelialisation across the openings of the fistula, rather than actual fistula healing, 
with the former often misinterpreted as evidence of the latter252; and fibrin glue is 
resorbed within five to ten days, which is insufficient time to act as a scaffold for 
tissue repair325. In contrast, porcine small intestine submucosa has been shown to 
successfully support tissue repair in clean environments, however there are 
conflicting reports as to whether it can reproduce such success in contaminated 
fields, due to relatively high rates of bacterial colonisation and subsequent premature 
lysis77;166;169;170;372. 
An alternative biomaterial is Permacol® (Tissue Science Laboratories Plc, Aldershot, 
UK), a porcine-derived acellular dermal collagen, which is cross-linked to prevent 
early enzymatic degradation180. It is available as a solid implant and as a milled fibre  
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suspension, and both preparations would seem to offer advantages for fistula repair. 
The solid implant can be easily sited and fashioned to the dimensions of a fistula, in 
a similar manner to the anal fistula plug, but as demonstrated in chapter 2, although 
biocompatible, full thickness host tissue integration can be prolonged. The milled 
fibres need to be retained within the fistula, and for this purpose could be suspended 
in fibrin glue. Following epithelialisation of the tract openings and rapid glue 
resorption, the remaining collagen fibres provide a robust network of bioscaffolds 
with the potential for rapid host tissue integration. 
The aims of this phase 1 trial were to assess the safety, feasibility and potential 
efficacy of using this cross-linked collagen, as either a solid implant or as milled 
fibres suspended in fibrin glue, to treat idiopathic anal fistulas. 
 
 
4.2 Methods and materials 
The study was approved by the local ethics committee (REC reference: P/03/870), 
and informed consent was obtained from all patients participating in the study. 
 
4.2.1 Selection criteria 
Consecutive patients with an anal fistula deemed idiopathic, under the care of a 
single surgeon, and in whom fistulotomy was deemed unsuitable (on the basis of the 
fistula type and level, threat to continence or patient choice) were prospectively 
invited to participate in the study. Invited patients were provided with an information 
sheet detailing pre-operative assessment, the aims and potential complications of 
treatment, and follow up arrangements. 
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4.2.2 Pre-operative assessment 
Patients underwent pre-operative symptom and continence assessment, and clinical 
examination. Patients also underwent station pull-through anal manometry to 
determine resting and squeeze pressures along the length of the anal sphincter, 
endoanal ultrasound (EAUS) to assess sphincter integrity, and magnetic resonance 
imaging (MRI) using standard anal fistula sequencing to determine fistula 
anatomy237. Patients with either clinical or radiological evidence of secondary tracts 
or acute sepsis were excluded from the trial until these had been eradicated, leaving 
a single (usually loose seton drained) primary tract. 
 
4.2.3 Materials 
Approval for the use of all materials had been obtained from the Medicines Control 
Agency. 
 
4.2.3.1 Permacol® 
Biological and manufacturing details as per Chapter 2. The solid implant was 
fashioned from sterile sheets 1.0 mm in thickness. The Permacol injection® (Tissue 
Science Laboratories Plc), is a 2.5 ml 60% (wet weight/volume) suspension in saline 
of the cryogenically milled implant, with a defined particle size of 150 μm in diameter. 
Tissue Science Laboratories Plc unconditionally donated both materials.  
 
4.2.3.2 Fibrin glue 
The 1.0 ml Tisseel Kit® -Two Component Fibrin Sealant (Baxter Healthcare Ltd, 
Newbury UK) was employed. 
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4.2.4 Surgical technique 
Patients were given venous thromboembolic prophylaxis, but no specific bowel 
preparation or perioperative antibiotics. Examination under anaesthesia was 
performed in the lithotomy position. Following confirmation of a single primary tract 
and position of the internal opening using a variety of angled fistula probes, the 
fistula was characterised according to Parks‟ classification228.  For trans-sphincteric 
fistulas the level was defined according to where the tract crossed the external anal 
sphincter in relation to the dentate line (high, mid [at the level of the dentate line] or 
low)373.  The extrasphincteric component of the primary tract was excised by core 
fistulectomy, using coagulation diathermy, and sent for histopathological appraisal. 
The primary tract traversing the sphincter was thoroughly curetted if granulation 
tissue was present, cored out if epithelialised, and chemically cleansed with dilute 
hydrogen peroxide followed by saline lavage. After tract preparation, patients were 
randomly assigned, by means of opening consecutively numbered sealed 
envelopes, to receiving either the collagen implant or the collagen suspended in 
fibrin glue. 
 
4.2.4.1 Collagen implant 
The collagen implant was cut into a strip that approximated the dimensions (width 
and length) of the fistula tract, so as to fit snugly within it. Once fashioned, it was 
drawn into position using a 0 ⁄ 0 nylon suture, one end of which was passed along a 
grooved fistula probe within the prepared tract, and the needle at the other end used 
to secure the implant so that it could be drawn into the tract. Excess material was 
trimmed at the internal and external openings, and the implant sutured into the tract 
at both openings, with the mucosa at the internal opening closed over the tip of the 
implant using 3/0 vicryl.  
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4.2.4.2 Collagen-fibrin glue 
One millilitre of the Permacol injection® was injected into a 1.5 ml sterile Eppendorf 
Biopur® pipette tip (Eppendorf UK Limited, Cambridge, UK), and centrifuged at 1100 
rpm for 5 minutes. The saline supernatant was discarded, and the residual collagen 
fibres resuspended in 1.0 ml calcium chloride solution supplied with the Tisseel Kit®. 
The individual components of the Tisseel Kit® were then prepared as per the 
manufacturers‟ instructions. mixed, warmed in a Fibrinotherm™ (Baxter AG, Vienna, 
Austria) and were then drawn up into two syringes (syringe 1: fibrinogen and 
aprotinin; syringe 2: thrombin and collagen fibres suspended in calcium chloride 
solution), which were subsequently placed in a Duploject™ (Baxter AG) two-syringe 
clip, where they shared a common plunger. A plastic double-lumen Y-connector 
joined these two syringes. This apparatus was then attached to a 21-gauge cannula, 
passed along a grooved fistula probe, the tip of which was visualized at the internal 
opening. On injection, the components combined at the cannula tip to form a 
collagen-fibrin glue mixture. Slow withdrawal of the cannula during instillation, and 
visualization of the mixture extruding from both internal and external openings 
ensured tract filling. The collagen-fibrin glue did not run out of the fistula, but on 
injection, almost instantaneously, formed a clot, which was retained within the tract; 
this was allowed to set for 2 – 3 minutes. Excess clot from each opening was 
removed with scissors, and the internal opening closed with 3/0 vicryl. 
 
In both techniques, the external opening was only partially closed, using 3/0 vicryl, 
so as to allow drainage of any inflammatory exudate. Gauze and mesh pants were 
used to protect the wound. Post-operatively, patients received regular stool softeners 
and bulking agents, and simple analgesics. Patients were discharged home within 24 
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hours of surgery. They were advised to keep the area dry for 48 hours, and to avoid 
swimming, cycling, horse-riding and sexual activity for 2 weeks following surgery. 
 
4.2.5 Follow-up 
At the initial 3-month follow-up, patients underwent symptom and continence 
assessment via a questionnaire as described in Chapter 3 (see Appendix)360, clinical 
examination, and repeat anal manometry and EAUS. The questionnaire also 
assessed the initial success of the procedure, time taken to return to work and for 
the perineal wound to heal, and symptoms associated with recurrence (perianal pain, 
swelling or discharge). Thereafter clinical follow-up was performed at 6, 9, 12, and 
18 months, and then annually. 
 
4.2.6 Statistical analysis 
Comparisons were made between the fistula healing rates in the two groups (Fishers 
exact test), and pre and post-operative anal resting and squeeze pressures (paired t-
test). Analysis was performed using a commercially available software package 
(Prism 4, Graftpad software, San Diego, CA, USA). Statistical significance was 
assigned at the 5% level. 
 
4.3 Results 
The flow of patients through each stage of the trial is summarised in Figure 4.1. 
Forty-three patients were invited to participate from September 2004 to December 
2007, of whom 29 were eligible for randomisation. All 14 ineligible patients were 
excluded on the basis of MRI findings of secondary tracts or abscess. Patient 
demographics, previous fistula surgery and fistula classification are presented in 
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Table 4.1. Of note, all patients had had previous fistula surgery, of whom 23 had 
undergone procedures to simplify the anatomy, i.e. to eradicate secondary 
extensions, confirmed on MRI. Sixteen patients were randomised to receive the 
collagen-fibrin glue, and 13 to the collagen implant. One patient in the former group 
was lost to follow-up, and two further patients in the same group declined 
postoperative physiological and ultrasound assessment. Thus, clinical data from 28, 
and physiological data from 26 patients were available for analysis. Histology of 
excised tracts revealed no features suggestive of a specific aetiology in any patient. 
The clinical findings are summarised in Table 4.2. No patient in either group 
experienced postoperative acute perineal sepsis, or continence disturbance, and 
sphincter integrity was unchanged. There was also no change in sphincter function. 
Maximum resting anal pressures and maximum squeeze increments were 
unaffected by surgery in either group (Table 4.3, Figure 4.2), and analysis of 
pressures at each station within the anal canal similarly revealed no changes in 
either parameter (Table 4.4). At a median of 29 (4 – 43) months, 12 of 15 (80%) 
patients treated with the collagen-fibrin glue were symptom free, with clinical 
evidence of a healed fistula, compared to 7 of 13 (54%) patients treated with the 
collagen implant (P = 0.2275). Evidence of recurrence in the three patients 
unsuccessfully treated with the collagen-fibrin glue arose at 1, 3 and 4 months, and 
in the 6 failures with collagen implants, at a median of 6 months (range 1 – 13). 
Those patients who were symptom free reported satisfaction and those whose 
symptoms recurred reported dissatisfaction with the treatment. 
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Allocated to collagen implant 
(n= 13) 
Received allocated intervention 
(n= 13) 
 
    
Randomised (n=29) 
C
h
a
p
te
r 
5
 
E
n r o l l m e n t 
C
h
a
p
te
r 
4
 
A
l l o c a t i o n
 
C
h
a
p
te
r 
3
 
F
o l l o w  u p
 
C
h
a
p
te
r 
2
 
n a l y s i s
 
 
F
o
ll
o
w
 u
p
 
Analyzed (n=13) 
 
Excluded from clinical analysis (n= 0) 
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sepsis evident (n= 14) 
- Refused to participate (n= 0) 
Lost to follow-up (n=1) 
- Patient no longer contactable 
Chapter 1  
Figure 4.1 Flow chart of patient progression through trial 
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Table 4.1 Patient demographics and fistula classification 
 
 Collagen Implant 
    (n = 13) 
Collagen-Fibrin Glue 
    (n = 16) 
 
Median age (range) 
 
 
43 (35 – 53) 
 
42 (26 – 56) 
Sex ratio (M : F) 
 
9 : 4 9 : 7 
Previous surgery: 
 Lay open 
 Cutting seton 
 Anal Fistula Plug 
 Conversion to 
primary tract & loose 
seton 
 
1 
1 
0 
11 
 
2 
1 
1 
12 
Classification: 
 Intersphincteric 
 Trans-sphincteric 
- High  
- Mid 
- Low 
 
2 
11 
0 
7 
4 
 
2 
14 
2 
10 
2 
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Table 4.2 Clinical outcome 
 
 Collagen Implant  
(n = 13) 
Collagen-Fibrin Glue 
(n = 15) 
 
Wound healing time in 
weeks: median (range) 
 
 
3 (2 – 4) 
 
4 (1 – 6) 
Return to work in weeks: 
median (range) 
 
2 (1 – 2) 1 (1 – 4) 
Patient satisfaction: 
 Very satisfied 
 Satisfied 
 Dissatisfied 
 Very dissatisfied 
 
 
4 
3 
2 
4 
 
8 
4 
1 
2 
Asymptomatic 
 
7 12 
Clinically healed 
 Intersphincteric 
 Trans-sphincteric 
- High  
- Mid  
- Low 
 
7 
2 / 2 
5 / 11 
- 
3 / 7 
2 / 4 
12 
2 / 2 
10 / 13 
2 / 2 
8 / 9 
0/ 2 
Continence disturbance: 
 Intersphincteric 
 Trans-sphincteric 
 
 
0 
0 
 
0 
0 
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Table 4.3 Pre- and postoperative maximum anal pressures. 
  
 
Collagen-fibrin glue 
(n = 13) 
 
Collagen implant 
(n = 13) 
 
Maximum 
resting pressure 
(cmH2O) 
 
 
Maximum 
squeeze increment 
(cmH2O) 
 
Maximum 
resting pressure 
(cmH2O) 
 
 
Maximum 
squeeze increment 
(cmH2O) 
pre-op post-op pre-op post-op pre-op post-op pre-op post-op 
 
89 (8.2) 
 
89 (7.2) 
 
91 (7.9) 
 
93 (7.9) 
 
90 (7.7) 
 
83 (4.5) 
 
127 (18.1) 
 
134 (18.6) 
 
P = 0.9459 
 
 P = 0.8651 
 
P = 0.4022 
 
P = 0.5464 
values represent: mean (SD) 
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Table 4.4 Results of pre- and postoperative station pull-through manometry  
  
 
distance from 
anal verge 
(cm) 
 
Resting pressure 
(cmH2O) 
 
Squeeze increment 
(cmH2O) 
 
pre-op 
 
post-op 
 
P 
 
pre-op 
 
post-op 
 
P 
 
4 
 
46 (5.6) 
 
39 (5.4) 
 
0.3034 
 
54 (7.0) 
 
67 (9.7) 
 
0.0774 
3 70 (7.2) 61 (5.1) 0.2800 70 (8.8) 74 (9.5) 0.5882 
2 69 (5.2) 70 (5.0) 0.8776 86 (10.4) 87 (9.6) 0.9246 
1 53 (4.4) 56 (4.5) 0.5680 83 (9.0) 80 (9.4) 0.6793 
values represent: mean (SD) 
results are combined (n = 26) 
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Figure 4.2 Individual changes to (A) maximum resting anal pressures and 
(B) maximum squeeze increments in both treatment groups. Mean values 
are indicated. 
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4.4 Discussion 
The results of this prospective phase 1 study to assess the role of porcine derived-
cross-linked collagen (Permacol®) in the management of idiopathic anal fistulas 
demonstrates that the two techniques used are safe, technically feasible and 
potentially efficacious. At the initial 3-month follow-up, no patient in either group 
experienced acute perianal sepsis, symptoms of incontinence, or changes to anal 
sphincter function or integrity. Technically, the procedures were not difficult to 
perform, and should not impact on any further treatment in the event of failure. 
Indeed, two patients in whom initial treatment failed (one from each arm of the trial) 
have subsequently undergone collagen-fibrin glue treatment (outside the trial) with 
healing to date. Both techniques have the potential to permanently heal idiopathic 
anal fistulas: at a median of 2½ years, 80% of patients treated with the collagen-
fibrin glue, and 54% of patients (P = NS) treated with the collagen implant were 
healed. Patient satisfaction was understandably linked to the successful eradication 
of their fistula and related symptoms. As this was primarily a proof of concept study, 
a third (control) arm was not included, and pre-study statistical considerations such 
as sample size calculations were not performed. It is acknowledged therefore that 
failure to demonstrate superiority of one technique over the other may have been 
due to the relatively small number of patients studied.  
It can be argued that patients should have undergone post-operative MRI to provide 
radiological confirmation of fistula healing over external opening epithelialisation. 
However, the evidence to date indicates that where skin healing is mistaken for 
evidence of actual fistula healing, almost all recurrences occur within 16-months252. 
Additionally, it is unlikely that standard anal fistula MRI protocols are of sufficient 
sensitivity to differentiate between a persistent fistulous tract, a healing tract with 
collagen in situ, or the scarred remnant of a healed fistula. An alternative sequencing 
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technique aimed at predicting fistula healing has been described252, and may be of 
future use in this setting. 
It is likely that the initial key to the success of all sphincter preservation techniques, 
regardless of whether they are purely „surgical‟ or employ a biological or synthetic 
material, is in providing the correct environment for healing to occur. Before the 
advent of biomaterial use in fistula surgery, the results of advanced techniques 
aimed at fistula eradication without sphincter compromise, notably advancement 
flaps, indicated that eradication of secondary extensions and abscesses were a pre-
requisite for success. Indeed, the presence of such complicating factors meant that 
the numbers of patients eligible for entry into this trial (n = 29) was lower than the 
number initially recruited (n = 43). The high prevalence of complex fistulas reflects 
the predominantly tertiary referral nature of the practice, with all 29 patients having 
previously undergone some form of fistula surgery, twenty-three of whom had 
undergone surgical treatment specifically to simplify fistula anatomy, subsequently 
confirmed on MRI. 
On theoretical grounds, attention to the primary tract is also necessary to optimise 
the chances of success by biomaterial track plugging. The aim is to convert the 
chronically inflamed or epithelialised tract, often surrounded by dense fibrosis, to an 
acute wound, thereby allowing the healing cascade to recommence with the potential 
for progression to complete tissue repair253. In the present study this was achieved 
through core out of the extrasphincteric component, and either de-epithelialisation or 
thorough curettage, followed by chemical cleansing, of the sphincteric component. 
Failure to adequately remove all granulation or epithelial tissue lining the fistulous 
tract affects fibroblast and endothelial cell migration, and possibly in conjunction with 
incomplete removal of the presumed source (the diseased intersphincteric anal 
gland), will inhibit healing252;253;374. Nonetheless, if adequate tract preparation alone 
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was sufficient to guarantee permanent fistula healing, it could be argued that those 
sphincter preservation techniques in which this is performed, such as fistulectomy, 
with or without closure of the internal opening (by stitch closure or mucosal 
advancement flaps) should be more successful than the evidence 
suggests268;297;298;375.  
An additional success limiting factor has therefore been proposed, that fistula 
persistence/ recurrence may be due to the lumen of the tract remaining as a void, 
and the lack of contact of apposing prepared walls thus preventing cellular 
interaction and void-filling tissue growth374. Fistulotomy is the most successful fistula 
eradication strategy to date, and the most likely reason is that by laying open the 
tract all the aforementioned aims are achieved in conjunction with the conversion of 
an enclosed void to an open wound. Hence, for any sphincter preserving techniques 
to achieve equivalent efficacy, following creation of an appropriate environment for 
fistula repair, an infill material is required, which not only bridges the defect but 
intuitively allows full host tissue incorporation and neovascularisation, whilst 
withstanding premature degradation and bacterial colonisation. 
Fibrin glue, the most widely studied biomaterial in the treatment of anal fistulas, is 
associated with recurrence rates up to a 100% at long-term follow-up263;306-310. A 
number of authors have suggested its failure is secondary to: a liquid consistency, 
allowing it to run out of the fistula tract; the inability of fibrin glue to securely close the 
internal opening; and extrusion of the glue shortly after surgery because of raised 
intra-anal pressures307;310.  However these concerns are not supported by the 
literature, or the personal experience of this technique by both the author and 
supervisor of this thesis318. The effect of excluding patients with sepsis and 
secondary extensions, and employing techniques to optimise the primary tract is not 
clear. Some studies have excluded patients with sepsis beyond the primary track 
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alone, many have not, and with numerous other variables in relation to management, 
it is impossible to determine their specific effect upon outcome307. Additionally, 
studies have shown that fibrin glue does not exhibit those specific biological 
requirements which are most likely to ensure fistula healing, namely host cell 
integration, neovascularisation323;324, and resistance to early degradation325. 
The anal fistula plug (AFP) technique, first published in 2006, was developed in 
order to address both the biological and perceived mechanical concerns associated 
with fibrin glue. Mechanically, the plug was solid, and therefore could not run out of 
the tract on insertion, and could be sutured within the fistula theoretically avoiding 
early extrusion333. Biologically, the material from which the plug was fashioned, 
porcine small intestinal mucosa, had been shown in both laboratory and clinical trials 
to be capable of supporting host soft tissue repair18;128, and certain studies have 
further demonstrated its resistance to infection and subsequent enzymatic 
breakdown77;170. This first report showed a significant improvement in early healing 
rates for high fistulas treated with the AFP compared to those treated with fibrin glue 
(87% versus 40%, P<0.05). However subsequent reports have revealed a similar 
range of healing (24 – 93%) to that associated with fibrin glue (see Table 1.8); and 
this is despite a published consensus, by surgeons experienced with procedure, on 
the proper technique (secondary tracts are not eliminated, and debridement or 
curettage of the primary tract is not advised as this is thought to increase its size and 
therefore the risk of plug expulsion), patient and fistula selection criteria, and pre- 
and postoperative management335. The majority of failures occur in the first 3-
months following surgery, and ironically up to 40% of these are due to early plug 
extrusion336. No published theory has been proposed as to the cause of the 
remaining failures, although certain reports have shown that untreated secondary 
extensions are not significantly associated with fistula recurrence334;340;341;344. 
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However whilst an unprepared fistula tract does not seem to prevent plug extrusion, 
it does (as previously discussed) prevent fibroblast and endothelial cell migration 
which is crucial for healing. Additionally, although Surgisis® (SIS) is capable of 
supporting soft tissue repair in clean wounds, whether it is the best scaffold for repair 
in a clean-contaminated or contaminated field is unclear from the available literature. 
In a canine study, SIS was reported as being relatively resistant to persistent 
infection, following deliberate bacterial contamination, and to support constructive 
tissue remodelling166; whereas in a murine model, SIS was found to serve as a nidus 
for microbial attachment and growth, thus exacerbating surgical site infection372. In 
clinical ventral hernia studies, some authors have concluded that the use of SIS in 
contaminated or potentially contaminated fields is safe, feasible and that, on later 
examination, in most cases the implant becomes totally integrated into the host77; 
others have reported accelerated degradation when SIS has been used to 
reconstruct abdominal wall defects in contaminated environments, which the authors 
hypothesized was responsible for early hernia recurrence169;170.  
Permacol® is a porcine-derived, acellular, isocyanate cross-linked, dermal collagen 
matrix, both preparations of which (a solid sheet and milled fibres in suspension) 
have been demonstrated in vitro and in animal model studies to be biocompatible 
constructs which, unlike fibrin glue and Surgisis®, support cellular integration and 
ECM deposition whilst resisting premature enzymatic degradation, 
respectively180;182;183;186;374;376. The differences in their morphology offer distinct 
individual advantages for fistula repair. The solid implant can be easily sited and 
fashioned to the dimensions of a fistula, in a similar manner to the anal fistula plug, 
although (as shown from the work in Chapter 2, and in conjunction with other 
laboratory studies) full thickness cellular integration can be prolonged182;183;186;377. 
The milled fibre preparation needs to be retained within the fistula, achieved in this 
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study by its suspension in fibrin glue, which through its more liquid nature at 
instillation enables more complete filling of the track. Following fibrin glue induced 
epithelialisation of the tract openings and glue resorption, the remaining collagen 
fibres can provide a robust network of bioscaffolds, with the spaces between 
potentially allowing more rapid full thickness cellular integration374;376. 
The main aim of this study was to establish whether a role existed for a xenogeneic 
cross-linked collagen (Permacol®) in the management of idiopathic anal fistulas, and 
secondarily whether efficacy was influenced by the physical format. Currently, 
greater numbers with longer follow up are required to answer these questions, and 
thus the study remains on going. If sufficient long term efficacy can be demonstrated, 
and one format proven over the other, then an appropriately powered randomised 
control trial would need to be constructed, although the choice of a suitable control 
(such as rectal mucosal or anodermal advancement flap, fistulectomy with direct 
closure, or fistulotomy with immediate sphincter repair) in a field in which there is no 
gold standard, and a wide-range of techniques, each with its proponents, presents a 
challenge in itself.  In the interim, efforts must continue to explore biological agents, 
both in respect of the agents themselves, and the optimum conditions for their use in 
the management of an often challenging condition. 
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Chapter 5  
  Discussion of thesis & 
Proposals for future work 
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This thesis has explored the role of biomaterials in the management of parastomal 
hernia and anal fistula, and identified areas where either adaptation of an existing 
technique, the cutting seton for anal fistulas, or use of a new biological material, 
xenogeneic cross-linked collagen (Permacol®), for prevention of parastomal hernia 
and treatment of idiopathic anal fistula can be utilised to potentially improve the 
clinical outcome for those patients afflicted by these chronic conditions. Both 
diseases essentially represent a failure to progress along the wound healing 
pathway, and their management should therefore involve strategies which address 
those specific areas in which healing has been impeded. 
Parastomal hernias, and indeed all abdominal wall hernias, are at least in part 
considered to represent the end-point of a condition in which there is a shift of the 
collagen ratio from type I collagen, that predominantly confers tensile strength, to 
„„immature‟‟ type III collagen, a temporary scaffold for fibroblast attachment50. The 
weakened abdominal wall is consequently prone to herniation secondary to any 
variety of situations or conditions that increase the intra-abdominal pressure. Any 
material used to reinforce or repair the abdominal wall should intuitively therefore 
either be predominantly composed of type I collagen or correct the balance of 
collagen metabolism. The logic behind the prophylactic placement of mesh to 
prevent parastomal herniation has been previously described, and its success well 
documented34;98;123;125;127. However, prior to the commencement of this thesis only 
the use of synthetic mesh had been described, which is associated with a chronic 
inflammatory foreign body response and therefore the potential for tissue fibrosis, 
bowel erosion, and increased susceptibility to sepsis. The role of Permacol®, a more 
biocompatible material composed of predominantly type 1 collagen, was investigated 
in Chapter 2. The aim of that phase 1 study was to assess the safety, feasibility and 
potential efficacy of using this implant to prevent parastomal hernias, and to evaluate 
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the human host response to its presence. Twenty-five patients were prospectively 
recruited, of whom 15 were randomised to a defunctioning stoma with the implant 
and 10 to a conventional stoma. Follow-up included regular symptom questionnaires, 
clinical examination, stoma site ultrasound, and serum inflammatory markers. At a 
median of 9.5 months a parastomal hernia was clinically evident in 3 of 10 patients 
without the implant, and in 1 of 15 patients with the implant. The latter patient 
prompted a change in the study methodology, in that the implant was subsequently 
sited in the pre-peritoneal opposed to fascial onlay position. There were no other 
associated clinical complications, ultrasound evidence of chronic seroma formation 
or serological evidence of a systemic inflammatory response. Histological data from 
90% of the patients who received the implant and underwent stoma reversal showed 
that all host responses were limited to the periphery of the implant and native pores. 
These included a minimal inflammatory response and implant degradation, evidence 
of fibrovascular infiltration and MMP-1 activity, and organized deposition of host 
collagen, fibronectin and laminin. The specific areas of trial methodology that could 
have been improved upon have been discussed in the aforementioned chapter, but 
nonetheless the data demonstrated that this particular cross-linked xenogeneic 
collagen implant is biocompatible and resistant to degradation in most patients, and 
that although fibrovascular in-growth and ECM deposition were limited, the implant 
has excellent potential for soft tissue reinforcement. It is therefore safe, technically 
feasible to use in this setting, and has the potential to prevent parastomal herniation. 
Following on from this work a multi-centre randomized controlled trial comparing 
Permacol® reinforcement of permanent stomas versus both standard stoma 
formation and reinforcement with a light-weight polypropylene mesh has been 
designed, and addresses both clinical outcome measures and cost benefits. Ethical 
approval has been obtained and patient recruitment is in progress. Future work in 
177 
 
this arena initially needs to focus on whether all patients required to have a stoma 
should undergo prophylactic primary mesh placement or if the procedure should be 
targeted at those most at risk of such a complication. Ultimately, however research 
needs to address abdominal wall hernias in general, and in this regard there seem to 
be two areas of interest. One involves identifying those factors (genetic and 
environmental) responsible for pathologically shifting the pattern of collagen 
deposition, with the aim being to employ measures which rectify this imbalance. 
These could include implants that contain locally acting constituents, or 
pharmaceutical agents that act systemically, to affect fibroblast proliferation and 
collagen metabolism50;356. An alternative strategy, rather than focusing on improving 
the quality of scar tissue, is to evaluate the role of skeletal muscle regeneration 
thereby restoring the native abdominal wall to its pre-pathological mechanical 
state378;379. 
 
Anal fistulas are characterised as being in a state of chronic inflammation and 
fibroblast induced granulation, with an inability of the ECM to progress to full tissue 
reconstitution. Fistulotomy is the most successful treatment to date presumably as it 
converts a chronic enclosed to an acute open wound and eradicates any causative 
and perpetuating pathological factors, which is generally accepted but not absolutely 
proven to be the diseased intersphincteric anal gland. As previously discussed, the 
variable amount of anal sphincter complex enclosed by the fistula means this 
strategy is not suitable for all patients, and techniques for managing such patients 
have been divided into those which traditionally attempt to minimise sphincter 
damage and functional outcome, and more recent treatments which attempt to 
preserve these completely. The cutting seton technique lies within the former group. 
Analysis of published results of this technique show that variations in the speed of 
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tissue severance have little effect on fistula eradication rates but impact considerably 
upon continence rates: the more rapidly the sphincter is divided the greater the 
degree of incontinence. This is hardly surprising when one considers that 
myofibroblast induced wound contraction and fibrosis only start to feature in the 
wound healing pathway 5-7 days following injury, tends to peak at two-weeks, and 
can persist for many more6. Additionally, the cutting seton technique is associated 
with pain and the need for repeat tightenings. Chapter 3 retrospectively assesses the 
short and intermediate outcomes of a modification of this technique, using a „snug‟ 
silastic seton, to treat idiopathic anal fistulas by dividing the enclosed tissue in a 
slower more comfortable fashion. Twenty-nine patients‟ notes were reviewed for 
short-term analysis, of whom 16 participated in a medium-term review at a median of 
42 months. The seton spontaneously cut out in 15 out of 29 (52%) fistulas after a 
median of 24 weeks, and the remainder required division of seton enclosed residual 
tissue (< 5 mm) at a median of 35 weeks. All the patients‟ fistulas healed, but 34% 
had minor continence disturbance in the short-term, and in 25% incontinence 
persisted into the medium-term. Interestingly, despite these levels of incontinence all 
the patients were at least „satisfied‟ with their outcome, which concurs with other 
studies that show that patients are prepared to accept minor degrees of functional 
impairment in preference to the discomfort associated with chronic anal sepsis250;360. 
Nonetheless complete preservation of continence whilst maintaining the high levels 
of fistula eradication described remains the primary goal of fistula surgeons. 
Attempts to achieve these aims by employing biological materials, such as fibrin glue 
and porcine small intestinal submucosa (Anal Fistula Plug™ SIS®), were based on 
sound principles but have demonstrated widely variable fistula eradication rates, 
although in general continence has not unsurprisingly been affected. Technical 
factors, such as early implant extrusion, have been cited as one of the more 
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consistent reasons for their failure, and although this appears to be the case in the 
early post-operative period, it does not account for those whose treatment failed 
despite the material remaining in situ. Two other factors are most likely responsible 
for treatment failure in this latter group of patients. The environment into which the 
materials were introduced does not seem to have been optimised to facilitate 
healing, and the materials themselves may lack one or more of the requirements for 
successful fistula repair. These include full host tissue incorporation and 
neovascularisation, withstanding premature degradation and avoiding bacterial 
colonisation. In vitro and animal model studies, and the human histological data 
presented in Chapter 2, indicate that Permacol® can mostly fulfil these criteria.  
A prospective phase 1 study to assess the potential role of Permacol® in the 
management of idiopathic anal fistulas was therefore constructed. On account of 
concerns regarding the ability of this implant to allow full host integration, two trial 
arms were incorporated in to this feasibility study. One involved suturing a strip of the 
implant (from the sheet format described in Chapter 2) within the fistula tract. The 
other involved using milled Permacol® fibres suspended in fibrin glue and thence 
injecting them into the fistula. The premise being that the fibrin glue would retain the 
collagen fibres within the tract, and that those qualities which most likely contributed 
to the failure of the glue as fistula repair material could be used advantageously. The 
fibrin clot would induce epithelialisation at the fistula openings and then rapidly 
degrade, allowing the individual collagen fibres to act as bridging scaffolds for 
fibroblast attachment and collagen synthesis, and eventually becoming part of the 
developing ECM. Additionally, the spaces between the fibres would potentially allow 
more rapid cellular integration and neovascularisation than the Permacol® sheet. 
Patients, unsuitable or unwilling to undergo fistulotomy were recruited. Pre-
operatively participants underwent symptom, continence and anal physiology 
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assessments, and magnetic resonance imaging. Patients with secondary extensions 
or acute sepsis were excluded. At operation, after removal of any granulation or 
epithelial tissue lining the fistula tract, participants were randomised to receiving one 
of the aforementioned collagen formats. Follow up included repeat symptom, 
continence and physiological assessments at 3 months, and thence regular clinical 
review. Twenty-nine of 43 entrants were eligible for inclusion. Thirteen patients 
received the collagen implant, and 16 collagen-fibrin glue. Three months post-
operation no patient experienced acute sepsis or continence disturbance, and 
sphincter function and integrity were unchanged. At 29 months, 12 of 15 (1 lost to 
follow-up) patients treated with collagen-fibrin glue were healed, compared to 7 of 13 
who received the implant. Therefore in the short to medium term, this study 
demonstrated that the two techniques using xenogeneic cross-linked collagen were 
safe, in terms of both avoiding acute sepsis and damaging the anal sphincter, 
technically feasible and had the potential to heal fistulas. There was a trend in favour 
of the fibre suspension although larger patient numbers and longer follow up are 
required to prove which of these techniques is superior. The difficulties of then 
comparing the more efficacious of the techniques to more established methods of 
fistula eradication in a field dominated by personal preferences, variable pre-
operative degrees of anal continence, and low levels of evidence has been 
previously discussed. An alternative may be to perform a multi-centre study 
comparing the technique under trial with that of the participating surgeons‟ preferred 
technique. There are a number of additional areas that will also need to be 
addressed in the future, and these include identifying why fistulas persist following 
an episode of acute sepsis and the possible role of any hitherto unrecognised 
pathogens (such as Helicobactor pylori in the pathogenesis of peptic ulcer disease); 
why males are more prone to fistulas than females and the possibility of differences 
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in anal gland sensitivity to androgens199; and to examine the local milieu required to 
facilitate tissue repair. The development of biomaterials specifically designed to 
combat any underlying pathological factors would also represent a great leap 
forward. Concepts include biomaterials impregnated with constituents for local 
hormonal or ECM manipulation, and in the case of cross-linked materials, reduced 
degrees of cross-linkage to allow for better tissue integration whilst still withstanding 
premature degradation. Lastly, the success of negative pressure vacuum assisted 
dressings for the management of chronic wounds380;381, and more recently rectal 
anastomotic dehiscence382;383, suggests a possible role for their use in the 
management of anal fistulas. 
 
In conclusion, this thesis has presented a number of novel applications for both 
traditional and contemporary biomaterials in the management of parastomal hernia 
and anal fistula, and although disparate pathologies were addressed, both they and 
the thesis were unified by demonstrating that an understanding of the specific 
disease pathology, wound healing, and the host response to materials (synthetic and 
biological) are central to their successful management. 
  
182 
 
Reference List 
 
 (1)  Peppas NA, Langer R. New challenges in biomaterials. Science 1994; 
263(5154):1715-1720. 
 (2)  Langer RS, Peppas NA. Present and future applications of biomaterials in 
controlled drug delivery systems. Biomaterials 1981; 2(4):201-214. 
 (3)  Ratner BD, Bryant SJ. Biomaterials: where we have been and where we are 
going. Annu Rev Biomed Eng 2004; 6:41-75. 
 (4)  Langer R, Tirrell DA. Designing materials for biology and medicine. Nature 
2004; 428(6982):487-492. 
 (5)  Cho CY, Lo JS. Dressing the part. Dermatol Clin 1998; 16(1):25-47. 
 (6)  Aukhil I. Biology of wound healing. Periodontol 2000 2000; 22:44-50. 
 (7)  Glat PM, Longaker MT. Wound healing. In: Aston SJ, Beasley WR TC, 
editors. Grabb and Smith's Plastic Surgery. 1997. 
 (8)  Bennett NT, Schultz GS. Growth factors and wound healing: biochemical 
properties of growth factors and their receptors. Am J Surg 1993; 
165(6):728-737. 
 (9)  Kumar V, Ramzi CS, Robbins SL. Chapters 1-3. Basic Pathology. 5th ed. 
1992. 3-60. 
 (10)  Habif TP. Dermatologic surgical procedures. Clinical Dermatology: A Colour 
Guide to Diagnosis & Therapy. 3rd ed. 1996. 809-810. 
183 
 
 (11)  Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc 
Biol 2001; 69(4):513-521. 
 (12)  Peled ZM, Chin GS, Liu W, Galliano R, Longaker MT. Response to tissue 
injury. Clin Plast Surg 2000; 27(4):489-500. 
 (13)  Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N 
Engl J Med 1994; 331(19):1286-1292. 
 (14)  Bennett NT, Schultz GS. Growth factors and wound healing: Part II. Role in 
normal and chronic wound healing. Am J Surg 1993; 166(1):74-81. 
 (15)  Anderson JM. Biological Responses to Materials. Annual Review of Material 
Research 2001; 31:81-100. 
 (16)  Cuypers PA, Willems GM, Hemker HC, Hermens WT. Adsorption kinetics of 
protein mixtures. A tentative explanation of the Vroman effect. Ann N Y 
Acad Sci 1987; 516:244-252. 
 (17)  Henson PM. Mechanisms of exocytosis in phagocytic inflammatory cells. 
Parke-Davis Award Lecture. Am J Pathol 1980; 101(3):494-511. 
 (18)  Badylak SF. The extracellular matrix as a scaffold for tissue reconstruction. 
Semin Cell Dev Biol 2002; 13(5):377-383. 
 (19)  Bosman FT, Stamenkovic I. Preface to extracellular matrix and disease. J 
Pathol 2003; 200:421-422. 
 (20)  Bosman FT, Stamenkovic I. Functional structure and composition of the 
extracellular matrix. J Pathol 2003; 200(4):423-428. 
184 
 
 (21)  Hodde J. Extracellular matrix as a bioactive material for soft tissue 
reconstruction. ANZ J Surg 2006; 76(12):1096-1100. 
 (22)  Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative 
functions during pathological stress. J Pathol 2003; 200(4):488-499. 
 (23)  Danen EH, Sonnenberg A. Integrins in regulation of tissue development and 
function. J Pathol 2003; 201(4):632-641. 
 (24)  Stamenkovic I. Extracellular matrix remodelling: the role of matrix 
metalloproteinases. J Pathol 2003; 200(4):448-464. 
 (25)  Badylak SF. Regenerative medicine and developmental biology: the role of 
the extracellular matrix. Anat Rec B New Anat 2005; 287(1):36-41. 
 (26)  Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann 
Med 2001; 33(1):7-21. 
 (27)  Franz MG. The biology of hernia formation. Surg Clin North Am 2008; 
88(1):1-15, vii. 
 (28)  Sorensen LT. Effect of lifestyle, gender and age on collagen formation and 
degradation. Hernia 2006; 10(6):456-461. 
 (29)  Binyamin G, Shafi BM, Mery CM. Biomaterials: a primer for surgeons. 
Semin Pediatr Surg 2006; 15(4):276-283. 
 (30)  Goligher J. Surgery of the Anus, Colon and Rectum. 5th ed. London: 
Bailliere Tindall; 1984. 
 (31)  Pearl RK. Parastomal hernias. World J Surg 1989; 13(5):569-572. 
185 
 
 (32)  Goligher JC. Extraperitoneal colostomy or ileostomy. Br J Surg 1958; 
46(196):97-103. 
 (33)  Carne PW, Robertson GM, Frizelle FA. Parastomal hernia. Br J Surg 2003; 
90(7):784-793. 
 (34)  Helgstrand F, Gogenur I, Rosenberg J. Prevention of parastomal hernia by 
the placement of a mesh at the primary operation. Hernia 2008. 
 (35)  Israelsson LA. Parastomal hernias. Surg Clin North Am 2008; 88(1):113-25, 
ix. 
 (36)  Cuthbertson AM, Collins JP. Strangulated para-ileostomy hernia. Aust N Z J 
Surg 1977; 47(1):86-87. 
 (37)  Goligher JC, Lloyd-Davies OV, Robertson CT. Small-gut obstructions 
following combined excision of the rectum with special reference to 
strangulation round the colostomy. Br J Surg 1951; 38(152):467-473. 
 (38)  McGrath A, Porrett T, Heyman B. Parastomal hernia: an exploration of the 
risk factors and the implications. Br J Nurs 2006; 15(6):317-321. 
 (39)  McAllister JD, D'Altorio RA. A rare cause of parastomal hernia: stomach 
herniation. South Med J 1991; 84(7):911-912. 
 (40)  Thorlakson RH. Technique of repair of herniations associated with colonic 
stomas. Surg Gynecol Obstet 1965; 120:347-350. 
 (41)  Cingi A, Cakir T, Sever A, Aktan AO. Enterostomy site hernias: a clinical and 
computerized tomographic evaluation. Dis Colon Rectum 2006; 
49(10):1559-1563. 
186 
 
 (42)  Moreno-Matias J, Serra-Aracil X, Darnell-Martin A, Bombardo-Junca J, 
Mora-Lopez L, Alcantara-Moral M et al. The prevalence of parastomal 
hernia after formation of an end colostomy. A new clinico-radiological 
classification. Colorectal Dis 2008. 
 (43)  Williams JG, Etherington R, Hayward MW, Hughes LE. Paraileostomy 
hernia: a clinical and radiological study. Br J Surg 1990; 77(12):1355-1357. 
 (44)  Leong AP, Londono-Schimmer EE, Phillips RK. Life-table analysis of stomal 
complications following ileostomy. Br J Surg 1994; 81(5):727-729. 
 (45)  Londono-Schimmer EE, Leong AP, Phillips RK. Life table analysis of stomal 
complications following colostomy. Dis Colon Rectum 1994; 37(9):916-920. 
 (46)  Abcarian H. Peristomal hernias. In: Wexner SD, Vernava AM, editors. 
Clinical Decision Making in Colorectal Surgery. New York: Igaku-Shoin; 
1995. 449-452. 
 (47)  Devlin HB. Peristomal hernia. In: Dudley H, editor. Operative Surgery 
Volume 1: Alimentary Tract and Abdominal Wall. 4th ed. London: 
Butterworths; 1983. 441-443. 
 (48)  Leslie D. The parastomal hernia. Surg Clin North Am 1984; 64(2):407-415. 
 (49)  Shellito PC. Complications of abdominal stoma surgery. Dis Colon Rectum 
1998; 41(12):1562-1572. 
 (50)  Jansen PL, Mertens PP, Klinge U, Schumpelick V. The biology of hernia 
formation. Surgery 2004; 136(1):1-4. 
187 
 
 (51)  Junge K, Klinge U, Rosch R, Mertens PR, Kirch J, Klosterhalfen B et al. 
Decreased collagen type I/III ratio in patients with recurring hernia after 
implantation of alloplastic prostheses. Langenbecks Arch Surg 2004; 
389(1):17-22. 
 (52)  Zheng H, Si Z, Kasperk R, Bhardwaj RS, Schumpelick V, Klinge U et al. 
Recurrent inguinal hernia: disease of the collagen matrix? World J Surg 
2002; 26(4):401-408. 
 (53)  Klinge U, Si ZY, Zheng H, Schumpelick V, Bhardwaj RS, Klosterhalfen B. 
Collagen I/III and matrix metalloproteinases (MMP) 1 and 13 in the fascia of 
patients with incisional hernias. J Invest Surg 2001; 14(1):47-54. 
 (54)  Cannon DJ, Read RC. Metastatic emphysema: a mechanism for acquiring 
inguinal herniation. Ann Surg 1981; 194(3):270-278. 
 (55)  Babcock G, Bivins BA, Sachatello CR. Technical complications of ileostomy. 
South Med J 1980; 73(3):329-331. 
 (56)  Martin L, Foster G. Parastomal hernia. Ann R Coll Surg Engl 1996; 78(2):81-
84. 
 (57)  Nguyen MH, Pittas F. How large should a skin trephine be for an end 
stoma? Aust N Z J Surg 1999; 69(9):675-676. 
 (58)  Etherington RJ, Williams JG, Hayward MW, Hughes LE. Demonstration of 
para-ileostomy herniation using computed tomography. Clin Radiol 1990; 
41(5):333-336. 
188 
 
 (59)  de RP, Bijnen AB. Successful local repair of paracolostomy hernia with a 
newly developed prosthetic device. Int J Colorectal Dis 1992; 7(3):132-134. 
 (60)  Ortiz H, Sara MJ, Armendariz P, de MM, Marti J, Chocarro C. Does the 
frequency of paracolostomy hernias depend on the position of the colostomy 
in the abdominal wall? Int J Colorectal Dis 1994; 9(2):65-67. 
 (61)  Sjodahl R, Anderberg B, Bolin T. Parastomal hernia in relation to site of the 
abdominal stoma. Br J Surg 1988; 75(4):339-341. 
 (62)  von SK, Husa A, Kyllonen L. Long-term results of sigmoidostomy in patients 
with anorectal malignancy. Acta Chir Scand 1986; 152:211-213. 
 (63)  Aguirre DA, Casola G, Sirlin C. Abdominal wall hernias: MDCT findings. AJR 
Am J Roentgenol 2004; 183(3):681-690. 
 (64)  Hojer AM, Rygaard H, Jess P. CT in the diagnosis of abdominal wall 
hernias: a preliminary study. Eur Radiol 1997; 7(9):1416-1418. 
 (65)  Toms AP, Cash CC, Fernando B, Freeman AH. Abdominal wall hernias: a 
cross-sectional pictorial review. Semin Ultrasound CT MR 2002; 23(2):143-
155. 
 (66)  Rieger N, Moore J, Hewett P, Lee S, Stephens J. Parastomal hernia repair. 
Colorectal Dis 2004; 6(3):203-205. 
 (67)  Rubin MS, Schoetz DJ, Jr., Matthews JB. Parastomal hernia. Is stoma 
relocation superior to fascial repair? Arch Surg 1994; 129(4):413-418. 
189 
 
 (68)  Baig MK, Larach JA, Chang S, Long C, Weiss EG, Nogueras JJ et al. 
Outcome of parastomal hernia repair with and without midline laparotomy. 
Tech Coloproctol 2006; 10(4):282-286. 
 (69)  Cheung MT, Chia NH, Chiu WY. Surgical treatment of parastomal hernia 
complicating sigmoid colostomies. Dis Colon Rectum 2001; 44(2):266-270. 
 (70)  Allen-Mersh TG, Thomson JPS. Surgical treatment of colostomy 
complications. Br J Surg 1998; 75(5):416-418. 
 (71)  Burger JW, Luijendijk RW, Hop WC, Halm JA, Verdaasdonk EG, Jeekel J. 
Long-term follow-up of a randomized controlled trial of suture versus mesh 
repair of incisional hernia. Ann Surg 2004; 240(4):578-583. 
 (72)  Luijendijk RW, Hop WC, van den Tol MP, de Lange DC, Braaksma MM, 
IJzermans JN et al. A comparison of suture repair with mesh repair for 
incisional hernia. N Engl J Med 2000; 343(6):392-398. 
 (73)  Rosin JD, Bonardi RA. Paracolostomy hernia repair with Marlex mesh: a 
new technique. Dis Colon Rectum 1977; 20(4):299-302. 
 (74)  Aycock J, Fichera A, Colwell JC, Song DH. Parastomal hernia repair with 
acellular dermal matrix. J Wound Ostomy Continence Nurs 2007; 34(5):521-
523. 
 (75)  Ballas KD, Rafailidis SF, Marakis GN, Pavlidis TE, Sakadamis AK. 
Intraperitoneal ePTFE mesh repair of parastomal hernias. Hernia 2006; 
10(4):350-353. 
190 
 
 (76)  Berger D, Bientzle M. Polyvinylidene fluoride: a suitable mesh material for 
laparoscopic incisional and parastomal hernia repair! : A prospective, 
observational study with 344 patients. Hernia 2008. 
 (77)  Franklin ME, Jr., Trevino JM, Portillo G, Vela I, Glass JL, Gonzalez JJ. The 
use of porcine small intestinal submucosa as a prosthetic material for 
laparoscopic hernia repair in infected and potentially contaminated fields: 
long-term follow-up. Surg Endosc 2008; 22(9):1941-1946. 
 (78)  Franks ME, Hrebinko RL, Jr. Technique of parastomal hernia repair using 
synthetic mesh. Urology 2001; 57(3):551-553. 
 (79)  Inan I, Gervaz P, Hagen M, Morel P. Multimedia article. Laparoscopic repair 
of parastomal hernia using a porcine dermal collagen (Permacol) implant. 
Dis Colon Rectum 2007; 50(9):1465. 
 (80)  Tekkis PP, Kocher HM, Payne JG. Parastomal hernia repair: modified 
thorlakson technique, reinforced by polypropylene mesh. Dis Colon Rectum 
1999; 42(11):1505-1508. 
 (81)  Zacharakis E, Hettige R, Purkayastha S, Aggarwal R, Athanasiou T, Darzi A 
et al. Laparoscopic parastomal hernia repair: a description of the technique 
and initial results. Surg Innov 2008; 15(2):85-89. 
 (82)  Berger D, Bientzle M. Laparoscopic repair of parastomal hernias: a single 
surgeon's experience in 66 patients. Dis Colon Rectum 2007; 50(10):1668-
1673. 
 (83)  Craft RO, Huguet KL, McLemore EC, Harold KL. Laparoscopic parastomal 
hernia repair. Hernia 2008; 12(2):137-140. 
191 
 
 (84)  Devalia K, Devalia H, Elzayat A. Parastomal hernia repair: a new technique. 
Ann R Coll Surg Engl 2005; 87(1):65. 
 (85)  Guzman-Valdivia G, Guerrero TS, Laurrabaquio HV. Parastomal hernia-
repair using mesh and an open technique. World J Surg 2008; 32(3):465-
470. 
 (86)  Kald A, Landin S, Masreliez C, Sjodahl R. Mesh repair of parastomal 
hernias: new aspects of the Onlay technique. Tech Coloproctol 2001; 
5(3):169-171. 
 (87)  Kanellos I, Vasiliadis K, Angelopoulos S, Kanellos D, Betsis D. Repair of 
parastomal hernia with the use of polypropylene mesh extraperitoneally. 
Tech Coloproctol 2004; 8 Suppl 1:s158-s160. 
 (88)  Geisler DJ, Reilly JC, Vaughan SG, Glennon EJ, Kondylis PD. Safety and 
outcome of use of nonabsorbable mesh for repair of fascial defects in the 
presence of open bowel. Dis Colon Rectum 2003; 46(8):1118-1123. 
 (89)  Amin SN, Armitage NC, Abercrombie JF, Scholefield JH. Lateral repair of 
parastomal hernia. Ann R Coll Surg Engl 2001; 83(3):206-208. 
 (90)  Leslie D. The parastomal hernia. Aust N Z J Surg 1981; 51(5):485-486. 
 (91)  McLemore EC, Harold KL, Efron JE, Laxa BU, Young-Fadok TM, Heppell 
JP. Parastomal hernia: short-term outcome after laparoscopic and 
conventional repairs. Surg Innov 2007; 14(3):199-204. 
 (92)  Saclarides TJ, Hsu A, Quiros R. In situ mesh repair of parastomal hernias. 
Am Surg 2004; 70(8):701-705. 
192 
 
 (93)  Guzman-Valdivia G, Guerrero TS, Laurrabaquio HV. Parastomal hernia-
repair using mesh and an open technique. World J Surg 2008; 32(3):465-
470. 
 (94)  Kish KJ, Buinewicz BR, Morris JB. Acellular dermal matrix (AlloDerm): new 
material in the repair of stoma site hernias. Am Surg 2005; 71(12):1047-
1050. 
 (95)  Abdu RA. Repair of paracolostomy hernias with Marlex mesh. Dis Colon 
Rectum 1982; 25(6):529-531. 
 (96)  Bayer I, Kyzer S, Chaimoff C. A new approach to primary strengthening of 
colostomy with Marlex mesh to prevent paracolostomy hernia. Surg Gynecol 
Obstet 1986; 163(6):579-580. 
 (97)  Venditti D, Gargiani M, Milito G. Parastomal hernia surgery: personal 
experience with use of polypropylene mesh. Tech Coloproctol 2001; 5(2):85-
88. 
 (98)  Israelsson LA. Preventing and treating parastomal hernia. World J Surg 
2005; 29(8):1086-1089. 
 (99)  Kasperk R, Klinge U, Schumpelick V. The repair of large parastomal hernias 
using a midline approach and a prosthetic mesh in the sublay position. Am J 
Surg 2000; 179(3):186-188. 
 (100)  Kingsnorth AN, LeBlanc KA. Parastomal hernia. Management of abdominal 
hernias. 3rd ed. London: Oxford University Press; 2003. 257-266. 
193 
 
 (101)  Aldridge AJ, Simson JN. Erosion and perforation of colon by synthetic mesh 
in a recurrent paracolostomy hernia. Hernia 2001; 5(2):110-112. 
 (102)  Egun A, Hill J, MacLennan I, Pearson RC. Preperitoneal approach to 
parastomal hernia with coexistent large incisional hernia. Colorectal Dis 
2002; 4(2):132-134. 
 (103)  Hopkins TB, Trento A. Parastomal ileal loop hernia repair with marlex mesh. 
J Urol 1982; 128(4):811-812. 
 (104)  Longman RJ, Thomson WH. Mesh repair of parastomal hernias--a safety 
modification. Colorectal Dis 2005; 7(3):292-294. 
 (105)  McCormack K, Wake BL, Fraser C, Vale L, Perez J, Grant A. 
Transabdominal pre-peritoneal (TAPP) versus totally extraperitoneal (TEP) 
laparoscopic techniques for inguinal hernia repair: a systematic review. 
Hernia 2005; 9(2):109-114. 
 (106)  Wake BL, McCormack K, Fraser C, Vale L, Perez J, Grant AM. 
Transabdominal pre-peritoneal (TAPP) vs totally extraperitoneal (TEP) 
laparoscopic techniques for inguinal hernia repair. Cochrane Database Syst 
Rev 2005;(1):CD004703. 
 (107)  Porcheron J, Payan B, Balique JG. Mesh repair of paracolostomal hernia by 
laparoscopy. Surg Endosc 1998; 12(10):1281. 
 (108)  Morris-Stiff G, Hughes LE. The continuing challenge of parastomal hernia: 
failure of a novel polypropylene mesh repair. Ann R Coll Surg Engl 1998; 
80(3):184-187. 
194 
 
 (109)  Stelzner S, Hellmich G, Ludwig K. Repair of paracolostomy hernias with a 
prosthetic mesh in the intraperitoneal onlay position: modified Sugarbaker 
technique. Dis Colon Rectum 2004; 47(2):185-191. 
 (110)  Sugarbaker PH. Peritoneal approach to prosthetic mesh repair of 
paraostomy hernias. Ann Surg 1985; 201(3):344-346. 
 (111)  van Sprundel TC, Gerritsen vdH. Modified technique for parastomal hernia 
repair in patients with intractable stoma-care problems. Colorectal Dis 2005; 
7(5):445-449. 
 (112)  Hansson BM, de Hingh IH, Bleichrodt RP. Laparoscopic parastomal hernia 
repair is feasible and safe: early results of a prospective clinical study 
including 55 consecutive patients. Surg Endosc 2007; 21(6):989-993. 
 (113)  Kozlowski PM, Wang PC, Winfield HN. Laparoscopic repair of incisional and 
parastomal hernias after major genitourinary or abdominal surgery. J 
Endourol 2001; 15(2):175-179. 
 (114)  LeBlanc KA, Bellanger DE, Whitaker JM, Hausmann MG. Laparoscopic 
parastomal hernia repair. Hernia 2005; 9(2):140-144. 
 (115)  Mancini GJ, McClusky DA, III, Khaitan L, Goldenberg EA, Heniford BT, 
Novitsky YW et al. Laparoscopic parastomal hernia repair using a nonslit 
mesh technique. Surg Endosc 2007; 21(9):1487-1491. 
 (116)  Muysoms EE, Hauters PJ, Van NY, Huten N, Claeys DA. Laparoscopic 
repair of parastomal hernias: a multi-centre retrospective review and shift in 
technique. Acta Chir Belg 2008; 108(4):400-404. 
195 
 
 (117)  Safadi B. Laparoscopic repair of parastomal hernias: early results. Surg 
Endosc 2004; 18(4):676-680. 
 (118)  Voitk A. Simple technique for laparoscopic paracolostomy hernia repair. Dis 
Colon Rectum 2000; 43(10):1451-1453. 
 (119)  Sajid MS, Bokhari SA, Mallick AS, Cheek E, Baig MK. Laparoscopic versus 
open repair of incisional/ventral hernia: a meta-analysis. Am J Surg 2008. 
 (120)  LeBlanc KA. Laparoscopic incisional hernia repair: are transfascial sutures 
necessary? A review of the literature. Surg Endosc 2007; 21(4):508-513. 
 (121)  Penttinen R, Gronroos JM. Mesh repair of common abdominal hernias: a 
review on experimental and clinical studies. Hernia 2008; 12(4):337-344. 
 (122)  Berger D. Prevention of parastomal hernias by prophylactic use of a 
specially designed intraperitoneal onlay mesh (Dynamesh IPST((R))). 
Hernia 2008; 12(3):243-246. 
 (123)  Gogenur I, Mortensen J, Harvald T, Rosenberg J, Fischer A. Prevention of 
parastomal hernia by placement of a polypropylene mesh at the primary 
operation. Dis Colon Rectum 2006; 49(8):1131-1135. 
 (124)  Israelsson LA, Smedberg S, Montgomery A, Nordin P, Spangen L. Incisional 
hernia repair in Sweden 2002. Hernia 2006; 10(3):258-261. 
 (125)  Janes A, Cengiz Y, Israelsson LA. Preventing parastomal hernia with a 
prosthetic mesh. Arch Surg 2004; 139(12):1356-1358. 
196 
 
 (126)  Janes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a 
prosthetic mesh to prevent parastomal hernia. Br J Surg 2004; 91(3):280-
282. 
 (127)  Marimuthu K, Vijayasekar C, Ghosh D, Mathew G. Prevention of parastomal 
hernia using preperitoneal mesh: a prospective observational study. 
Colorectal Dis 2006; 8(8):672-675. 
 (128)  Bellows CF, Alder A, Helton WS. Abdominal wall reconstruction using 
biological tissue grafts: present status and future opportunities. Expert Rev 
Med Devices 2006; 3(5):657-675. 
 (129)  Hutmacher DW, Goh JC, Teoh SH. An introduction to biodegradable 
materials for tissue engineering applications. Ann Acad Med Singapore 
2001; 30(2):183-191. 
 (130)  Cumberland VH. A preliminary report on the use of prefabricated nylon 
weave in the repair of ventral hernia. Med J Aust 1952; 1(5):143-144. 
 (131)  Scales JT. Tissue reactions to synthetic materials. Proc R Soc Med 1953; 
46(8):647-652. 
 (132)  Eriksen JR, Gogenur I, Rosenberg J. Choice of mesh for laparoscopic 
ventral hernia repair. Hernia 2007; 11(6):481-492. 
 (133)  Klinge U, Zheng H, Si ZY, Schumpelick V, Bhardwaj R, Klosterhalfen B. 
Synthesis of type I and III collagen, expression of fibronectin and matrix 
metalloproteinases-1 and -13 in hernial sac of patients with inguinal hernia. 
Int J Surg Investig 1999; 1(3):219-227. 
197 
 
 (134)  Klinge U, Zheng H, Si Z, Schumpelick V, Bhardwaj RS, Muys L et al. 
Expression of the extracellular matrix proteins collagen I, collagen III and 
fibronectin and matrix metalloproteinase-1 and -13 in the skin of patients 
with inguinal hernia. Eur Surg Res 1999; 31(6):480-490. 
 (135)  Klinge U, Si ZY, Zheng H, Schumpelick V, Bhardwaj RS, Klosterhalfen B. 
Abnormal collagen I to III distribution in the skin of patients with incisional 
hernia. Eur Surg Res 2000; 32(1):43-48. 
 (136)  Amid PK. Classification of biomaterials and their related complications in 
abdominal wall hernia surgery. Hernia 1997; 1:15-21. 
 (137)  Cobb WS, Kercher KW, Heniford BT. The argument for lightweight 
polypropylene mesh in hernia repair. Surg Innov 2005; 12(1):63-69. 
 (138)  Klinge U, Junge K, Spellerberg B, Piroth C, Klosterhalfen B, Schumpelick V. 
Do multifilament alloplastic meshes increase the infection rate? Analysis of 
the polymeric surface, the bacteria adherence, and the in vivo 
consequences in a rat model. J Biomed Mater Res 2002; 63(6):765-771. 
 (139)  Fitzgibbons RJ, Greenburg AG. Nyhus and Condons Hernia. 5th ed. 
Philadelphia: Lippincott Williams & Wilkins; 2002. 
 (140)  Greca FH, de Paula JB, Biondo-Simoes ML, da Costa FD, da Silva AP, 
Time S et al. The influence of differing pore sizes on the biocompatibility of 
two polypropylene meshes in the repair of abdominal defects. Experimental 
study in dogs. Hernia 2001; 5(2):59-64. 
 (141)  Usher FC. Marlex mesh in repair of direct inguinal hernias. Med Rec Ann 
1963; 56:208-209. 
198 
 
 (142)  Usher FC. Hernia repair with knitted polypropylene mesh. Surg Gynecol 
Obstet 1963; 117:239-240. 
 (143)  Robinson TN, Clarke JH, Schoen J, Walsh MD. Major mesh-related 
complications following hernia repair: events reported to the Food and Drug 
Administration. Surg Endosc 2005; 19(12):1556-1560. 
 (144)  Stoppa R. About biomaterials and how they work in groin hernia repairs. 
Hernia 2003; 7(2):57-60. 
 (145)  Klinge U, Klosterhalfen B, Muller M, Ottinger AP, Schumpelick V. Shrinking 
of polypropylene mesh in vivo: an experimental study in dogs. Eur J Surg 
1998; 164(12):965-969. 
 (146)  Rodgers BM, Maher JW, Talbert JL. The use of preserved human dura for 
closure of abdominal wall and diaphragmatic defects. Ann Surg 1981; 
193(5):606-611. 
 (147)  Bachman S, Ramshaw B. Prosthetic material in ventral hernia repair: how 
do I choose? Surg Clin North Am 2008; 88(1):101-12, ix. 
 (148)  Simmermacher RK, Schakenraad JM, Bleichrodt RP. Reherniation after 
repair of the abdominal wall with expanded polytetrafluoroethylene. J Am 
Coll Surg 1994; 178(6):613-616. 
 (149)  Bujan J, Contreras LA, Carrera-San MA, Bellon JM. The behavior of 
different types of polytetrafluoroethylene (PTFE) prostheses in the 
reparative scarring process of abdominal wall defects. Histol Histopathol 
1997; 12(3):683-690. 
199 
 
 (150)  Koehler RH, Begos D, Berger D, Carey S, LeBlanc K, Park A et al. Minimal 
adhesions to ePTFE mesh after laparoscopic ventral incisional hernia repair: 
reoperative findings in 65 cases. Zentralbl Chir 2003; 128(8):625-630. 
 (151)  Matthews BD, Pratt BL, Pollinger HS, Backus CL, Kercher KW, Sing RF et 
al. Assessment of adhesion formation to intra-abdominal polypropylene 
mesh and polytetrafluoroethylene mesh. J Surg Res 2003; 114(2):126-132. 
 (152)  Engelsman AF, van der Mei HC, Ploeg RJ, Busscher HJ. The phenomenon 
of infection with abdominal wall reconstruction. Biomaterials 2007; 
28(14):2314-2327. 
 (153)  Diaz JJ, Jr., Gray BW, Dobson JM, Grogan EL, May AK, Miller R et al. 
Repair of giant abdominal hernias: does the type of prosthesis matter? Am 
Surg 2004; 70(5):396-401. 
 (154)  McGinty JJ, Hogle NJ, McCarthy H, Fowler DL. A comparative study of 
adhesion formation and abdominal wall ingrowth after laparoscopic ventral 
hernia repair in a porcine model using multiple types of mesh. Surg Endosc 
2005; 19(6):786-790. 
 (155)  Baptista ML, Bonsack ME, Delaney JP. Seprafilm reduces adhesions to 
polypropylene mesh. Surgery 2000; 128(1):86-92. 
 (156)  Matthews BD, Mostafa G, Carbonell AM, Joels CS, Kercher KW, Austin C et 
al. Evaluation of adhesion formation and host tissue response to intra-
abdominal polytetrafluoroethylene mesh and composite prosthetic mesh. J 
Surg Res 2005; 123(2):227-234. 
200 
 
 (157)  Pans A, Elen P, Dewe W, Desaive C. Long-term results of polyglactin mesh 
for the prevention of incisional hernias in obese patients. World J Surg 1998; 
22(5):479-482. 
 (158)  Holl-Allen RT. Porcine dermal collagen implants in man. J R Coll Surg Edinb 
1984; 29(3):151-153. 
 (159)  James NL, Poole-Warren LA, Schindhelm K, Milthorpe BK, Mitchell RM, 
Mitchell RE et al. Comparative evaluation of treated bovine pericardium as a 
xenograft for hernia repair. Biomaterials 1991; 12(9):801-809. 
 (160)  Tyrell J, Silberman H, Chandrasoma P, Niland J, Shull J. Absorbable versus 
permanent mesh in abdominal operations. Surg Gynecol Obstet 1989; 
168(3):227-232. 
 (161)  van der Laan JS, Lopez GP, van Wachem PB, Nieuwenhuis P, Ratner BD, 
Bleichrodt RP et al. TFE-plasma polymerized dermal sheep collagen for the 
repair of abdominal wall defects. Int J Artif Organs 1991; 14(10):661-666. 
 (162)  van Wachem PB, van Luyn MJ, Olde Damink LH, Dijkstra PJ, Feijen J, 
Nieuwenhuis P. Tissue regenerating capacity of carbodiimide-crosslinked 
dermal sheep collagen during repair of the abdominal wall. Int J Artif Organs 
1994; 17(4):230-239. 
 (163)  Badylak SF. Regenerative medicine approach to heart valve replacement. 
Circulation 2005; 111(21):2715-2716. 
 (164)  Clarke KM, Lantz GC, Salisbury SK, Badylak SF, Hiles MC, Voytik SL. 
Intestine submucosa and polypropylene mesh for abdominal wall repair in 
dogs. J Surg Res 1996; 60(1):107-114. 
201 
 
 (165)  Badylak SF, Park K, Peppas N, McCabe G, Yoder M. Marrow-derived cells 
populate scaffolds composed of xenogeneic extracellular matrix. Exp 
Hematol 2001; 29(11):1310-1318. 
 (166)  Badylak SF, Wu CC, Bible M, McPherson E. Host protection against 
deliberate bacterial contamination of an extracellular matrix bioscaffold 
versus Dacron mesh in a dog model of orthopedic soft tissue repair. J 
Biomed Mater Res B Appl Biomater 2003; 67(1):648-654. 
 (167)  Konstantinovic ML, Lagae P, Zheng F, Verbeken EK, De RD, Deprest JA. 
Comparison of host response to polypropylene and non-cross-linked porcine 
small intestine serosal-derived collagen implants in a rat model. BJOG 2005; 
112(11):1554-1560. 
 (168)  Soiderer EE, Lantz GC, Kazacos EA, Hodde JP, Wiegand RE. Morphologic 
study of three collagen materials for body wall repair. J Surg Res 2004; 
118(2):161-175. 
 (169)  Helton WS, Fisichella PM, Berger R, Horgan S, Espat NJ, Abcarian H. 
Short-term outcomes with small intestinal submucosa for ventral abdominal 
hernia. Arch Surg 2005; 140(6):549-560. 
 (170)  Ueno T, Pickett LC, de la Fuente SG, Lawson DC, Pappas TN. Clinical 
application of porcine small intestinal submucosa in the management of 
infected or potentially contaminated abdominal defects. J Gastrointest Surg 
2004; 8(1):109-112. 
202 
 
 (171)  Napolitano L, Di BN, Aceto L, Waku M, Innocenti P. [Use of prosthetic 
materials in incisional hernias: our clinical experience]. G Chir 2004; 
25(4):141-145. 
 (172)  Gupta A, Zahriya K, Mullens PL, Salmassi S, Keshishian A. Ventral 
herniorrhaphy: experience with two different biosynthetic mesh materials, 
Surgisis and Alloderm. Hernia 2006; 10(5):419-425. 
 (173)  Menon NG, Rodriguez ED, Byrnes CK, Girotto JA, Goldberg NH, Silverman 
RP. Revascularization of human acellular dermis in full-thickness abdominal 
wall reconstruction in the rabbit model. Ann Plast Surg 2003; 50(5):523-527. 
 (174)  Silverman RP, Li EN, Holton LH, III, Sawan KT, Goldberg NH. Ventral hernia 
repair using allogenic acellular dermal matrix in a swine model. Hernia 2004; 
8(4):336-342. 
 (175)  Carbonell AM, Matthews BD, Dreau D, Foster M, Austin CE, Kercher KW et 
al. The susceptibility of prosthetic biomaterials to infection. Surg Endosc 
2005; 19(3):430-435. 
 (176)  Buinewicz BR, Rosen B. Acellular cadaveric dermis (Alloderm): a new 
alternative for abdominal hernia repair . Ann Plast Surg 2004; 52:188-194. 
 (177)  Holton LH, III, Kim D, Silverman RP, Rodriguez ED, Singh N, Goldberg NH. 
Human acellular dermal matrix for repair of abdominal wall defects: review 
of clinical experience and experimental data. J Long Term Eff Med Implants 
2005; 15(5):547-558. 
203 
 
 (178)  Kolker AR, Brown DJ, Redstone JS, Scarpinato VM, Wallack MK. Multilayer 
reconstruction of abdominal wall defects with acellular dermal allograft 
(AlloDerm) and component separation. Ann Plast Surg 2005; 55(1):36-41. 
 (179)  Gaertner WB, Bonsack ME, Delaney JP. Experimental evaluation of four 
biologic prostheses for ventral hernia repair. J Gastrointest Surg 2007; 
11(10):1275-1285. 
 (180)  Jarman-Smith ML, Bodamyali T, Stevens C, Howell JA, Horrocks M, 
Chaudhuri JB. Porcine collagen crosslinking, degradation and its capability 
for fibroblast adhesion and proliferation. J Mater Sci Mater Med 2004; 
15(8):925-932. 
 (181)  Kimuli M, Eardley I, Southgate J. In vitro assessment of decellularized 
porcine dermis as a matrix for urinary tract reconstruction. BJU Int 2004; 
94(6):859-866. 
 (182)  Kaleya RN. Evaluation of implant/host tissue interactions following 
intraperitoneal implantation of porcine dermal collagen prosthesis in the rat. 
Hernia 2005; 9(3):269-276. 
 (183)  Zheng F, Lin Y, Verbeken E, Claerhout F, Fastrez M, De RD et al. Host 
response after reconstruction of abdominal wall defects with porcine dermal 
collagen in a rat model. Am J Obstet Gynecol 2004; 191(6):1961-1970. 
 (184)  Macleod TM, Williams G, Sanders R, Green CJ. Prefabricated skin flaps in a 
rat model based on a dermal replacement matrix Permacol. Br J Plast Surg 
2003; 56(8):775-783. 
204 
 
 (185)  Macleod TM, Sarathchandra P, Williams G, Sanders R, Green CJ. 
Evaluation of a porcine origin acellular dermal matrix and small intestinal 
submucosa as dermal replacements in preventing secondary skin graft 
contraction. Burns 2004; 30(5):431-437. 
 (186)  Macleod TM, Williams G, Sanders R, Green CJ. Histological evaluation of 
Permacol as a subcutaneous implant over a 20-week period in the rat 
model. Br J Plast Surg 2005; 58(4):518-532. 
 (187)  Ayubi FS, Armstrong PJ, Mattia MS, Parker DM. Abdominal wall hernia 
repair: a comparison of Permacol and Surgisis grafts in a rat hernia model. 
Hernia 2008; 12(4):373-378. 
 (188)  Pentlow A, Smart NJ, Richards SK, Inward CD, Morgan JD. The use of 
porcine dermal collagen implants in assisting abdominal wall closure of 
pediatric renal transplant recipients with donor size discrepancy. Pediatr 
Transplant 2008; 12(1):20-23. 
 (189)  Richards SK, Lear PA, Huskisson L, Saleem MA, Morgan JD. Porcine 
dermal collagen graft in pediatric renal transplantation. Pediatr Transplant 
2005; 9(5):627-629. 
 (190)  Parker DM, Armstrong PJ, Frizzi JD, North JH, Jr. Porcine dermal collagen 
(Permacol) for abdominal wall reconstruction. Curr Surg 2006; 63(4):255-
258. 
 (191)  Adedeji OA, Bailey CA, Varma JS. Porcine dermal collagen graft in 
abdominal-wall reconstruction. Br J Plast Surg 2002; 55(1):85-86. 
205 
 
 (192)  Verey F, Munikrishnan V, Kenefick NJ, DeFriens DJ, Pullan RD. A novel 
biomaterial for use in complex abdominal wall reconstruction (abstract). 
Colorectal Dis 2004; 6(1):37-85. 
 (193)  Cobb GA, Shaffer J. Cross-linked acellular porcine dermal collagen implant 
in laparoscopic ventral hernia repair: case-controlled study of operative 
variables and early complications. Int Surg 2005; 90(3 Suppl):S24-S29. 
 (194)  Liyanage SH, Purohit GS, Frye JN, Giordano P. Anterior abdominal wall 
reconstruction with a Permacol implant. J Plast Reconstr Aesthet Surg 2006; 
59(5):553-555. 
 (195)  Saettele TM, Bachman SL, Costello CR, Grant SA, Cleveland DS, Loy TS et 
al. Use of porcine dermal collagen as a prosthetic mesh in a contaminated 
field for ventral hernia repair: a case report. Hernia 2007; 11(3):279-285. 
 (196)  Catena F, Ansaloni L, Gazzotti F, Gagliardi S, Di SS, D'Alessandro L et al. 
Use of porcine dermal collagen graft (Permacol) for hernia repair in 
contaminated fields. Hernia 2007; 11(1):57-60. 
 (197)  Shaikh FM, Giri SK, Durrani S, Waldron D, Grace PA. Experience with 
porcine acellular dermal collagen implant in one-stage tension-free 
reconstruction of acute and chronic abdominal wall defects. World J Surg 
2007; 31(10):1966-1972. 
 (198)  Hsu PW, Salgado CJ, Kent K, Finnegan M, Pello M, Simons R et al. 
Evaluation of porcine dermal collagen (Permacol) used in abdominal wall 
reconstruction. J Plast Reconstr Aesthet Surg 2008. 
206 
 
 (199)  Lunniss PJ, Phillips RKS. Anal fistula: evaluation and management. In: 
Phillips RKS, editor. Colorectal Surgery. 3 ed. Netherlands: Elsevier 
Saunders; 2005. 241-264. 
 (200)  Marks CG, Ritchie JK, Lockhart-Mummery HE. Anal fistulas in Crohn's 
disease. Br J Surg 1981; 68(8):525-527. 
 (201)  Shukla HS, Gupta SC, Singh G, Singh PA. Tubercular fistula in ano. Br J 
Surg 1988; 75(1):38-39. 
 (202)  Culp CE. Chronic hidradenitis suppurativa of the anal canal. A surgical skin 
disease. Dis Colon Rectum 1983; 26(10):669-676. 
 (203)  Nelson RL, Prasad ML, Abcarian H. Anal carcinoma presenting as a 
perirectal abscess or fistula. Arch Surg 1985; 120(5):632-635. 
 (204)  Lockhart-Mummery JP. Discussion on fistula in ano. Proc R Soc Med 1929; 
22:1331-1341. 
 (205)  Ewerth S, Ahlberg J, Collste G, Holmstrom B. Fistula-in-ano. A six year 
follow up study of 143 operated patients. Acta Chir Scand Suppl 1978; 
482:53-55. 
 (206)  Sainio P. Fistula-in-ano in a defined population. Incidence and 
epidemiological aspects. Ann Chir Gynaecol 1984; 73(4):219-224. 
 (207)  Zanotti C, Martinez-Puente C, Pascual I, Pascual M, Herreros D, Garcia-
Olmo D. An assessment of the incidence of fistula-in-ano in four countries of 
the European Union. Int J Colorectal Dis 2007; 22(12):1459-1462. 
207 
 
 (208)  Lilius HG. Fistula-in-ano, an investigation of human foetal anal ducts and 
intramuscular glands and a clinical study of 150 patients. Acta Chir Scand 
Suppl 1968; 383:7-88. 
 (209)  McColl I. The comparative anatomy and pathology of anal glands. Arris and 
Gale lecture delivered at the Royal College of Surgeons of England on 25th 
February 1965. Ann R Coll Surg Engl 1967; 40(1):36-67. 
 (210)  Lunniss PJ, Jenkins PJ, Besser GM, Perry LA, Phillips RK. Gender 
differences in incidence of idiopathic fistula-in-ano are not explained by 
circulating sex hormones. Int J Colorectal Dis 1995; 10(1):25-28. 
 (211)  Marks CG, Ritchie JK. Anal fistulas at St Mark's Hospital. Br J Surg 1977; 
64(2):84-91. 
 (212)  Sainio P. A manometric study of anorectal function after surgery for anal 
fistula, with special reference to incontinence. Acta Chir Scand 1985; 
151(8):695-700. 
 (213)  Eisenhammer S. Long-tract anteroposterior intermuscular fistula. Dis Colon 
Rectum 1964; 7:438-440. 
 (214)  Shafik A. A new concept of the anatomy of the anal sphincter mechanism 
and the physiology of defecation. VIII. Levator hiatus and tunnel: anatomy 
and function. Dis Colon Rectum 1979; 22(8):539-549. 
 (215)  Parks AG. Pathogenesis and treatment of fistuila-in-ano. Br Med J 1961; 
1(5224):463-469. 
208 
 
 (216)  Lawson JO. Pelvic anatomy. II. Anal canal and associated sphincters. Ann R 
Coll Surg Engl 1974; 54(6):288-300. 
 (217)  Walls EW. Anorectal Anatomy. Sci Basis Med Annu Rev 1963; 84:113-124. 
 (218)  Goligher JC, Leacock AG, Brossy JJ. The surgical anatomy of the anal 
canal. Br J Surg 1955; 43(177):51-61. 
 (219)  Anatomy and physiological investigations. In: Keighley MRB, Williams NS, 
editors. Surgery of the Anus, Rectum & Colon. 2nd ed. 2008. 1-49. 
 (220)  Haas PA, Fox TA, Jr. Age-related changes and scar formations of perianal 
connective tissue. Dis Colon Rectum 1980; 23(3):160-169. 
 (221)  Parks AG. The surgical treatment of haemorrhoids. Br J Surg 1956; 
43(180):337-351. 
 (222)  Lunniss PJ, Phillips RK. Anatomy and function of the anal longitudinal 
muscle. Br J Surg 1992; 79(9):882-884. 
 (223)  Fenger C, Filipe MI. Mucin histochemistry of the anal canal epithelium. 
Studies of normal anal mucosa and mucosa adjacent to carcinoma. 
Histochem J 1981; 13(6):921-930. 
 (224)  Eisenhammer S. The internal anal sphincter and the anorectal abscess. 
Surg Gynecol Obstet 1956; 103(4):501-506. 
 (225)  Lunniss PJ, Faris B, Rees HC, Heard S, Phillips RK. Histological and 
microbiological assessment of the role of microorganisms in chronic anal 
fistula. Br J Surg 1993; 80(8):1072. 
209 
 
 (226)  Seow-Choen F, Hay AJ, Heard S, Phillips RK. Bacteriology of anal fistulae. 
Br J Surg 1992; 79(1):27-28. 
 (227)  Lunniss PJ, Sheffield JP, Talbot IC, Thomson JP, Phillips RK. Persistence of 
idiopathic anal fistula may be related to epithelialization. Br J Surg 1995; 
82(1):32-33. 
 (228)  Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J 
Surg 1976; 63(1):1-12. 
 (229)  Goodsall DH, Miles WH. Diseases of the anus and rectum. London: 
Longmans, Green; 1890. 
 (230)  Choen S, Burnett S, Bartram CI, Nicholls RJ. Comparison between anal 
endosonography and digital examination in the evaluation of anal fistulae. Br 
J Surg 1991; 78(4):445-447. 
 (231)  Fazio VW. Complex anal fistulae. Gastroenterol Clin North Am 1987; 
16(1):93-114. 
 (232)  Law PJ, Talbot RW, Bartram CI, Northover JM. Anal endosonography in the 
evaluation of perianal sepsis and fistula in ano. Br J Surg 1989; 76(7):752-
755. 
 (233)  Lunniss PJ, Barker PG, Sultan AH, Armstrong P, Reznek RH, Bartram CI et 
al. Magnetic resonance imaging of fistula-in-ano. Dis Colon Rectum 1994; 
37(7):708-718. 
 (234)  Buchanan GN, Halligan S, Bartram CI, Williams AB, Tarroni D, Cohen CR. 
Clinical examination, endosonography, and MR imaging in preoperative 
210 
 
assessment of fistula in ano: comparison with outcome-based reference 
standard. Radiology 2004; 233(3):674-681. 
 (235)  Lengyel AJ, Hurst NG, Williams JG. Pre-operative assessment of anal 
fistulas using endoanal ultrasound. Colorectal Dis 2002; 4(6):436-440. 
 (236)  Lindsey I, Humphreys MM, George BD, Mortensen NJ. The role of anal 
ultrasound in the management of anal fistulas. Colorectal Dis 2002; 
4(2):118-122. 
 (237)  Lunniss PJ, Armstrong P, Barker PG, Reznek RH, Phillips RK. Magnetic 
resonance imaging of anal fistulae. Lancet 1992; 340(8816):394-396. 
 (238)  Beckingham IJ, Spencer JA, Ward J, Dyke GW, Adams C, Ambrose NS. 
Prospective evaluation of dynamic contrast enhanced magnetic resonance 
imaging in the evaluation of fistula in ano. Br J Surg 1996; 83(10):1396-
1398. 
 (239)  Heiken JP, Lee JK. MR imaging of the pelvis. Radiology 1988; 166(1 Pt 
1):11-16. 
 (240)  Schaefer O, Lohrmann C, Kreisel W, Rasenack J, Ruf G, Hopt U et al. 
Differentiation of perianal fistulas with digital subtraction magnetic 
resonance fistulography. Inflamm Bowel Dis 2005; 11(4):383-387. 
 (241)  Sun MR, Smith MP, Kane RA. Current techniques in imaging of fistula in 
ano: three-dimensional endoanal ultrasound and magnetic resonance 
imaging. Semin Ultrasound CT MR 2008; 29(6):454-471. 
211 
 
 (242)  Buchanan G, Halligan S, Williams A, Cohen CR, Tarroni D, Phillips RK et al. 
Effect of MRI on clinical outcome of recurrent fistula-in-ano. Lancet 2002; 
360(9346):1661-1662. 
 (243)  Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA et 
al. Efficacy of fibrin sealant in the management of complex anal fistula: a 
prospective trial. Dis Colon Rectum 2003; 46(9):1167-1174. 
 (244)  Duthie HL, Watts JM. Contribution of the external anal sphincter to the 
pressure zone in the anal canal. Gut 1965; 6:64-68. 
 (245)  Williams AB, Cheetham MJ, Bartram CI, Halligan S, Kamm MA, Nicholls RJ 
et al. Gender differences in the longitudinal pressure profile of the anal canal 
related to anatomical structure as demonstrated on three-dimensional anal 
endosonography. Br J Surg 2000; 87(12):1674-1679. 
 (246)  Lestar B, Penninckx F, Kerremans R. The composition of anal basal 
pressure. An in vivo and in vitro study in man. Int J Colorectal Dis 1989; 
4(2):118-122. 
 (247)  Engel AF, Kamm MA, Bartram CI, Nicholls RJ. Relationship of symptoms in 
faecal incontinence to specific sphincter abnormalities. Int J Colorectal Dis 
1995; 10(3):152-155. 
 (248)  Lunniss PJ, Thompson JPS. The loose seton. In: Phillips RKS, Lunniss PJ, 
editors. Anal fistula: Surgical evaulation and management. London: 
Chapman & Hall Medical; 1996. 87-94. 
212 
 
 (249)  Pescatori M, Maria G, Anastasio G, Rinallo L. Anal manometry improves the 
outcome of surgery for fistula-in-ano. Dis Colon Rectum 1989; 32(7):588-
592. 
 (250)  Lunniss PJ, Kamm MA, Phillips RK. Factors affecting continence after 
surgery for anal fistula. Br J Surg 1994; 81(9):1382-1385. 
 (251)  Garcia-Aguilar J, Belmonte C, Wong WD, Goldberg SM, Madoff RD. Anal 
fistula surgery. Factors associated with recurrence and incontinence. Dis 
Colon Rectum 1996; 39(7):723-729. 
 (252)  Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA et 
al. Efficacy of fibrin sealant in the management of complex anal fistula: a 
prospective trial. Dis Colon Rectum 2003; 46(9):1167-1174. 
 (253)  Buchanan GN, Sibbons P, Osborn M, Bartram CI, Ansari T, Halligan S et al. 
Pilot study: fibrin sealant in anal fistula model. Dis Colon Rectum 2005; 
48(3):532-539. 
 (254)  Classic articles in colonic and rectal surgery. Treatises of fistula-in-ano, 
haemorrhoids, and clysters. By John Arderne, from an early fifteenth-century 
manuscript translation.  Dis Colon Rectum 1983;(26):74-78. 
 (255)  Abcarian H. The 'lay open' technique. In: Phillips RKS, Lunniss PJ, editors. 
Anal fistula: Surgical evaluation and management. London: Chapman & Hall 
Medical; 1996. 73-80. 
 (256)  Hammond TM, Lunnis PJ. Principles and management of anal fistulas. 
Gastrointestinal Nursing 2007; 5(2):32-40. 
213 
 
 (257)  Ho YH, Tan M, Leong AF, Seow-Choen F. Marsupialization of fistulotomy 
wounds improves healing: a randomized controlled trial. Br J Surg 1998; 
85(1):105-107. 
 (258)  Pescatori M, Ayabaca SM, Cafaro D, Iannello A, Magrini S. Marsupialization 
of fistulotomy and fistulectomy wounds improves healing and decreases 
bleeding: a randomized controlled trial. Colorectal Dis 2006; 8(1):11-14. 
 (259)  Parkash S, Lakshmiratan V, Gajendran V. Fistula-in-ano: treatment by 
fistulectomy, primary closure and reconstitution. Aust N Z J Surg 1985; 
55(1):23-27. 
 (260)  Perez F, Arroyo A, Serrano P, Candela F, Perez MT, Calpena R. 
Prospective clinical and manometric study of fistulotomy with primary 
sphincter reconstruction in the management of recurrent complex fistula-in-
ano. Int J Colorectal Dis 2006; 21(6):522-526. 
 (261)  Filingeri V, Rosati R, Gravante G, Pietrasanta D, Fiorito R, Casciani CU. 
[Milligan-Morgan hemorrhoidectomy with a radiofrequency scalpel]. Minerva 
Chir 2003; 58(3):355-359. 
 (262)  Gupta PJ. Radiofrequency fistulotomy in anal fistula. An alternative to 
conventional surgical fistulotomy. Bratisl Lek Listy 2003; 104(4-5):165-166. 
 (263)  Malik AI, Nelson RL. Surgical management of anal fistulae: a systematic 
review. Colorectal Dis 2008; 10(5):420-430. 
 (264)  Kuypers HC. Use of the seton in the treatment of extrasphincteric anal 
fistula. Dis Colon Rectum 1984; 27(2):109-110. 
214 
 
 (265)  Parks AG, Stitz RW. The treatment of high fistula-in-ano. Dis Colon Rectum 
1976; 19(6):487-499. 
 (266)  Ramanujam PS, Prasad ML, Abcarian H. The role of seton in fistulotomy of 
the anus. Surg Gynecol Obstet 1983; 157(5):419-422. 
 (267)  Thompson JPS, Ross AHMcL. Can the external sphincter be preserved in 
the treatment of transsphincteric fistula-in-ano?  Int J Colorectal Dis 
1989;(4):247-250. 
 (268)  Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR. 
Long-term outcome following loose-seton technique for external sphincter 
preservation in complex anal fistula. Br J Surg 2004; 91(4):476-480. 
 (269)  Adams F. On fistulae. In: Adams F, editor. The Genuine Work Of 
Hippocrates. Baltimore: Williams & Wilkins; 1939. 
 (270)  Culp CE. Use of Penrose drains to treat certain anal fistulas: a primary 
operative seton. Mayo Clin Proc 1984; 59(9):613-617. 
 (271)  Misra MC, Kapur BM. A new non-operative approach to fistula in ano. Br J 
Surg 1988; 75(11):1093-1094. 
 (272)  Chuang-Wei C, Chang-Chieh W, Cheng-Wen H, Tsai-Yu L, Chun-Che F, 
Shu-Wen J. Cutting seton for complex anal fistulas. Surgeon 2008; 6(3):185-
188. 
 (273)  Dziki A, Bartos M. Seton treatment of anal fistula: experience with a new 
modification. Eur J Surg 1998; 164(7):543-548. 
215 
 
 (274)  Goldberg SM, Garcia-Aguilar J. The cutting seton. In: Phillips RKS, Lunniss 
PJ, editors. Anal fistula. Surgical evaluation and Management. London: 
Chapman & Hall Medical; 1996. 95-102. 
 (275)  Joy HA, Williams JG. The outcome of surgery for complex anal fistula. 
Colorectal Dis 2002; 4(4):254-261. 
 (276)  Mentes BB, Oktemer S, Tezcaner T, Azili C, Leventoglu S, Oguz M. Elastic 
one-stage cutting seton for the treatment of high anal fistulas: preliminary 
results. Tech Coloproctol 2004; 8(3):159-162. 
 (277)  Ustynoski K, Rosen L, Stasik J, Riether R, Sheets J, Khubchandani IT. 
Horseshoe abscess fistula. Seton treatment. Dis Colon Rectum 1990; 
33(7):602-605. 
 (278)  Williams JG, MacLeod CA, Rothenberger DA, Goldberg SM. Seton 
treatment of high anal fistulae. Br J Surg 1991; 78(10):1159-1161. 
 (279)  Graf W, Pahlman L, Ejerblad S. Functional results after seton treatment of 
high transsphincteric anal fistulas. Eur J Surg 1995; 161(4):289-291. 
 (280)  Hamalainen KP, Sainio AP. Cutting seton for anal fistulas: high risk of minor 
control defects. Dis Colon Rectum 1997; 40(12):1443-1446. 
 (281)  Durgan V, Perek A, Kapan M, Kapan S, Perek S. Partial fistulotomy and 
modified cutting seton procedure in the treatment of high extrasphincteric 
perianal fistulae. Digestive Surgery 2002; 19:56-58. 
 (282)  Isbister WH, Al SN. The cutting seton: an experience at King Faisal 
Specialist Hospital. Dis Colon Rectum 2001; 44(5):722-727. 
216 
 
 (283)  McCourtney JS, Finlay IG. Cutting seton without preliminary internal 
sphincterotomy in management of complex high fistula-in-ano. Dis Colon 
Rectum 1996; 39(1):55-58. 
 (284)  Theerapol A, So BY, Ngoi SS. Routine use of setons for the treatment of 
anal fistulae. Singapore Med J 2002; 43(6):305-307. 
 (285)  Zbar AP, Ramesh J, Beer-Gabel M, Salazar R, Pescatori M. Conventional 
cutting vs. internal anal sphincter-preserving seton for high trans-sphincteric 
fistula: a prospective randomized manometric and clinical trial. Tech 
Coloproctol 2003; 7(2):89-94. 
 (286)  Gurer A, Ozlem N, Gokakin AK, Ozdogan M, Kulacoglu H, Aydin R. A novel 
material in seton treatment of fistula-in-ano. Am J Surg 2007; 193(6):794-
796. 
 (287)  Vatansev C, Alabaz O, Tekin A, Aksoy F, Yilmaz H, Kucukkartallar T et al. A 
new seton type for the treatment of anal fistula. Dig Dis Sci 2007; 
52(8):1920-1923. 
 (288)  Christensen A, Nilas L, Christiansen J. Treatment of transsphincteric anal 
fistulas by the seton technique. Dis Colon Rectum 1986; 29(7):454-455. 
 (289)  Hasegawa H, Radley S, Keighley MR. Long-term results of cutting seton 
fistulotomy. Acta Chir Iugosl 2000; 47(4 Suppl 1):19-21. 
 (290)  Pescatori M, Ayabaca S, Caputo D. Can anal manometry predict anal 
incontinence after fistulectomy in males? Colorectal Dis 2004; 6(2):97-102. 
217 
 
 (291)  Deshpande PJ, Sharma KR. Treatment of fistula-in-ano by a new technique. 
Review and follow-up of 200 cases. Am J Proctol 1973; 24(1):49-60. 
 (292)  Deshpande PJ, Sharma KR. Successful non-operative treatment of high 
rectal fistula. Am J Proctol 1976; 27(1):39-47. 
 (293)  Ho KS, Tsang C, Seow-Choen F, Ho YH, Tang CL, Heah SM et al. 
Prospective randomised trial comparing ayurvedic cutting seton and 
fistulotomy for low fistula-in-ano. Tech Coloproctol 2001; 5(3):137-141. 
 (294)  Shukla NK, Narang R, Nair NGK. Multicentric randomised controlled clinical 
trial of Kshaarasootra (ayurvedic medicated thread) in the management of 
fistula-in-ano. Ind J Med Res 1991; 94:177-185. 
 (295)  Kronborg O. To lay open or excise a fistula-in-ano: a randomized trial. Br J 
Surg 1985; 72(12):970. 
 (296)  Lewis A. Excision of fistula in ano. Int J Colorectal Dis 1986; 1(4):265-267. 
 (297)  Lewis A. Core out. In: Phillips RKS, Lunniss PJ, editors. Anal Fistula. 
Surgical Evaluation and Management. London: Chapman & Hall Medical; 
1996. 81-86. 
 (298)  Tasci I. The fistulectome: a new device for treatment of complex anal fistulas 
by "Core-Out" fistulectomy. Dis Colon Rectum 2003; 46(11):1566-1571. 
 (299)  Elting AW. X. The Treatment of Fistula in Ano: With Especial Reference to 
the Whitehead Operation. Ann Surg 1912; 56(5):744-752. 
218 
 
 (300)  Finan P. Management by advancement flap technique. In: Phillips RKS, 
Lunniss PJ, editors. Anal Fistula. Surgical evaluation and management. 
London: Chapman & Hall Medical; 1996. 107-113. 
 (301)  Stone JM, Goldberg SM. The endorectal advancement flap procedure. Int J 
Colorectal Dis 1990; 5(4):232-235. 
 (302)  Lunniss PJ. The role of the advancement flap technique. Seminars Colon 
Rectal Surg 1998; 9:192-197. 
 (303)  Ho KS, Ho YH. Controlled, randomized trial of island flap anoplasty for 
treatment of trans-sphincteric fistula-in-ano: early results. Tech Coloproctol 
2005; 9(2):166-168. 
 (304)  Perez F, Arroyo A, Serrano P, Sanchez A, Candela F, Perez MT et al. 
Randomized clinical and manometric study of advancement flap versus 
fistulotomy with sphincter reconstruction in the management of complex 
fistula-in-ano. Am J Surg 2006; 192(1):34-40. 
 (305)  Athanasiadis S, Kohler A, Nafe M. Treatment of high anal fistulae by primary 
occlusion of the internal ostium, drainage of the intersphincteric space, and 
mucosal advancement flap. Int J Colorectal Dis 1994; 9(3):153-157. 
 (306)  Deeba S, Aziz O, Sains PS, Darzi A. Fistula-in-ano: advances in treatment. 
Am J Surg 2008; 196(1):95-99. 
 (307)  Hammond TM, Grahn MF, Lunniss PJ. Fibrin glue in the management of 
anal fistulae. Colorectal Dis 2004; 6(5):308-319. 
219 
 
 (308)  Person B, Wexner SD. Novel technology and innovations in colorectal 
surgery: the circular stapler for treatment of hemorrhoids and fibrin glue for 
treatment of perianal fistulae. Surg Innov 2004; 11(4):241-252. 
 (309)  Singer M, Cintron J. New techniques in the treatment of common perianal 
diseases: stapled hemorrhoidopexy, botulinum toxin, and fibrin sealant. Surg 
Clin North Am 2006; 86(4):937-967. 
 (310)  Swinscoe MT, Ventakasubramaniam AK, Jayne DG. Fibrin glue for fistula-
in-ano: the evidence reviewed. Tech Coloproctol 2005; 9(2):89-94. 
 (311)  Grey E. Fibrin as a haemostatic agent in cerebral surgery. Surg Gynecol 
Obstet 1915; 21:452-454. 
 (312)  Harvey S. The use of fibrin paper and forms in surgery. Boston Med Surg J 
1916; 174:658. 
 (313)  Cronkite E, Lozner E, Deaver J. Use of thrombin and fibrinogen in skin 
grafting. J Am Med Assoc 1944; 124:976-978. 
 (314)  Matras H, Dinges HP, Lassmann H, Mamoli B. [Suture-free interfascicular 
nerve transplantation in animal experiments]. Wien Med Wochenschr 1972; 
122(37):517-523. 
 (315)  Hedelin H, Nilson AE, Teger-Nilsson AC, Thorsen G. Fibrin occlusion of 
fistulas postoperatively. Surg Gynecol Obstet 1982; 154(3):366-368. 
 (316)  Kirkegaard P, Madsen PV. Perineal sinus after removal of the rectum. 
Occlusion with fibrin adhesive. Am J Surg 1983; 145(6):791-794. 
220 
 
 (317)  Lindsey I, Smilgin-Humphreys MM, Cunningham C, Mortensen NJ, George 
BD. A randomized, controlled trial of fibrin glue vs. conventional treatment 
for anal fistula. Dis Colon Rectum 2002; 45(12):1608-1615. 
 (318)  Hammond TM, Lunniss PJ. Novel biomaterials in the management of anal 
fistulas. Dis Colon Rectum 2006; 49(9):1463-1464. 
 (319)  Singer M, Cintron J, Nelson R, Orsay C, Bastawrous A, Pearl R et al. 
Treatment of fistulas-in-ano with fibrin sealant in combination with intra-
adhesive antibiotics and/or surgical closure of the internal fistula opening. 
Dis Colon Rectum 2005; 48(4):799-808. 
 (320)  Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a 
randomized, controlled study. Dis Colon Rectum 2006; 49(11):1736-1740. 
 (321)  Alexander SM, Mitalas LE, Gosselink MP, Oom DM, Zimmerman DD, 
Schouten WR. Obliteration of the fistulous tract with BioGlue adversely 
affects the outcome of transanal advancement flap repair. Tech Coloproctol 
2008; 12(3):225-228. 
 (322)  van Koperen PJ, Wind J, Bemelman WA, Slors JF. Fibrin glue and transanal 
rectal advancement flap for high transsphincteric perianal fistulas; is there 
any advantage? Int J Colorectal Dis 2008; 23(7):697-701. 
 (323)  Becker JC, Domschke W, Pohle T. Biological in vitro effects of fibrin glue: 
fibroblast proliferation, expression and binding of growth factors. Scand J 
Gastroenterol 2004; 39(10):927-932. 
 (324)  Saed GM, Kruger M, Diamond MP. Expression of transforming growth 
factor-beta and extracellular matrix by human peritoneal mesothelial cells 
221 
 
and by fibroblasts from normal peritoneum and adhesions: effect of Tisseel. 
Wound Repair Regen 2004; 12(5):557-564. 
 (325)  Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and 
tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 
108(6):1713-1726. 
 (326)  El-Shobaky M, Khafagy W, El-Awady S. Autologous fibrin glue in treatment 
of fistula-in-ano [abstract]. Colorectal Dis 2000; 2 (Suppl):17. 
 (327)  Zmora O, Mizrahi N, Rotholtz N, Pikarsky AJ, Weiss EG, Nogueras JJ et al. 
Fibrin glue sealing in the treatment of perineal fistulas. Dis Colon Rectum 
2003; 46(5):584-589. 
 (328)  Adams T, Yang J, Kondylis LA, Kondylis PD. Long-term outlook after 
successful fibrin glue ablation of cryptoglandular transsphincteric fistula-in-
ano. Dis Colon Rectum 2008; 51(10):1488-1490. 
 (329)  Sentovich SM. Fibrin glue for anal fistulas: long-term results. Dis Colon 
Rectum 2003; 46(4):498-502. 
 (330)  Edelman DS. Laparoscopic herniorrhaphy with porcine small intestinal 
submucosa: a preliminary study. JSLS 2002; 6(3):203-205. 
 (331)  Oelschlager BK, Barreca M, Chang L, Pellegrini CA. The use of small 
intestine submucosa in the repair of paraesophageal hernias: initial 
observations of a new technique. Am J Surg 2003; 186(1):4-8. 
222 
 
 (332)  Schultz DJ, Brasel KJ, Spinelli KS, Rasmussen J, Weigelt JA. Porcine small 
intestine submucosa as a treatment for enterocutaneous fistulas. J Am Coll 
Surg 2002; 194(4):541-543. 
 (333)  Johnson EK, Gaw JU, Armstrong DN. Efficacy of anal fistula plug vs. fibrin 
glue in closure of anorectal fistulas. Dis Colon Rectum 2006; 49(3):371-376. 
 (334)  Champagne BJ, O'Connor LM, Ferguson M, Orangio GR, Schertzer ME, 
Armstrong DN. Efficacy of anal fistula plug in closure of cryptoglandular 
fistulas: long-term follow-up. Dis Colon Rectum 2006; 49(12):1817-1821. 
 (335)  The Surgisis AFP anal fistula plug: report of a consensus conference. 
Colorectal Dis 2008; 10(1):17-20. 
 (336)  Amrani S, Zimmern A, O'Hara K, Corman ML. The Surgisis AFP anal fistula 
plug: a new and reasonable alternative for the treatment of anal fistula. 
Gastroenterol Clin Biol 2008; 32(11):946-948. 
 (337)  Christoforidis D, Etzioni DA, Goldberg SM, Madoff RD, Mellgren A. 
Treatment of complex anal fistulas with the collagen fistula plug. Dis Colon 
Rectum 2008; 51(10):1482-1487. 
 (338)  Echenique I, Mella JR, Rosado F, Echenique IA, Mella MT, Quevedo G. 
Puerto Rico experience with plugs in the treatment of anal fistulas. Bol Asoc 
Med P R 2008; 100(1):8-12. 
 (339)  Ellis CN. Bioprosthetic plugs for complex anal fistulas: an early experience. 
J Surg Educ 2007; 64(1):36-40. 
223 
 
 (340)  Garg P. To determine the efficacy of anal fistula plug in the treatment of high 
fistula-in-ano- an initial experience. Colorectal Dis 2008. 
 (341)  Ky AJ, Sylla P, Steinhagen R, Steinhagen E, Khaitov S, Ly EK. Collagen 
fistula plug for the treatment of anal fistulas. Dis Colon Rectum 2008; 
51(6):838-843. 
 (342)  Lawes DA, Efron JE, Abbas M, Heppell J, Young-Fadok TM. Early 
experience with the bioabsorbable anal fistula plug. World J Surg 2008; 
32(6):1157-1159. 
 (343)  Schwandner O, Stadler F, Dietl O, Wirsching RP, Fuerst A. Initial experience 
on efficacy in closure of cryptoglandular and Crohn's transsphincteric 
fistulas by the use of the anal fistula plug. Int J Colorectal Dis 2008; 
23(3):319-324. 
 (344)  Thekkinkattil D, Botterill I, Ambrose S, Lundby L, Sagar P, Buntzen S et al. 
Efficacy of the Anal Fistula Plug in Complex Anorectal Fistulae. Colorectal 
Dis 2008. 
 (345)  van Koperen PJ, D'Hoore A, Wolthuis AM, Bemelman WA, Slors JF. Anal 
fistula plug for closure of difficult anorectal fistula: a prospective study. Dis 
Colon Rectum 2007; 50(12):2168-2172. 
 (346)  van Koperen PJ, Bemelman WA, Bossuyt PM, Gerhards MF, Eijsbouts QA, 
van Tets WF et al. The anal fistula plug versus the mucosal advancement 
flap for the treatment of anorectal fistula (PLUG trial). BMC Surg 2008; 8:11. 
224 
 
 (347)  O'Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME, 
Armstrong DN. Efficacy of anal fistula plug in closure of Crohn's anorectal 
fistulas. Dis Colon Rectum 2006; 49(10):1569-1573. 
 (348)  Amid PK, Shulman AG, Lichtenstein IL, Hakakha M. Biomaterials for 
abdominal wall hernia surgery and principles of their applications. 
Langenbecks Arch Chir 1994; 379(3):168-171. 
 (349)  Kaufman Z, Engelberg M, Zager M. Fecal fistula: a late complication of 
Marlex mesh repair. Dis Colon Rectum 1981; 24(7):543-544. 
 (350)  Schneider R, Herrington JL, Jr., Granda AM. Marlex mesh in repair of a 
diaphragmatic defect later eroding into the distal esophagus and stomach. 
Am Surg 1979; 45(5):337-339. 
 (351)  Stone HH, Fabian TC, Turkleson ML, Jurkiewicz MJ. Management of acute 
full-thickness losses of the abdominal wall. Ann Surg 1981; 193(5):612-618. 
 (352)  Klinge U, Klosterhalfen B, Muller M, Schumpelick V. Foreign body reaction 
to meshes used for the repair of abdominal wall hernias. Eur J Surg 1999; 
165(7):665-673. 
 (353)  Smart N, Immanuel A, Mercer-Jones M. Laparoscopic repair of a Littre's 
hernia with porcine dermal collagen implant (Permacol). Hernia 2007; 
11(4):373-376. 
 (354)  Bradbury P, Gordon KC. Connective tissue stains. In: Bancroft JD, Stevens 
A, editors. Theory and Practice of Histological Techniques. 3rd ed. New 
York: Churchill Livingstone; 1990. 119-142. 
225 
 
 (355)  Badylak SF, Kokini K, Tullius B, Simmons-Byrd A, Morff R. Morphologic 
study of small intestinal submucosa as a body wall repair device. J Surg Res 
2002; 103:190-202. 
 (356)  Bendavid R. The unified theory of hernia formation. Hernia 2004; 8(3):171-
176. 
 (357)  Courtman DW, Errett BF, Wilson GJ. The role of crosslinking in modification 
of the immune response elicited against xenogenic vascular acellular 
matrices. J Biomed Mater Res 2001; 55(4):576-586. 
 (358)  Hulbert SF, Morrison SJ, Klawitter JJ. Tissue reaction to three ceramics of 
porous and non-porous structures. J Biomed Mater Res 1972; 6(5):347-374. 
 (359)  Liang HC, Chang Y, Hsu CK, Lee MH, Sung HW. Effects of crosslinking 
degree of an acellular biological tissue on its tissue regeneration pattern. 
Biomaterials 2004; 25(17):3541-3552. 
 (360)  Garcia-Aguilar J, Davey CS, Le CT, Lowry AC, Rothenberger DA. Patient 
satisfaction after surgical treatment for fistula-in-ano. Dis Colon Rectum 
2000; 43(9):1206-1212. 
 (361)  Nelson R. Operative procedures for fissure in ano. Cochrane Database Syst 
Rev 2005;(2):CD002199. 
 (362)  Thompson JE, Jr., Bennion RS, Hilliard G. Adjustable seton in the 
management of complex anal fistula. Surg Gynecol Obstet 1989; 
169(6):551-552. 
226 
 
 (363)  Brewer NT, Hallman WK, Fiedler N, Kipen HM. Why do people report better 
health by phone than by mail? Med Care 2004; 42(9):875-883. 
 (364)  Aitken JF, Youl PH, Janda M, Elwood M, Ring IT, Lowe JB. Comparability of 
skin screening histories obtained by telephone interviews and mailed 
questionnaires: a randomized crossover study. Am J Epidemiol 2004; 
160(6):598-604. 
 (365)  Porrett T, Knowles CH, Lunniss PJ. Creation of a treatment protocol for 
nurse-led management of anal fissure. Colorectal Dis 2003; 5(1):63-72. 
 (366)  deSouza NM, Hall AS, Puni R, Gilderdale DJ, Young IR, Kmiot WA. High 
resolution magnetic resonance imaging of the anal sphincter using a 
dedicated endoanal coil. Comparison of magnetic resonance imaging with 
surgical findings. Dis Colon Rectum 1996; 39(8):926-934. 
 (367)  Stoker J, Fa VE, Eijkemans MJ, Schouten WR, Lameris JS. Endoanal MRI 
of perianal fistulas: the optimal imaging planes. Eur Radiol 1998; 8(7):1212-
1216. 
 (368)  Beets-Tan RG, Beets GL, van der Hoop AG, Kessels AG, Vliegen RF, 
Baeten CG et al. Preoperative MR imaging of anal fistulas: Does it really 
help the surgeon? Radiology 2001; 218(1):75-84. 
 (369)  Buchanan G, Halligan S, Williams A, Cohen CR, Tarroni D, Phillips RK et al. 
Effect of MRI on clinical outcome of recurrent fistula-in-ano. Lancet 2002; 
360(9346):1661-1662. 
 (370)  Spencer JA, Ward J, Ambrose NS. Dynamic contrast-enhanced MR imaging 
of perianal fistulae. Clin Radiol 1998; 53(2):96-104. 
227 
 
 (371)  Lunniss PJ, Gladman MA, Hetzer FH, Williams NS, Scott SM. Risk factors in 
acquired faecal incontinence. J R Soc Med 2004; 97(3):111-116. 
 (372)  Bhende S, Barbolt T, Rothenburger S, Piccoli L. Infection potentiation study 
of synthetic and naturally derived surgical mesh in mice. Surg Infect 
(Larchmt ) 2007; 8(3):405-414. 
 (373)  Hammond TM, Knowles CH, Porrett T, Lunniss PJ. The Snug Seton: short 
and medium term results of slow fistulotomy for idiopathic anal fistulae. 
Colorectal Dis 2006; 8(4):328-337. 
 (374)  Himpson RC, Cohen CRG, Sibbons P, Phillips RKS. Histological evidence 
for enhanced anal fistula repair using autologous fibroblasts in a dermal 
collagen matrix. Comparative Clinical Pathology 2007; 16:9-14. 
 (375)  Tyler KM, Aarons CB, Sentovich SM. Successful sphincter-sparing surgery 
for all anal fistulas. Dis Colon Rectum 2007; 50(10):1535-1539. 
 (376)  Shevchenko RV, Sibbons PD, Sharpe JR, James SE. Use of a novel 
porcine collagen paste as a dermal substitute in full-thickness wounds. 
Wound Repair Regen 2008; 16(2):198-207. 
 (377)  Hammond TM, Chin-Aleong J, Navsaria H, Williams NS. Human in vivo 
cellular response to a cross-linked acellular collagen implant. Br J Surg 
2008; 95(4):438-446. 
 (378)  Falco EE, Roth JS, Fisher JP. EH Networks as a scaffold for skeletal muscle 
regeneration in abdominal wall hernia repair. J Surg Res 2008; 149(1):76-
83. 
228 
 
 (379)  Falco EE, Roth JS, Fisher JP. Skeletal muscle tissue engineering 
approaches to abdominal wall hernia repair. Birth Defects Res C Embryo 
Today 2008; 84(4):315-321. 
 (380)  Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative 
pressure for treating chronic wounds. Cochrane Database Syst Rev 
2008;(3):CD001898. 
 (381)  Ubbink DT, Westerbos SJ, Nelson EA, Vermeulen H. A systematic review of 
topical negative pressure therapy for acute and chronic wounds. Br J Surg 
2008; 95(6):685-692. 
 (382)  Nagell CF, Holte K. Treatment of anastomotic leakage after rectal resection 
with transrectal vacuum-assisted drainage (VAC). A method for rapid control 
of pelvic sepsis and healing. Int J Colorectal Dis 2006; 21(7):657-660. 
 (383)  van Koperen PJ, van Berge Henegouwen MI, Rosman C, Bakker CM, Heres 
P, Slors JF et al. The Dutch multicenter experience of the Endo-Sponge 
treatment for anastomotic leakage after colorectal surgery. Surg Endosc 
2008. 
 
 
  
229 
 
Appendix  
Follow-up questionnaire for fistula recurrence, postoperative anal 
incontinence, and quality of life. 
 
1. Name:    
 
2. Date of operation:        
 
3. Did the operation heal the fistula      Yes or No 
(Please ring correct answer) 
 
4. How long did it take for the fistula wound to heal after the operation? ___weeks 
 
5. How long after your operation did you return to work?   ___weeks 
 
 
6. Since your operation have you experienced any pain in the region of your anal 
fistula, similar in nature to the pain you were experiencing before your operation 
 
(Please ring correct answer)       Yes or No 
 
 
7. Since your operation have you experienced any discharge (fluid/ pus) from your 
anal fistula?  
Never            
For a short period of time after my operation      
Ever since my operation        
    
 
8. Since your operation have you noticed any swelling in the region of your anal 
fistula?    
(Please ring correct answer)       Yes or No 
 
9. Since your operation have you had any difficulty distinguishing between gas and 
stool? 
A. Never            
B. For a short period of time after my operation      
C. Ever since my operation        
  
  Rarely (less than once a month)     
Sometimes (more than once a month)    
Frequently (more than once a week)    
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10. Since your operation have you had any problem holding gas? 
A. Never            
B. For a short period of time after my operation      
C. Ever since my operation         
  Rarely (less than once a month)     
Sometimes (more than once a month)    
Frequently (more than once a week)    
 
11. Since your operation have you had any problem with soiling of your underwear? 
A. Never            
B. For a short period of time after my operation      
C. Ever since my operation         
  Rarely (less than once a month)     
Sometimes (more than once a month)    
Frequently (more than once a week)    
 
 
12. Since you operation have you had accidental bowel movements? 
A. Never            
B. For a short period of time after my operation      
C. Ever since my operation         
Rarely (less than once a month)      
Sometimes (more than once a month)     
Frequently (more than once a week)     
 
13. Do you have to wear a pad? 
Never            
Only at night           
Sometimes (Daytime)          
All the time (Daytime)          
 
 
14. Are you satisfied with the results of the operation?  
Very satisfied           
Satisfied            
Dissatisfied           
Very dissatisfied           
 
 
15. Does this problem affect your lifestyle? (Mark the best answer for each column) 
 
 
 Physical Activities 
 
Social Activities Sexual Activities 
Not at all    
To some extent    
Greatly    
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16. Have you experienced any other symptoms/ problems since your operation 
(please list): 
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